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Abstract 
The glycine receptor (GlyR) is a Cys-loop ligand-gated anion channel that mediates fast 
synaptic inhibition in brain and spinal cord. Heritable malfunction of glycinergic transmission 
in man causes hyperekplexia, a neuromotor disorder characterised by exaggerated startle 
responses to normal sensory stimuli. Many mutations responsible for the disease are found in 
GlyR subunits, where they highlight residues essential for channel activation. 
I evaluated the effects of four human hyperekplexia 1 subunit mutations located in different 
parts of the GlyR including the extracellular domain (ECD), transmembrane domain (TM1) 
and transmembrane domain (TM2). Human α1 and 1 GlyR bearing the E103K, S231N, 
Q266H or S267N mutations in α1 were expressed in HEK293 cells.  Glycine concentration-
response curves obtained by whole-cell patch-clamp recordings confirmed previous reports 
(Bode & Lynch, 2014) that these mutations decrease the channel sensitivity to glycine, 
increasing its EC50.  
To understand the mechanism of action of these mutations, I performed also single-channel 
recordings (cell-attached, pipette potential +100 mV) at saturating glycine concentrations.  
This allowed measurement of the channel maximum open probability (Popen = cluster open 
time / total cluster time).  The mutations tested decreased the GlyR maximum Popen to 0.37 – 
0.67, cf. the wild-type value of 0.98. This reduction in maximum Popen was clear, despite the 
presence of distinct gating modes (stretches of activations with different Popen) in mutant 
receptors. These data suggest that the human hyperekplexia mutations tested here increase 
glycine EC50 by reducing gating efficacy.  
To determine whether the function of the mutant GlyRs can be rescued, the intravenous 
anasthetic, propofol was used. Propofol (50 μM) was found to enhance responses to 
submaximal glycine concentrations in all heteromeric receptors (by 2.71 - 5.19-fold).  
However, the impaired maximum response of mutant receptors was increased by propofol 
only for the S231N mutant GlyR.  
Residues in the ECD are likely to be vital for agonist recognition and might have influence on 
channel gating. This was the case with the hyperkplexia α1 E103K GlyR mutation. In order 
to explain that, I investigated the role of residues at the back of the binding site, in loops A 
and E, E103 and R131, respectively, and established that they interact, probably by forming 
an intersubunit  salt-bridge that is crucial for channel gating of the glycine receptor. The 
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interruption of this interaction might explain the reason behind the effect of the E103K 
hyperekplexia mutation. 
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Chapter 1 : Introduction 
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1.1 The pentameric ligand-gated ion channel superfamily  
Ligand-gated ion channels (LGICs) are membrane embedded receptors that allow ion passage 
through their pore, when a specific agonist binds to them. These channels mediate fast 
synaptic transmission, as the ionic flux changes the membrane potential of the postsynaptic 
cell. There are three major families of LGIC: glutamate receptors, ATP-gated channels (P2X 
receptors) and Cys-loop receptors. In vertebrates, the Cys-loop (or nicotinic) superfamily 
comprises nicotinic acetylcholine receptors (nAChR), 5-hydroxytryptamine receptors (5-
HT3R), γ-amino-butyric acid GABA type A receptors (GABAA), glycine receptors (GlyRs) 
and zinc-activated channel (ZAC).  The name of the superfamily (Cys-loop) is due to the 
presence of a disulfide bond between cysteine residues, which forms a highly conserved 13 
amino acid loop within the extracellular domain (ECD).  In addition to that, the nicotinic 
superfamily comprises also channels expressed by invertebrates, notably the glutamate-gated 
chloride channel (GluCl), which is activated by glutamate in nematodes such as C. elegans, 
and prokaryotic channels, such as Erwinia chrysanthemi ligand-gated ion channel (ELIC) and 
Gloebacter violaceous ligand-gated ion channel (GLIC).  Both ELIC and GLIC are cation-
selective, but GLIC is gated by low pH (i.e., protons), whereas ELIC is activated by primary 
amines such as cysteamine (Bocquet et al., 2007; Zimmermann and Dutzler, 2011). ELIC is 
also activated by GABA and modulated by benzodiazepines (Spurny et al., 2012). Although 
they are part of the nicotinic LGIC superfamily, the prokaryotic channels lack the disulfide 
bond and therefore have no Cys-loop in the ECD (and virtually no M3-M4 cytoplasmic 
domain, see below). Soluble acetylcholine binding proteins (AChBP) found in molluscs are 
an additional related group of proteins, which are homologous to the ECD of the channels, 
but do not contain a transmembrane domain (Brejc et al., 2001). 
All Cys-loop family members are pentamers with their subunits arranged pseudo-
symmetrically around a central pore. Homomeric receptors are formed by a single subunit 
type and heteromeric receptors are formed by more than one subunit type. Channels can 
mediate either excitatory, or inhibitory, synaptic transmission as they can be selective for 
cations, or anions, respectively. Inhibitory channels include glycine, GABAA receptors, the 
excitatory channels include nicotinic, 5-HT3 receptors and ZAC.  
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1.2 Glycinergic transmission 
Discovery of the transmitter 
The main concepts of GlyR neurotransmission and physiological properties are based on key 
in vivo experiments conducted in the 1950s and 1960s. Based on detailed analysis of glycine 
distribution in the spinal cord of cats, glycine was originally proposed as an inhibitory 
neurotransmitter by Aprison and Werman (1965). They noticed that the highest levels of 
glycine are localized in the ventral horn, where the spinal inhibitory interneurons are located. 
Several studies document the role of glycine as an inhibitory neurotransmitter (see Bowery 
and Smart, 2006; Callister and Graham, 2010). Electrophysiological studies by Curtis and 
Watkins (1960) and Werman et al. (1967) demonstrated that glycine application caused a 
reduction of action potential firing in spinal neurons. Subsequently, an in vivo study showed 
that glycine can be synthesized by neurons (Shank and Aprison, 1970). Hopkin and Neal 
(1970) reported the release of glycine from isolated slices of spinal cord post stimulus 
application (Hopkin and Neal., 1970). Following its release, glycine it is removed by Na
+
-
dependent high-affinity transporters. All these findings lead to the acceptance of glycine as a 
neurotransmitter due to its fulfilling the criteria set by Werman (1966) (Werman, 1966). 
Moreover, it was reported that the alkaloid strychnine is the most potent antagonist of GlyR 
(Curtis et al., 1967; Young and Snyder, 1973). Strychnine has been a valuable tool in 
radioligand binding studies and affinity purification of GlyRs. GlyR can be photochemically 
labeled by UV irradiation as 
3
H-strychnine can bind irreversibly to GlyR post UV exposure 
(photoaffinity labeling; Graham et al., 1983).  
Role of GlyR 
In the adult nervous system GlyR mediates fast inhibitory synaptic transmission (mainly in 
the spinal cord and brainstem). GlyR has a vital role in coordination of spinal motor reflex 
circuits, respiratory rhythm regulation, sensory processing and (Lynch, 2004; Dutertre et al., 
2012). Defects in glycinergic neurotransmission result in the neuromotor disorder 
hyperekplexia. GlyR also play role in controlling pain as mice lacking the α3 GlyR displayed 
less pain sensitization induced by peripheral inflammation or injection of spinal prostaglandin 
E2. Prostaglandin E2 is a mediator of inflammatory pain sensitization. It induces chronic 
inflammatory pain by inhibiting and phosphorylating of α3 GlyR. (Ahmadi et al., 2002; 
Harvey et al., 2004).  Strychnine poisoning affects the inhibitory function of GlyR causing 
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severe muscle and unregulated muscle contractions, indicating the vital role of GlyRs in 
motor control. In addition, sensory perception is also affected as minimal acoustic or tactile 
stimuli cause convulsive episodes. GlyRs are also involved in the processing of visual and 
auditory signals, as GlyR α3 is found at inhibitory synapses in the retina and inner ear 
(Dutertre et al., 2012).   
In embryonic neurons GlyRs (and GABAARs) are excitatory and their activation results in 
depolarisation of the cell membrane that triggers the activation of voltage-gated Ca
2+
 
channels. This excitatory action might be important for synaptogenesis as Ca
2+
 influx has a 
role in GlyR clustering at the post-synapse (Ye, 2008). During neurodevelopment, α2 GlyR is 
the dominant isoform of GlyR expressed in neurons. α2 GlyRs are vital for neuronal 
migration and synapse formation. Patients with autism spectrum disorder have defects in the 
α2 GlyR encoding gene GLRA2 (Pilorge et al., 2016). 
In addition, glycine has a vital excitatory role as a neurotransmitter at glutamatergic synapses. 
Like D-serine, it acts as an essential co-agonist of L-glutamate at N-methyl-D-aspartate 
receptors (NMDA receptors, a subtype of glutamate receptors). Simultaneous binding of both 
glycine and L-glutamate is required for the full activation of conventional Ca
2+
-permeable 
NMDA receptors. Those receptors are composed of two glycine-binding NR1 and two 
glutamate-binding NR2 subunits (Johnson and Ascher, 1987; Kuryatov et al., 1994; Laube et 
al., 1997). Glycine can also exclusively activate NMDA receptors that are composed of 
glycine-binding subunits NR1 and NR3 and lack a glutamate-binding site (Chatterton et al., 
2002; Madry et al., 2007). 
Key processes of glycinergic synapse   
Glycinergic neurotransmission follows the same concept of synaptic transmission (Figure 
1.1; Bowery and Smart, 2006). Glycine is packed into synaptic vesicles via the vesicular 
inhibitory amino-acid transporter (VIAAT), which requires a proton concentration gradient to 
transport glycine (and GABA; Gasnier, 2004). In adult neurons, the arrival of action potential 
causes activation of the pre-synaptic voltage-gated Ca
2+
 channels. Ca
2+
 influx leads to fusion 
of the vesicles to the plasma membrane of the pre-synaptic terminal and thereby results in the 
release of glycine (and GABA) into the synaptic cleft. Upon the binding of glycine to the 
post-synaptic GlyR, conformational change allows channel opening and an influx of Cl
−
 ions 
into the post-synaptic cytoplasm. The resulting hyperpolarization inhibits neuronal firing of 
the post-synaptic membrane. Eventually, glycinergic synaptic transmission is terminated by 
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glycine removal and reuptake from the synaptic cleft via Na
+
-/Cl
−
-dependent, high-affinity 
glycine transporters one isoform of which is expressed in glial cells (glycine transporter 1: 
GlyT1, Figure 1.1) and the other in glycinergic pre-synaptic terminals (glycine transporter 2: 
GlyT2; Zafra et al., 1995; Eulenburg et al., 2005; Betz et al., 2006a). Glycine is then either 
re-packed into synaptic vesicles or degraded via the glycine cleavage system (GCS) in 
astroglial mitochondria.  
 
 
Figure  1.1 Glycinergic transmission  
In the pre-synaptic terminal, glycine is concentrated in synaptic vesicles by the vesicular 
inhibitory amino-acid transporter (VIAAT). Post synaptic stimulation glycine is released in 
the synaptic cleft and binds to GlyR. Once glycine is dissociated from the receptor either of 
the glycine transporters GlyT1 (located at glial cells) or GlyT2 (located at the pre-synaptic 
plasma membrane) reuptake it. Glycine is then either repacked into synaptic vesicles or 
degraded via the glycine cleavage system (GCS). GlyRs are presented in the figure with two 
stoichiometries: 3α:2β and 2α:3β. The synaptic clustering of GlyRs is mediated by direct 
interaction of the GlyR β-subunit to the scaffolding protein gephyrin and then to the 
cytoskeleton. The Figure is adapted from Bowery and Smart, (2006).  
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1.3 Glycine receptors  
Glycine receptors (GlyRs) are Cys-loop ion channels that mediate fast inhibitory 
neurotransmission in several parts of the CNS. Although the glycine receptor is found in 
higher brain regions including hypothalamus, nucleus accumbens, and cerebellum, the major 
synaptic role of glycine receptors is in the spinal cord, brain stem and retina (Lynch et al., 
2004). Binding of glycine to the postsynaptic glycine receptor allows permeation of chloride 
and bicarbonate ions and hyperpolarization, or depolarization, might result depending on the 
value of the equilibrium potential relative to cell resting potential.  In adult neurons a low 
intracellular Cl‾ concentration (10 mM, or less) is maintained by the expression of the K+-Cl‾ 
co-transporter KCC2. Given that the extracellular chloride concentration is high 
(approximately 110-130 mM), the equilibrium potential (ECl) for chloride in the adult central 
nervous system is hyperpolarizing with respect to the resting membrane potential (Delpy et 
al., 2008). This means that if ECl is more negative than the membrane potential, activation of 
GlyR will hyperpolarize the membrane and inhibit action potential generation (Lynch et al., 
2004). In embryonic neurons the intracellular Cl‾ concentration is high due to absence of the 
K
+
-Cl‾ co-transporter KCC2. Because of that ECl is depolarising and the action of GlyR is 
excitatory instead of inhibitory (Betz and Laube, 2006).   
1.4 Isoforms of GlyR 
The GlyR can exist as a homomer (composed by α subunits only), or as a heteromer (α 
subunit along with β subunit). Among GlyR subunits, there is only one β subunit isoform and 
4 isoforms of α subunits (α1- α4), although the α4 gene is not functional in man. The major 
proteins associated with the GlyR are the 48 kD α1 subunit, 58 kD β subunit and the 93 kD 
gephyrin accessory protein (Graham et al., 1985; Grenningloh et al., 1990; Schmitt et al., 
1987). Gephyrin is an anchoring protein that links the TM3-TM4 of the β subunit to the 
cytoskeleton tubulin and F-actin providing receptor clustering and anchoring to the 
postsynaptic membrane (Sola et al., 2004; Fritschy et al., 2008). There is a 80-90% sequence 
identity between the α subunits, but the β subunit displays ~47% amino-acid sequence 
identity with the α subunits (Lynch et al., 2004). 
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Alternative splicing produces additional α subunit isoforms. Rat α1 subunit has a α1ins variant 
that includes eight additional amino-acids in the intracellular loop (Malosio et al., 1991). The 
rat α2 subunit has two splicing variants, α2A and α2B (Kuhse et al., 1990; Kuhse et al., 
1991). The human α3 gene has two transcripts, α3K and α3L. The α3K transcript lacks a 15 
amino-acids segment in the intracellular loop (TM3-4) that is present in α3L. The rat α3 
subunit has the intracellular insert (Kuhse et al., 1990; Nikolic et al., 1998). The β subunit 
has only one known form (Sola et al., 2004).   
Based on a UniProt search human, rat, and mouse has α1-α4 subunits and only one β subunit, 
although, the α4 subunit is a pseudogene in human. Between the human and rat α1 subunit 
there are four different amino acids and these residues are between the TM3 and TM4 
domains. For the UniProt search only the high quality manually annotated and non-redundant 
protein sequence database “Swiss-Prot” reviewed results were included. This database 
combines the experimental results, computed features and the scientific conclusions.  
Recombinant expression of any α GlyR subunit (other than human α4) in Human embryonic 
kidney (HEK 293) cells produces functional homopentameric receptors (Kuhse et al., 1993). 
On the other hand, β subunits expressed alone cannot form functional receptors and need co-
expression with α subunits to form glycine receptors. There are different views about the 
stoichiometry of GlyR: one favours (α1)3(β)2 based on cross-linking experiments, 
electrophysiological techniques, and single molecule imaging and stepwise photobleaching 
techniques (Langosch et al., 1988; Kuhse et al., 1993; Burzomato et al., 2003; Durisic et al., 
2012). The effects of mutating the highly conserved hydrophobic residues 9' of TM2 on the 
receptor sensitivity to glycine were more marked when the α subunit bore the mutation than 
when the mutation was inserted into β subunit. This supports (α1)3(β)2 stoichiometry of GlyR 
(Burzomato et al., 2003). Using another expression system, Xenopus oocytes, the group of 
Durisic et al used subunit counting by stepwise photobleaching.  They found that GlyR 
stoichiometry is independent of the expression levels of individual subunits. Stepwise 
photobleaching of venus fluorescent protein (VFP)-tagged subunits was used to determine 
and count individual α1-or β-subunits within single GlyR channels and suggested a subunit 
ratio of (α1)3 (β)2. The VFP was inserted into the intracellular loop between TM3 and TM4 of 
human GlyR α1- and β- subunits. Even when different ratios of α: β VFP were used only 
receptors containing two β subunits were formed, suggesting the stoichiometry of two β 
subunits per heteromeric GlyR is strictly controlled (Durisic et al., 2012).  
 
23 
 
On the other hand, other findings support (α1)2(β)3 with β-α-β-α-β arrangement based on 
expression of a tandem α1β construct and metabolic labelling analyses of recombinant GlyRs 
and imaging of single antibody-bound α1β GlyRs using atomic force microscopy  
(Grudzinska et al., 2005; Yang et al., 2012). Tandem subunits were constructed in which the 
C terminus of the α1 subunit was linked to the N terminus of the β subunit via a 7-fold 
alanine-glycine-serine repeat and expressed in oocytes.  Expressing tandem α1- β did not 
produce functional receptors, unless the wild type β subunit was co-expressed.  These 
receptors had EC50 identical to the heteromeric α1β GlyR (Grudzinska et al., 2005). 
Quantitation of radiolabeled methionine levels in recombinant α1 and α1β GlyRs also 
indicated (α1)2(β)3 stoichiometry of heteromeric GlyR (Grudzinska et al., 2005). Another 
study also indicated a (α1)2(β)3 stoichiometry using atomic force microscopy technique 
(Yang et al., 2012). FLAG and His6 epitopes were introduced into α1 and β subunits, 
respectively, and atomic force microscopy allowed imaging of single antibody-bound α1β 
receptors. Electrophysiology verified the functional expression of the α1 and β subunits with 
epitopes (Yang et al., 2012). In either case, it is thought that three glycine molecules must 
bind to activate homomeric, or heteromeric, receptors fully (Beato et al., 2004; Burzomato et 
al., 2004; Lynch, 2009; Marabelli et al., 2013). 
1.5 Expression of glycine receptors in the CNS  
The regional distribution and the developmental expression of GlyR in the CNS are different 
for the different subunits. In the CNS of rodents, glycine immunoreactivity against GlyR 
appears from  embryonic day 12 (E12) (Chalphin and Saha, 2010). Before birth, the 
predominant α subunit is α2, and the expression of the β subunit is low. This was supported 
by analysis of mRNA and protein expression level studies (Becker et al., 1988; Malosio et 
al., 1991b; Watanabe and Akagi, 1995). The existence of α2 homomers in embryonic 
neuronal membranes was also suggested by functional work (Takahashi et al., 1992). The 
mean channel life time (single-channel properties) of embryonic (E20) receptors correspond 
to recombinant α2 receptors and the adult (P22) rat spinal GlyRs correspond better to α1 
receptors (Takahashi et al., 1992). By the third postnatal week, expression of α2 subunits 
decreases, and that of α1 and β increases.  In the adult, it is likely that the predominant 
synaptic form of the receptor is the α1β heteromer, with few exceptions (Lynch, 2009).  This 
may be in part due to the fact that gephyrin, which is important for GlyR clustering in the 
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postsynaptic membrane, binds only to the β subunit of GlyR. α3 is expressed only in discrete 
areas of the CNS, notably the superficial dorsal horn of the spinal cord (Malosio et al., 1991). 
GlyR containing  are thought to play a role in controlling pain, as mice lacking the α3 
GlyR showed less pain sensitization by inflammation (Harvey et al., 2004).  
In situ hybridization data show α1 transcripts are abundant in the brainstem and spinal cord of 
adult rat. α1 subunits also expressed in the superior and inferior colliculi, the cerebral deep 
nuclei and the hypothalamus but at lower levels (Malosio et al., 1991; Sato et al., 1992; 
Garcia-Alcocer et al., 2008). The β subunit is expressed in the brain from around embryonic 
day 14 and its expression increases in adults. The mRNA expression of β subunit is fairly 
high in brain regions where α subunit mRNA expression is absent (Malosio et al., 1991). 
Considering that β subunits do not form homomers, the physiological role of this expression 
is not known. 
GlyRs are located in the caudal part of the adult CNS, at low levels in the hippocampus, mid 
brain, thalamus and hypothalamus and at higher levels in the grey matter of the pons, 
medulla, and spinal cord. Different approaches were used to study the functional distribution 
of GlyR including in vitro autoradiography of [3H]-glycine (Bristow et al., 1986) or 
strychnine (Young and Snyder, 1973; Zarbin et al., 1981; Probst et al., 1986) and 
immunocytochemistry studies for the GlyR anchoring protein gephyrin (Araki et al., 1988; 
Triller et al., 1985; Racca et al., 1997).   
The distribution of GlyR subunits is anatomically segregated across the synapse as shown in 
a study of rat calyx of Held synapse from the auditory brainstem. GlyRs at these pre-synaptic 
terminals are composed of α1 homomeric subunits (Hruskova et al., 2012). Heteromeric 
GlyRs cluster at the postsynaptic terminal, as the β subunit interacts with gephyrin. Most of 
the glycinergic inhibitory transmissions are carried by heteromeric α1β GlyRs in adult CNS 
(Kneussel and Betz, 2000; Grudzinska et al., 2005; Lynch, 2009). Homomeric GlyRs can be 
functional as shown in embryonic neurons (Flint et al., 1998). However, the evidence for 
existence of homomeric GlyRs in the adult CNS is limited (Turecek and Trussell, 2001, 
2002; Deleuze et al., 2005).  
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1.6 Glycinergic synaptic currents 
The physiological consequence of the developmental switch from α2 to α1 GlyR subunit at 
~P20 in rat (Malosio et al., 1991) is the change in the time course of the IPSCs. As the 
expression of the α1 subunit increases, the glycinergic IPSCs become faster (Ali et al., 2000; 
Legendre and Korn, 1994; Singer et al., 1998; Singer and Berger, 1999 and 2000). The time 
course of glycinergic IPSCs is characterised by a fast mono-exponential rising phase and a 
mono- or bi-exponential deactivation phase (Beato, 2008; Burzomato et al., 2004; Legendre, 
2001; Singer et al., 1998; Singer and Berger, 1999). In the adult, the time course of glycine 
synaptic currents is very fast, with decay time constants between 5 and 10 ms (Singer et al., 
1998; Burzomato et al., 2004). This is determined by the kinetic properties of α1β GlyR 
heteromers (Burzomato et al., 2004; Pitt et al., 2008). Glycine is removed from the synaptic 
cleft by glycine transporters with an estimated time constant of 0.3-0.9 ms (Beato et al., 
2008; Legendre, 2001).  
The main inhibitory transmitters in the CNS are GABA and glycine. Many synapses in the 
spinal cord (Jonas et al., 1998), brain stem (Kotak et al., 1998; O’Brien et al., 1999; Russier 
et al., 2002) and cerebellum (Dumoulin et al., 2001) may be mixed GABAergic-glycinergic 
synapses. The existence of mixed GABA-glycine synaptic terminals was shown by 
immunohistochemical studies (Todd et al., 1996; Triller et al., 1987). Mixed inhibitory 
interneurons in the spinal cord co-release glycine and GABA from the same vesicle (Jonas et 
al., 1998). The deactivation of GABAA receptors is much slower than that of GlyR and this is 
reflected in the duration of the synaptic currents.  For instance, GABA and glycine inhibitory 
neurotransmitters co-exist in the hypoglossal nucleus of the brainstem where most of the 
local cells are motoneurons. The GABAergic and glycinergic Cl¯ mediated synaptic 
transmission in the brain stem motoneurons of neonatal rats differ in terms of kinetics. 
GABAergic responses had slower rise and decay times than glycinergic. This applies to 
glycinergic sPSCs, mPSC and ePSCs  (Donato and Nistri, 2000). In embryonic motoneurons 
the density of expressed GABAA receptors is higher than of glycine receptors (Gao and 
Ziskind-Conhaim 1995). With development in most spinal brainstem synapses, the 
transmission changes from the long-duration GABAergic inhibitory post synaptic potentials 
(IPSPs) to short-duration glycine IPSPs (Gao et al., 2001; Baccei and Fitzgerald, 2004). In 
several brain regions with development the co-transmission is shifted to glycine only 
(Nabekura et al., 2004; Awatramani et al., 2005; Muller et al., 2006). 
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A different situation occurs when GABA, co-released with glycine acts directly on glycine 
receptors in auditory pathways in the brainstem (Lu et al., 2008).  GABA is a weak partial 
agonist of GlyR (see below), and thus GABA co-released with glycine can act can modulate 
the decay of glycinergic neurotransmission (Lu et al., 2008). It is shown in most of the 
medial nucleus of the trapezoid body (MNTB) in P16 rats that co-released GABA modifies 
the response of glycine receptor to glycine, speeding it. Fine-tuning of the glycinergic 
transmission in the mature auditory system seems to be one of the functions of co-release. 
GABA and glycine might work together on single receptor to enhance the temporal 
resolution of inhibition.  
The physiological importance of GlyR mediated transmission is confirmed by the reported 
effects of loss of function mutations or gene deletions in man and in rodents.  These are 
described in the introduction of the chapter three). 
1.7 Pharmacology of GlyR 
1.7.1 Agonists of GlyR 
GlyR has several ligands that are capable of channel opening, but these have differing 
efficacies. The most potent agonist for GlyR is glycine, but there are other agonists that can 
activate the receptor (Legendre, 2001; Lynch, 2004). These include the amino acids β-
alanine, L and D stereoisomers of α-alanine, sarcosine, taurine, L-serine and GABA 
(Schmieden and Betz, 1995). The potency of these endogenous amino acids acting on GlyRs 
is as follows: glycine has the highest potency, followed by β-alanine, taurine and then GABA 
(Lewis et al., 1991; Fucile et al., 1999; de Saint Jan et al., 2001). Whereas glycine is a full 
agonist of GlyR, β-alanine, taurine and GABA are partial agonists as they have a lower 
efficacy than glycine (Figure 1. 2). Some GlyR ligands are listed in Table 1.1 and the most 
relevant GlyR agonists are described below.  
Glycine. The simple amino acid glycine is a full agonist of GlyR, as it can keep the wild-type 
α1β GlyR open 96% of the time (Lape et al., 2008). Glycine sensitivity is similar between α1, 
α2, α3 and α4 GlyR, incorporation of the β subunit alters the channel sensitivity to glycine 
(Lynch, 2004).  
Taurine. Taurine can keep the wild-type α1β GlyR open only 54% of the time (Lape et al., 
2008). It is thought to act as a partial agonist because it has a reduced ability to induce the 
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conformational changes that precede channel opening (Lape et al., 2008). Some reports imply 
that agonist efficacy is different in different expression systems. Taurine provides an example 
for this, as it appears to be a full agonist in α1 GlyRs expressed in mammalian cells (Rajendra 
et al., 1995) but is less efficacious than glycine for GlyR expressed in Xenopus oocytes 
(Schmieden et al. 1989, 1992). Differences in the rate of agonist application and in the 
relative desensitisation of the peak current may underlie this phenomenon. Taurine acts as 
antagonist in  homomeric GlyR bearing the hyperekplexia mutations α1(R271Q) and 
α1(R271L) (Laube et al., 1995). Mutations at E53 and E57 α1 GlyR residues GlyR also 
change taurine into an antagonist (Absalom et al., 2003). 
Sarcosine. The endogenous amino acid sarcosine (N-methylglycine) acts as a GlyT1 inhibitor 
(Smith et al., 1992; Lopez-Corcuera et al., 1998; Herdon et al., 2001; Mallorga et al., 2003) 
and an NMDA receptor co-agonist together with glutamate (Zhang et al., 2009). Sarcosine 
was also found to be a GlyR agonist (Zhang et al., 2009) on embryonic mouse hippocampal 
neurons (GlyT1 was blocked pharmacologically with the irreversible GlyT1 inhibitor N[3-(4-
fluorophenyl)-3-(4-phenylphenoxy) propyl] sarcosine (NFPS) or by culturing neurons in the 
absence of glia upon which GlyT1 is expressed). The authors found sarcosine to be less 
potent than glycine (EC50 3.2 ± 0.7 mM vs. 57 ± 8.0 μM) and less efficacious (ca. 75%), 
possibly because of the extra methyl group on the N-terminus compared to glycine (Zhang et 
al., 2009). Results from recombinantly expressed human homomeric α1 GlyR confirm that 
sarcosine is a partial agonist. The maximum current response of sarcosine relative to glycine 
reached only 80% when saturating concentrations of glycine and sarcosine were applied to 
the same cell of α1 GlyR using whole-cell recordings. This is further confirmed by single-
channel recordings using a saturating concentration of sarcosine (Safar et al., 2016). 
With the sequence similarity between rat and human α1 GlyR (except for four different 
residues between the TM3 and TM4 regions) it is possible that agonists of human and rat α1 
GlyR are similar. 
1.7.2 Antagonist of GlyR 
GlyRs have both competitive and non-competitive antagonists. The former act by competing 
with the agonist for the binding sites (identical, or overlapping, i.e. orthosteric sites), the 
latter exert their effect by binding at another site, either the ion channel pore, or an allosteric 
site. A wide variety of GlyR antagonists exist. A few of the more relevant GlyR antagonists 
are discussed below.  
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Strychnine. The inhibitory action of glycine is antagonized by the alkaloid strychnine. 
Strychnine is a highly potent competitive antagonist of GlyR, with a dissociation constant 
(Kd) in the range 5-15 nM for α1β GlyR (Lewis et al,. 1998; Alexander et al,. 2017). The 
structure of GlyR for α1 zebrafish and α3 human isoforms in complex with strychnine was 
solved recently (Du et al., 2015; Huang et al., 2015). Similar to glycine the binding site of 
strychnine is in the ECD. The binding sites are overlapping but not identical, because 
strychnine is a large, rigid molecule. The high potency and selectivity of strychnine for GlyR 
makes it a useful tool to discriminate between glycinergic and GABAergic synaptic currents. 
Strychnine interrupts GlyR function by eliminating glycinergic synaptic inhibition. This 
results in overexcitation of the motor system leading to muscular convulsions.  
Picrotoxin. The plant convulsant alkaloid picrotoxin, which contains equimolar 
concentrations of picrotin and picrotoxinin, inhibits GlyR and it is a channel blocker (Lynch, 
2004). It binds within the channel pore as indicated in the crystal structure of C. elegans 
GluCl (Hibbs and Gouaux, 2011). The inhibitory action of picrotoxin is influenced by 
inclusion of the β subunit of GlyR and this makes it a useful tool for discriminating between 
homomeric and heteromeric GlyRs. Both recombinantly expressed αβ GlyR and native 
GlyRs are less sensitive to picrotoxin than homomeric α GlyRs (Pribilla et al., 1992). 
However, picrotoxin lacks specificity for GlyRs as it is also a non-competitive GABAA 
receptor antagonist. Whereas homomeric α1 GlyR is equally sensitive to picrotoxinin and 
picrotin (Lynch et al., 1995), homomeric α2 GlyR shows increased sensitivity to picrotoxinin 
and reduced sensitivity to picrotin. Both homomeric α2 and α3 GlyR are more sensitive to 
block by picrotoxinin than α1 GlyR (Yang et al., 2007). Heteromeric α1β GlyR is equally 
sensitive to picrotoxinin and picrotin and α3β is more sensitive to picrotoxinin than α1β 
(Yang et al., 2007). This compound could therefore be used for discriminating between 
different isoforms of GlyR. 
Ginkgolide B. Ginkgolide B, a component of extracts from the leaves of the Ginkgo biloba 
tree, is another chloride channel blocker (Alexander et al., 2017). Glycine-induced currents in 
native GlyRs in isolated hippocampal neurons and of recombinantly GlyRs expressed in 
Xenopus oocytes are inhibited by Ginkgolide (Kondratskaya et al., 2002, 2005). It can be 
used to discriminate between homomeric and heteromeric GlyRs as inclusion of the β subunit 
increased the sensitivity of recombinant α1β GlyRs expressed in Xenopus oocytes by up to 
20-fold compared with that of homomeric GlyRs. It was reported that homomeric α1 GlyR is 
more sensitive to ginkgolide B inhibition than homomeric α2 and α3 isoforms of GlyRs using 
29 
 
recombinant GlyRs expressed in Xenopus oocytes (Kondratskaya et al., 2005). Ginkgolide B 
is also selective in blocking GlyR because it is inactive at GABAA receptors (Kondratskaya et 
al., 2005).  
RU 5135. The convulsant steroid derivative, RU 5135 (3α-hydroxy-16-imino-5β-17-
azaandrostan-11-one), is a glycine antagonist that targets all subtypes of rat GlyR (Simmonds 
and Turner, 1985). While strychnine is useful in discriminating between glycinergic and 
GABAergic synaptic currents, RU5135 lacks specificity as it is an antagonist of both glycine 
and GABAA receptors (Curtis and Malik, 1985).   
Other antagonists. In addition to the above antagonists there are some inhibitors that are 
helpful in discriminating between different isoforms of GlyR; however, they are not selective 
for the GlyR. For instance, the neurosteroid pregnenolone sulphate is a more potent blocker 
on α1 than α2 GlyR. Co-expression of the β subunit does not affect the potency of 
pregnenolone sulphate at α1β but reduces the potency at α2β GlyR (Lynch, 2004; Alexander 
et al., 2017). Moreover, the function of GlyR might be enhanced or inhibited by tropisetron 
(ICS 205-930), which is a 5-HT3 receptor antagonist. It is more potent on α2 than on α1 
GlyRs and co-expression of the β subunit increases the potency at both receptors (Lynch, 
2004; Betz and Laube, 2006; Alexander et al., 2017). Also, the homomeric α1 GlyR, but not 
the α2, is blocked by cyanotriphenylborate, an open-channel blocker (Rundstrom et al., 
1994). 
1.7.3 Modulators of GlyR 
Drugs that are capable of modulating GlyR function might be interesting for their potential 
therapeutic applications in pain alleviation and muscle relaxation (Laube et al., 2002a; 
Lynch, 2004). A wide variety of agents can modulate the function of GlyR. While these will 
be further discussed in Chapter Four, a few are briefly described below. 
Zn
2+
. The divalent cation Zn
2+
 has a putative physiological relevance (Smart et al., 2004). In 
different areas of the brain such as the cortex, hippocampus and spinal cord Zn
2+
 is 
concentrated into synaptic boutons along with GABA, glycine or glutamate (Frederickson 
and Danscher, 1990; Birinyi et al,. 2001; Brown and Dyck, 2002). It is released after 
neuronal stimulation in sufficient concentration (<10 μM) to modulate GlyR current (Assaf 
and Chung, 1984; Howell et al., 1984; Xie and Smart, 1991, Miller et al., 2005b).  
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The physiological role of Zn
2+
 for proper glycinergic inhibition has been demonstrated in 
homozygous knock-in mice models carrying the Glra1(D80A) mutation. The affected mice 
exhibited hyperekplexia-like phenotypes such as tremors and delayed righting reflexes (a 
measure of how long a mouse needs to right itself after being turned on its back). This point-
mutation abolished Zn
2+
 potentiation of glycine-induced currents from spinal cord neuronal 
circuits and brainstem slices. GlyR expression levels or agonist sensitivity were not affected. 
This explains how a lack of Zn
2+
 modulation might affect glycinergic neurotransmission in 
vivo (Hirzel et al., 2006). 
 
Zn
2+
 has dual effects: at low concentrations (<10 μM) it enhances the GlyR function but at 
high concentrations (>10 μM) it inhibits the action of glycine. This biphasic effect is found 
for both native and recombinant expressed GlyRs (Harvey et al., 1999; Laube et al., 2000; 
Smart et al., 2004; Miller et al., 2005a; Miller et al., 2005b). The molecular sites for Zn
2+
 
potentiation differ from those for inhibition. While Zn
2+ 
potentiation of glycine-activated 
GlyR involve α1(D80), α1(E192), α1(D194), α1(H215) residues (Lynch et al., 1998; Laube 
et al., 2000, 2002; Miller et al., 2005b), its inhibition is affected by α1(H107), α1(H109), 
α1(T112) and α1(T133) (Harvey et al., 1999; Laube et al., 2000; Miller et al., 2005a).  
Zn
2+
 potentiation of glycine response is abolished by α1(D80A)β GlyR mutation (Laube et 
al., 2000, 2002). However, Zn
2+
 modulation of response to the partial agonist taurine is 
maintained for the same mutation (Lynch et al., 1998). This suggests either the existence of 
different binding sites for Zn
2+ 
or that the mutation only affects glycine response but not 
taurine.  
The homomeric α1 GlyR is more sensitive to the modulation action of Zn2+ than the α2 GlyR 
isoform. This difference in the sensitivity between the α1 and α2 isoforms of GlyR is 
maintained with the incorporation of the β subunit (Miller et al., 2005a). 
 
Alcohol. Alcohol is one of the most widely studied modulators of GlyR. It has been shown to 
enhance the function of both glycine and GABAA receptors in recombinant expression 
systems (Mihic et al., 1997; Harris et al., 2008). High alcohol concentrations of 50–200 mM 
are needed to observe the 40–150 % potentiation effect (Borghese et al., 2012). Binding of 
alcohols to transmembrane binding pockets has been demonstrated in the crystal structure of 
GLIC (Howard et al., 2011).  
Endocannabinoids. Other allosteric GlyR modulators include endocannabinoids, which are 
endogenous lipid-signalling molecules that activate G-protein-coupled cannabinoid receptors 
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(CB1 and CB2 receptors; Piomelli, 2003). Endocannabinoids that modulate GlyR include 
anandamide (AEA, 10–30 μM), N-arachidonyl glycine (NA-Gly, 10 μM), and virodhamine 
(VIR, 10 μM; Xiong et al., 2012; Yevenes & Zeilhofer, 2011).  
 
Ivermectin. Ivermectin, an antiparasitic drug that is used to treat humans as well as animals, 
can at sub-micromolar concentrations modulate homomeric α1 and heteromeric α1β GlyRs 
(Shan et al., 2001; Lynagh and Lynch, 2012). Its modulation effect was also observed in 
other electrophysiological studies (Lynagh and Lynch, 2010; Lynagh et al., 2011). Ivermectin 
can directly activate GlyR and its activation effect is poorly reversible (Shan et al., 2001; 
Lynagh and Lynch, 2010). The binding site for ivermectin is within the TMD as explored by 
the crystal structure of C. elegans GluCl receptor, the electron microscopy structure of 
zebrafish α1 GlyR and the most recent crystal structure of human α3 GlyR (Hibbs and 
Gouaux, 2011, Du et al., 2015, Huang et al., 2017). 
General anaesthetics. In addition, several general anaesthetics such as isoflurane, enflurane, 
halothane, sevoflurane and propofol potentiate GlyRs (Downie et al., 1996; Mascia et al., 
1996; Krasowski and Harrison, 1999; Yamakura et al., 2001; O’Shea et al., 2004; Lynagh 
and Laube, 2014; Nguyen et al., 2009). See Chapter Four for more details on the effect of 
propofol. 
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Table  1.1 GlyR ligands 
Ligand Ligand class Reference 
Glycine Agonist Bormann, (1993); Lynch et al. (1997); 
Alexander et al. (2017) 
β - alanine Agonist Lynch et al. (1997); Alexander et al. 
(2017) 
Taurine Partial agonist Lynch et al. (1997); Alexander et al. 
(2017) 
GABA  Partial agonist Schmieden et al. (1993); De Saint Jan et 
al. (2001) 
Sarcosine Partial agonist Zhang et al. (2009) 
strychnine Antagonist Vandenberg et al. (1992), Alexander et 
al. (2017) 
RU5135 Antagonist Curtis and Malik, (1985); Simmonds and 
Turner, (1985); Alexander et al. (2017) 
Picrotoxin Antagonist Alexander et al. (2017) 
Picrotoxinin Antagonist Yang et al. (2007) 
Picrotin Antagonist Yang et al. (2007) 
Ginkgolide B Antagonist Kondratskaya et al, 2002, 2005  
Zinc Allosteric modulator Miller et al. (2005a); Miller et al. 
(2005b); Alexander et al. (2017) 
Alcohols Allosteric modulator Mihic et al. (1997); Borghese et al. 
(2012); Alexander et al. (2017) 
Anesthetics (isoflurane, 
enflurane, propofol etc.) 
Allosteric modulator Downie et al. (1996); Mascia et al. 
(1996); Krasowski and Harrison, (1999); 
Yamakura et al. (2001); O’Shea et al. 
(2004); Lynagh and Laube, (2014); 
Nguyen et al. (2009) 
Ivermectin Allosteric modulator Shan et al. (2001); Lynagh and Lynch, 
(2010) 
Endocannabinoids 
(anandamide) 
Allosteric modulator Xiong et al. (2012); Yevenes and 
Zeilhofer, (2011) 
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Figure  1.2 Agonists of GlyRs. 
The chemical structure of the endogenous ligands acting on GlyRs. 
 
 
1.8 Biophysical properties of GlyR: permeability and chloride 
modulation   
The GlyR contains an anion conducting pore and it mainly conducts chloride ions.  GlyR has 
been tested for anion permeability in vitro. The anion permeability preference of SCN‾ > 
NO3‾ > I ‾ > Br‾ > Cl‾ > F‾ was found (Bormann et al., 1987; Fatima-Shad and Barry, 1993; 
Lynch, 2004).   
The time course of decay of synaptic-like GlyR currents is affected by the concentration and 
structure of the permeating ion. For instance, replacing chloride with another permeable 
anion, thiocyanate (SCN¯), suppressed the voltage dependence of GlyR. For α1β GlyR 
deactivation in SCN¯ was slower than in chloride (Moroni et al., 2011b). For homomeric α1 
GlyR, however, the deactivation in thiocyanate was faster. The nature of the permeating ion 
affects the voltage dependence for wild-type α1 and α1β GlyRs. Whereas currents carried by 
chloride slow with depolarization, currents carried by thiocyanate are insensitive. In both 
homomeric and heteromeric GlyRs chloride-impermeant mutants α1 A251E and α1R271A the 
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voltage dependence is abolished (Moroni et al., 2011b). It is possible that an interaction is 
needed between the activated gate and ions passing through the channel (Marchais and 
Marty, 1979). Two rings of positive charges, R252 and R271, are believed to attract anions 
before they are transported across the gate (Keramidas et al., 2004). Conductance is discussed 
further down.  
The duration of the synaptic glycinergic inhibition is influenced by chloride concentration. It 
was found that increasing intracellular chloride concentration slows the decay time constant 
of glycinergic IPSC. This was based on agonist concentration jumps experiments as 
recording with high chloride concentration in the patch pipette (130 mM) slowed the current 
decay by three fold compared to recording with low intracellular chloride concentration (10 
mM) (Pitt et al., 2008). In addition, the extracellular chloride concentration also influences 
the time course of the synaptic-like GlyR. In symmetrical high chloride concentration (131 
mM) on both sides of the membrane the decay was slower than in case of the presence of low 
intracellular chloride concentration (10 mM) (Moroni et al., 2011b). In order to have the 
effect of the intracellular chloride on the time course of the inward current, anion selectivity 
is required. If the glycine channels are mutated to be cationic, the modulation by the 
intracellular chloride disappears.  The presence of high or low chloride did not affect the 
decay of currents evoked by rapid application of glycine to α1A251E GlyR (Moroni et al., 
2011b). 
 
1.9 Receptor Structure 
All the members of the Cys-loop family share similar topology. I will summarise the main 
findings general to the superfamily and discuss in more detail those that are relevant to 
GlyRs. 
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Figure  1.3 General structure of a Cys-loop receptor and constituent subunits. 
Ribbon structure of the Torpedo nicotinic acetylcholine receptor (nAChR) (Protein Data 
Bank (PDB): 2BG9) showing the extracellular domain (ECD), transmembrane domain (TM) 
and a partial structure of the intracellular domain (ICD) (Unwin, 2005). 
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Each of the five subunits have a large N-terminal extracellular domain (ECD) followed by 
four α -helical transmembrane domains (TM1-TM4) terminating a short C-sequence.  The 
TM1-TM4 are connected by one extracellular and two intracellular linkers. The large 
intracellular domain between TM3 and TM4 is mostly unstructured (Figure 1.3). The ion 
conducting pore is surrounded by the TM2 helices from each subunit. This central pore is 
lined by polar and hydrophobic residues that determine ion selectivity and constitute the 
channel gate. The ion channel is closed at rest. Binding of the agonist to the ECD triggers a 
conformational change that result in gating, or opening, of the transmembrane pore.  A high 
resolution structure of a nicotinic ECD was first obtained for the AChBP with 2.7 A° 
resolution.  (Brejc et al., 2001).  The first images of the nicotinic channel were obtained by 
Nigel Unwin by cryo-electron microscopy of Torpedo muscle-type nAChRs.  Analysis of 
increasing image datasets led to a structure with 4 A° resolution defining the EC, the TM and 
partially the cytoplasmic domains (Unwin, 2005). 
The increasing availability of crystal structures of other Cys-members from invertebrate and 
prokaryotic organisms has provided further details. These structural data all refer to 
homomeric channels and  include the crystal structure of the prokaryotic channels ELIC from 
Erwinia chrysanthemi and GLIC from Gloeobacter violaceus with 3.3 A° and 3.9 - 4.35 A° 
resolution, respectively (Hilf and Dutzler, 2008; Bocquet et al., 2009; Hilf and Dutzler, 2009; 
Sauguet et al., 2014). The crystal-structures of several eukaryotic receptors were recently 
solved. They include GluCl from Caenorhabditis elegans (3.3 A°; Hibbs and Gouaux, 2011), 
5-HT3 from mouse with 3.5 A° and 4.3 A° resolution, respectively (Hassaine et al., 2014; 
Basak et al., 2018), and GABAA β3 receptor from man (Miller and Aricescu, 2014). A list of 
the main solved structures of pLGIC is provided in Table 1.1.  
For glycine receptors, the NMR structure of only the transmembrane domain of the α1 
subunit is has been published (Mowrey et al., 2013). The structure of Lily, which is a 
chimeric construct produced by merging the EC domain from GLIC and the TM domain from 
GlyR, was solved in the locally-closed state (Moraga-Cid et al., 2015). Recent electron cryo-
microscopy structures of the zebrafish α1 GlyR has been solved. It provided the structure of 
the homopentamers GlyR in three channel conformations: an open channel conformation 
with glycine, a desensitized or partial open conformation with glycine/ivermectin, and a 
closed channel conformation with strychnine (Du et al., 2015). Another study provided 
crystal- structure of homomeric human α3 GlyR in closed state bond with strychnine (3.0 A°; 
Huang et al., 2015).  
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These recent resolved structures of GlyR provided further advancement for understanding the 
ion channel. The structures of GlyR supported the classic topology of Cys-loop receptors 
including all main parts of the subunit from the ECD to the extracellular C-terminal region 
(Moss and Smart et al., 2001; Thompson et al., 2010). Formation of functional pentameric 
receptor with TM2 surrounding the ion channel pore and TM4 facing towards the plasma 
membrane is also confirmed.  
Even with the availability of the recent solved structure of several pLGICs, there are key 
questions needed to be determined such as the conformational coupling from ECD to ICD. 
Given that there are no high resolution structure of some of the pLGIC, inference have to be 
made from related homologues receptors despite the limited degree of homology (Figure 1.4 
shows three channels). From a physiological perspective, a highly conserved structure 
indicates a conserved function. While these data offer the hope of a new understanding of 
structure-function relation in these channels, there is much controversy about what 
conformational state the different structures are in.  This is made more difficult as most 
channels have been imaged only in one state, irrespective of their state of ligation.  One of the 
best results have been obtained for GLIC, which has been imaged by X-ray crystallography 
in both the open and the closed conformation (and in a “locally closed” conformation of 
unknown significance).  However, GLIC poses its own problems, as it is thought that the 
protonation that opens GLIC is not confined to the canonical agonist binding site (Wang et 
al., 2012).  
Molecular dynamics computational modelling may be useful to make sense of all the static 
structural data and yield a dynamic model of channel activation that can relate to function  
(daCosta and Baenziger, 2013; Yu et al., 2014; Cecchini and Changeux, 2015).  
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Figure  1.4 Structure of three nicotinic superfamily LGICs. 
ELIC (left, PDB ID code 2VLO), GLIC (Middle, PDB ID code 3EAM), and GluCl (Left, 
PDB ID code 3RIF). The Figure is adapted from daCosta and Baenziger, (2013). ECD 
highlighted in red, TM highlighted in blue. Yellow spheres indicate the narrowest 
constrictions in the channel pore. 
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Table  1.2 Main structures of pLGICs 
Receptor Method Resolution (Å) Conformation Reference 
AChBP  XRD 2.7 - Brejc et al. (2001) 
Torpedo AChR  ECM 4.0 closed channel Unwin (2005)  
Torpedo AChR  ECM 6.2 
open/closed 
channel 
Unwin and Fujiyoshi 
(2012) 
ELIC  XRD 3.3 Closed channel Hilf and Dutzler (2008) 
GLIC  XRD 2.9 Open channel Bocquet et al. (2009) 
GLIC  XRD 3.1 Open channel Hilf and Dutzler (2009) 
GLIC XRD 4.35 Closed channel Sauguet et al. ( 2014) 
GluCl  XRD 3.3 Open channel Hibbs and Gouaux (2011) 
GluCl XRD 3.6 Closed channel Althof et al.(2014) 
5-HT3A XRD 3.5 Open channel Hassaine et al.(2014) 
5-HT3A ECM 4.3 Closed channel Basak et al.(2018) 
GABAAβ3 XRD 3 Closed channel Miller and Aricescu (2014) 
GlyR α1 (TMs) NMR - - Mowrey et al.(2013) 
GlyR α1 ECM 3.9 
Open/Closed 
channel 
Du et al.(2015) 
GlyR α3 XRD 3.0 Closed channel Huang et al.(2015) 
GlyR α3 XRD 2.6 Open channel Huang et al.(2017) 
Chimera  
GLIC-GlyRα1 
XRD 3.5 Closed channel Moraga-Cid et al.(2015) 
Summary of the main resolved structures of pLGICs. Methods used to obtain the structures 
are X-ray diffraction (XRD), electron cryo-microscopy (ECM), or solution nuclear magnetic 
resonance (NMR). 
1.9.1 General structural features: the binding site 
The ECD is formed by a highly conserved β-sandwich with an inner and an outer sheet and a 
total of ten β strands. The neurotransmitter binds at the interface between subunits. In a 
pentameric receptor there are five potential binding sites.  The binding pocket consists of 
three regions from the “principal” or (+) side (the anticlockwise subunit, namely the A, B, 
and C loops and the four ‘’complementary’’ or (-) subunits strands D, E, F, and G (Figure 
1.5; Galzi & Changeux, 1995; Corringer et al., 2000;Figure 1.6; Hibbs and Gouax, 2011).  
Although only few residues face the binding pocket directly, other nearby residues can affect 
binding by maintaining pocket structure, or taking part in conformational changes in this 
area.  
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Once the neurotransmitter binds to the ECD structural movements occur to allow channel 
opening 60 Å away. Not all the residues in the binding site are directly involved in the 
binding.   
Structure-function studies on Cys-loop receptors such as nAChRs, GABAA, and the 5-HT3 
receptors indicate that the agonist binding occur in the N-terminal domain at interfaces 
between adjacent subunits (Corringer et al., 2000). The identification of binding site loops 
was confirmed by the crystallographic data on the AChBP (Brejc et al., 2001), where the 
principal (+) side contributes true loops, whereas the complementary (-) side contributes β 
strands.  
AChBP lacks the transmembrane and intracellular domains but shares 15-20% sequence 
identity with other Cys-loop receptors (Sixma and Smit, 2003; Sixma, 2007). Despite the low 
homology, AChBP has been used to model the binding site as it can bind agonists, toxins and 
competitive antagonists (Karlin, 2002; Sixma and Smit, 2003; Ulens et al., 2006).  
Each AChBP subunit (Brejc et al., 2001) consists of 10 β-strands, with an outer sheet formed 
by four strands (β4, β7, β9, and β10) and an inner sheet located towards the central formed of 
a six strands (β1, β2, β3, β5, β6, and β8). This structure is conserved in other receptors 
including α1 muscle ACh subunit (Dellisanti et al., 2007), ELIC (Hilf and Dutzler, 2008), 
GLIC (Hilf and Dutzler, 2009) and GluCl (the most relevant for GlyR, Hibbs and Gouaux, 
2011).  
The ligand binding sites for homomeric and heteromeric GlyRs were investigated using 
electrophysiological and molecular modelling techniques (Grudzinska et al., 2005). They 
suggested that the α-amino and α-carboxylate groups of bound glycine interact with two 
oppositely charged residues located on the principal and the complementary sides of all the 
GlyR subunits. These residues are R65 and E157 in loop D and B of the α1 subunit and the 
homologous residues R86 and E180 in the β subunit (Grudzinska et al., 2005). 
 
All the Cys-loop receptors contain aromatic residues that are believed to form a cation-π 
interaction with the ligand. The cation-π interaction in Cys-loop receptors can be provided by 
different aromatic side chains (Trp, Phe, or Tyr) (Beene et al., 2002; Lummis et al., 2005; 
Pless et al., 2008; Xiu et al., 2009; Hibbs and Gouaux, 2011). The aromatic box is formed by 
these aromatic side chains that are located in the three loops on the principal subunit. 
Similar to all Cys-loop receptors the glycine binding site is lined with aromatic residues. 
There is a strong cation-π interaction of α1 F159 GlyR with glycine.   This was proved by 
41 
 
incorporating a range of fluorinated phenylalanine derivatives by using unnatural amino acid 
mutagenesis (Pless et al., 2008). Glycine and the partial agonists β-alanine and taurine 
compete for the same binding site (Schmieden et al., 1992; Schmieden and Betz, 1995). 
Weaker cation-π interactions were found with the lower efficacy agonist β-alanine and 
taurine than for glycine (Pless et al., 2011).  
A homology model of homomeric hGlyR based on GluCl from Caenorhabditis elegans was 
used to investigate the binding site for glycine and strychnine (Yu et al., 2014). The model 
suggested the presence of a water molecule in the binding site and added to the ligand 
receptor interactions a glycine interaction with S129 residue in loop E. Also, the model 
suggested that strychnine binding induces a conformational state different from the glycine-
bound or apo states, within both the ligand binding domain and the TM domain. 
1.10 Channel activation: from the binding site to the TM domain 
The picture that we have of activation is inferred by comparison of the different structures. 
The most marked movement for agonist binding involves C-loop that is made up of β strands 
9 and 10 and therefore connected to pre-TM1. The inward movement of the C-loop traps the 
agonist inside the pocket (Celie et al., 2004; Gao et al., 2005; Hansen et al., 2005). In the 
absence of agonist the C-loop is uncapped (Unwin, 2005) and it moves outwards in the 
presence of antagonist (Bourne et al., 2005; Hansen et al., 2005). Similar evidence loop C 
changing position is also suggested by GluCl structure (Hibbs and Gouaux 2011). 
 
The interface between the EC domain and TM domain is formed by several loops and the pre 
TM1 region between β10 and TM1. Thus the bottom of the ECD comprises loop 2 (between 
β1 and β2), the Cys-loop (loop 7), and loop 9 (between β8 and β9) (Grosman et al., 2000a; 
Rovira et al., 1999; Lee and Sine, 2005). A progressive isomerization begins from the 
neurotransmitter site high in the ECD spreading to the EC/TM domains interface and then to 
the TM domains.  
 
The opening of the pore is not completely understood. It is thought to involve tilting of the  
TM2 helices outwards as suggested by functional mapping of the TM2 (Grosman et al., 2000; 
Cymes and Grosman, 2005; Purohit et al., 2007; Calimet et al., 2013; Sauguet et al., 2014a). 
During channel activation TM2 moves first to open the channel resulting in increasing the 
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channel diameter and the retraction of the TM2 towards TM1 and TM3 (Miyazawa et al., 
2003; Unwin, 2005). 
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Figure  1.5 The extracellular and transmembrane domains 
A) A single GluCl subunit viewed from two different angles (adapted from Hibbs and 
Gouaux, 2011). The Cys-loop and the loop C disulphide bonds are shown as spheres. B) 
Interface of ECD of 2 adjacent subunits. The outer β sheet of the green subunit form the 
principal side and the inner β sheet of the blue subunit form the complementary. C) Agonist 
binding site showing the principal loops (A, B, C) and the complementary strands (D,E,F,G). 
Images are based on the glutamate-bound Caenorhabditis elegans α GluCl crystal structure 
(Hibbs and Gouaux,2011), B and C adapted from Lynagh and Pless (2014). 
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Figure  1.6 Loop alignments of different Cys-loop receptors and related proteins 
Sequence alignment based on GluCl receptor showing principal and complementary 
sequences adapted from Hibbs and Gouaux, (2011). GluCl α (559559), C. elegans GluCl β 
(559561), human glycine α1 (119372310), human GABAA ρ1 (194097386), human 
GABAA α1 (38327554), human α7 nAChR (496607), L. stagnalis AChBP (14285341), A. 
californica AChBP (325296909), four ACh subunits from T. marmorata (α, β, δ, γ: 
213216, 39653645, 39653649, 39653647), human 5-HT3A (37514834),  GLIC (37523766) 
and ELIC receptor (169791754). Red lines represent loops that form the neurotransmitter 
site. Grey highlighted residues are involved in disulfide bonds and yellow highlighted 
residues are highly conserved residues. Grey lines identify the Cys-loop. 
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1.10.1 The transmembrane domain structure 
It has been known for a long time that TM2 from each subunit lines the channel pore, largely 
because of the effects of mutating residues within conductance and gating (Galzi et al., 
1992).  
Charged amino-acids are located at the beginning and the end of TM1, TM3, and TM4 
(Miyazawa et al., 2003). TM1 is in contact with the lipid environment and with TM2. It 
might participate in the signal transduction from the neurotransmitter binding site in the ECD 
to the TM2 as several mutations in the TM1 domain produced non-functional receptors or 
changed EC50 (Akabas and Karlin, 1995; Dang et al., 2000; Unwin et al., 2002; Miyazawa et 
al., 2003; Lobo et al., 2004; Cymes and Grosman, 2008). The lower end of the TM1 and the 
TM1-TM2 linker are likely to be exposed to the pore (Filippova et al., 2004).  
The channel gate is located in the middle of the TM2 domain (Figure 1.7; Miyazawa et al., 
2003, Unwin, 2005). A hydrophobic girdle is formed as a result of the interaction between the 
hydrophobic side chains of the 9’, 10’, 13’, 14’ residues of TM2 with the adjacent residues 
(e.g. 13’ with 14’) (Miyazawa et al., 2003). It was documented that disturbance of the 
hydrophobic girdle by substitution of a 9’ leucine residue  with a hydrophilic residue (serine, 
S or threonine, T) tends to produce spontaneous activity as demonstrated for neuronal 
nicotinic receptor (Revah et al., 1991) and for the muscle nicotinic receptor (Labarca et al., 
1995) and for the glycine receptor (Burzomato et al., 2003). 
The narrowest part of the open channel is at the intracellular side (-2’). Based on the NMR 
structure of the TM of the human glycine α1 receptor, the TM2 is formed by residues from -
2’ to 18’ (Mowrey et al., 2013).   The selectivity filter was proposed to be provided in the -2 
to 2 region  (Imoto et al., 1988; Corringer et al., 1999; Keramidas et al., 2004; Hibbs and 
Gouaux, 2011).  The estimated diameter for GABAA and GlyR pore is 5.2-6.2 Å (Bormann et 
al., 1987; Mowrey et al., 2013) and it is bigger than the estimated value for GluCl 4.6 Å 
(Hibbs and Gouaux, 2011). TM3 and TM4 shield TM2 from the lipid bilayer.  
Another part that has a role in the conformational change is the extracellular TM2-TM3 loop. 
It is part of the interface between the ECD and the TMD (Lynch et al., 1997). Mutations in 
this region disturb channel function (Rajendra et al., 1994; Lape et al., 2012) and cause 
hyperekplexia in man (Shiang et al., 1993; Elmslie et al., 1996). 
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1.10.2 Intracellular domain 
Five amino acids form the TM1-TM2 loop of the glycine α1 receptor. This loop might be 
involved in the binding gating signal transduction (Lynch et al., 1997; Czajkowski, 2005). 
The intracellular domain between TM1 and TM2 is involved in zinc potentiation of GlyRs 
(Lynch et al., 1998) and in desensitisation (Saul et al., 1999).  The main intracellular domain 
(ICD) is formed by the TM3-TM4 loop and is poorly conserved in sequence and length 
across the Cys-loop receptors (Le Novere and Changeux, 1999, 2005). Homologous receptors 
in bacteria have a very short heptapeptide in this position (Bocquet et al., 2007; Hilf and 
Dutzler, 2008). The ICD is involved in intracellular modulation by internal molecules and is 
thought to interact with kinases and phosphatases (Lynch, 2004). Such interactions can 
modulate receptor assembly and trafficking (Meyer et al., 1995; Kneussel and Betz, 2000; 
Kneussel and Loebrich, 2007; Melzer et al., 2010). 
The gephyrin binding domain is located in the TM3-TM4 loop of the β subunit. These 18 
amino-acid residues are required for interaction with gephyrin favouring receptor clustering 
and anchoring to synapses (Meyer et al., 1995; Kneussel and Betz, 2000; Kneussel and 
Loebrich, 2007). 
Unwin’s data (Unwin, 2005) show that the intracellular domain is in part composed of an α-
helical segment within the intracellular TM3–TM4 loop (called the membrane-associated 
helix, MA) which precedes TM4. The MA helices from each subunit form a pentagonal cone 
structure with similar size fenestrations between adjacent subunits. These openings allow ions 
to pass into and out of the intracellular vestibule. The maximum width of the window is 
suitable for sodium, or potassium ion passage in cation-selective LGICs and Cl‾ in anion 
selective channels. These fenestrations prevent passage of larger ions and provide the only 
pathway for the passage of ions to and from the cytoplasm. The role of the intracellular 
domain in conductance will be discussed below.  
1.10.3 The pore: selectivity and conductance 
It is has long been thought that in Cys loop receptors rings of charged residues in the channel 
pore are the main determinants of the ionic selectivity and conductance, as was shown by 
early work on the AChRs (Imoto et al., 1988; Imoto, 1993; Konno et al., 1991, reviewed in 
Peters et al., 2010).   
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The -2/2 region of the channel pore has been proposed to act as charge selectivity filter in the 
Cys-loop receptors Figure 1.7 (Imoto et al., 1988; Corringer et al., 1999; Keramidas et al., 
2004; Hibbs and Gouaux, 2011). For anion permeation the key residues are -1' Ala and -2' 
Pro and for cations -1' Glu (Thompson et al., 2010; Sunesen et al., 2006; Hibbs and Gouaux, 
2011).  Thus, a cation-selective receptor such as α7 neuronal can be converted into an anion-
selective receptor by mutating particular residues and vice-versa (Galzi et al., 1992). 
Conversion of ion selectivity can be achieved for α homomeric GlyRs by the mutation 
A251E (-1') GlyR (Keramidas et al., 2002). 
The M1-M2 loop, which is composed of five amino acids, might have a role in ion selectivity 
as indicated by substituted cysteine accessibility data (Keramidas et al., 2000; Filippova et 
al., 2004).  
TM2 domain is the major determinant of ion selectivity and conductance in the Cys-loop 
receptors (Cohen et al., 1992a, b; Imoto et al., 1991; Labarca et al., 1995). 
Single channel conductance of the nAChR of Torpedo californica is determined by three 
rings of negatively charged residues. These rings include the extracellular (20'), the 
intermediate (-1') and cytoplasmic ring (-4') (Imoto et al., 1988; Langosch et al., 1994; Wang 
et al., 1999; Moorhouse et al., 2002). Ion conduction and selectivity for the anion selective 
GABAA and GlyRs is determined by a ring of positive charge at the extracellular end of the 
channel (19') and at the intermediate ring (0') (Keramidas et al., 2004). There are additional 
key residues for anion/cation selective permeability.  For anion permeation these are -1' Ala 
and -2' Pro and for cations  -1' Glu (Thompson et al., 2010; Sunesen et al., 2006; Hibbs and 
Gouaux, 2011) (Figure 1.7).  
 
The ionic permeability can be switched from cationic to anionic for nAChRs and 5-HT3Rs by 
mutating residues that are the same between nAChRs and 5-HT3Rs but different from α1 
GlyR and α1 GABAA. This includes alteration of three residues: the point mutations V13ʼT 
and E-1ʼA, and proline residue insertion between G-2ʼ and E-1ʼ (Corringer et al., 1999; 
Gunthorpe and Lummis 2001). The permeability of α1 GlyR can be made cationic by the 
analogous reverse triple mutations A-1Eʼ, T13ʼV, P-2ʼΔ (Keramidas et al., 2000, 2002). 
 
All the Cys-loop receptors have different sequence and length of the large intracellular M3-
M4 loops. Prokaryotic members of the nicotinic superfamily have a very short M3-M4 
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domain, but in all the others  the TM3-TM4 loop exceeds 70 residues, a length that was found 
vital for their portal-associated function (Baptista-Hon et al., 2013). 
Recently, regions other than the TM2 domain were found to have a role in ion conductance 
including the TM3-TM4 and the extracellular domain (Peters et al., 2010). The TM3-TM4 
can have an effect on conductance because of its shape. As shown by  
Unwin’s data the narrow diameter fenestrations or portals between adjacent subunits (8Å in 
the closed Torpedo nicotinic ACh receptor) prevent large ion passage and facilitate cation ion 
transport. By this way the intracellular fenestrations contribute to the conductance is most 
affected of the channel (Unwin, 2005).  
This was confirmed by mutations in this region (Kelley et al., 2003; Peters et al., 2004; Hales 
et al., 2006; Carland et al., 2009). A series of 5-HT3A/3B chimeras and 5-HT3A receptor 
mutagenesis work suggested that residues within the MA-stretch contribute to cation 
conductance. The cytoplasmic loop of 5-HT3 receptors is partly responsible for the difference 
in the conductance of homomeric 5-HT3A vs heteromeric 5-HT3AB channels. For instance 
mutations of three conserved positively charged arginine residues within the MA-stretch of 
the human 5-HT3A subunit (R432, R436 and R440) caused a ~28 fold increase in single-
channel conductance for the triple mutant (Kelley et al., 2003; Peters et al., 2004 and 2005). 
This cytoplasmic region, within the MA-stretch, also contributes to regulating the single-
channel conductance of α1 homomeric glycine receptors, indicating that the portals for ions 
accessing the channel from the cytoplasm have a similar role in cationic and anionic pLGICs 
(Carland et al., 2009). This was suggested based on the effect of charged residues within MA 
stretch on channel conductance of homomeric GlyR (Carland et al., 2009). Mutation of eight 
basic residues each to a negatively charged glutamate produced a non-functional receptor. 
The major influence on conductance was observed at R377, K378, K385, and K386 residues 
(Carland et al., 2009).  
ECD can also affect the conductance. A negatively charged residue in loop 5 of the ECD of 
the cation-permeable α1Torpedo nACh nicotinic receptor was found to affect ion 
conductance (Hansen et al., 2008). Similarly, the conductance of glycine receptor is 
influenced by a positively charged residue (Moroni et al., 2011a) in the same domain. The 
conductance of glycine α1 homomeric and α1β heteromeric receptor is increased by 
positively charged Lys residues in loop 5, a position homologous to α1 Torpedo Asp 97 
(Moroni et al., 2011a). Reversing the charge into negative Glu in the α subunit (K104E) 
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decreased the single-channel conductance. The effect on conductance is dependent on the 
subunit, as mutating β subunit (K127E) produced no effect (Moroni et al., 2011a).  
The type of the residues that are along the ion flow pathway from the extracellular domain to 
the intracellular domain passing within the TM2 pore affect the single-channel conductance. 
However, the main determinant of conductance of glycine receptor is the TM2 domain.  
Heteromeric GlyR has lower single channel conductance and different channel kinetic than 
the homomeric receptor (Lynch, 2009). For GlyRs single-channel experiments have shown 
that heteromeric α1β GlyRs have approximately half the single-channel conductance of 
homomeric α1 receptors with channel amplitude of 4.7 ± 0.1 and 3.1 ±0.1 pA for homomeric 
and heteromeric channels at +100 mV holding potential, respectively (Burzomato et al., 
2003; Beato et al., 2004). This difference in single-channel conductance is determined by 
residues within and close to the TM2 domain and this was confirmed by co-expression of α1 
subunit with mutant β subunits. Mutating TM2 residues in the β subunit to corresponding 
residues of the α1 subunit, such as β E290Q (14 ʼ) and β E297S (21ʼ) produced a range of 
conductances similar to α1 subunit conductance. 
The only non-conserved residue within the TM2 domain of α1, α2, and α3 subunits of GlyR 
is 2ʼ gly in α1 and ala in α2, and α3 subunit (Figure 1.7). So in order to determine the main 
state conductance difference of α1 vs α2/α3 homomeric GlyRs, G221 was mutated from 
glycine into alanine. Mutating residue G221 in this domain was shown to modify the single-
channel conductance of the α1 homomeric GlyRs. The main state conductance of G221A α1 
GlyR was similar to α2/α3 conductance. This indicates that the TM2 G221 residue 
determines the main conductance in homomeric GlyRs (Bormann et al., 1993).  
Depending on the recording configuration a number of different conductance levels can be 
observed in a patch. While recordings in the cell-attached configuration show practically only 
one conductance level, regardless of the receptor subtype (Beato et al., 2004; Burzomato et 
al., 2004; Beato and Sivilotti, 2007), GlyRs are found to open to different conductance levels 
in recordings performed using excised patches. This difference in conductance levels was 
shown for both recombinant (Bormann et al., 1993; Beato et al., 2002) and native GlyRs 
(Bormann et al., 1987; Takahashi and Momiyama, 1991; Twyman and MacDonald, 1991). 
 
50 
 
 
 
Figure  1.7 TM2 of several Cys-loop receptors. 
Alignment of different Cys-loop receptor TM2 domains. The boxed parts indicate residues 
lining the channel lumen. The structural model shows the TM2 of open GLIC (green and 
blue) and closed ELIC (pink and red). Adapted from Smart and Paoletti (2012). 
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1.11 A quantitative mechanism for the activation of GlyR 
In order to activate ligand-gated ion channels must bind agonist/neurotransmitter and go 
through conformational changes that open the pore.  These steps can be characterised 
quantitatively by defining activation mechanisms. Del Castillo and Katz postulated the first 
mechanism on frog endplate nicotinic receptor in 1957 (Scheme 1.1, R stands for receptor 
and A for ligand; Del Castillo and Katz, 1957). Their simple mechanism provided the first 
basic framework for interpreting differences in agonist efficacy. In this mechanism, the 
channel can exist in three different states, closed R, or AR (e.g. unliganded and liganded), or 
open AR*. Resting (R) closed-channel state occurs in the absence of the agonist and the other 
state (AR) occurs once the agonist binds but has not activated the channel. The AR* state is 
open. The transition rate constants names are shown near the arrows. In the del Castillo-Katz 
mechanism, the sensitivity of the receptor for the agonist is determined by the equilibrium 
dissociation constant for binding KA (ratio between k-1/k+1) and by the equilibrium constant 
for conformational change, E efficacy (ratio between β and α, β is opening, α is closing), 
which varies for different agonists and different receptors (Colquhoun, 1998). The EC50 
expression from del Castillo-Katz is shown in equation 2. For muscle nicotinic and glycine 
receptors two or three agonists must bind to open the channel with maximum efficacy 
reaching an opening probability of more than 95%. The expression for maximum Popen in del 
Castillo-Katz mechanism is illustrated in Equation 3. 
 
 
 
 
 
Equation 1 
Equation 2 
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The del Castillo-Katz mechanism is very simple and it is now clear that its features are not 
sufficient fully to describe the function of Cys-loop channels. Model fitting techniques 
allowed detection of intermediate states following agonist binding and before channel 
opening. The channel is still closed in these states but its affinity has increased from the 
resting state (Burzomato et al., 2004, Mukhtasimova et al., 2009, Jadey and Auerbach, 2012). 
Burzomato et al., 2004 postulated the flip mechanism in order to interpret the single-channel 
activity of heteromeric α1β GlyR (Scheme 1). In this scheme, an additional shut state was 
postulated before channel opening. This state is thought to represent an intermediate when the 
agonist is bound to the ECD, which has changed its conformational state so that the affinity 
for the agonist has increased, but the conformational changes have not yet reached the 
channel gate. The flip mechanism was postulated to explain the activation mechanism of 
several glycine receptor isoforms including glycine receptor α1 homomeric and heteromeric 
(Burzomato et al., 2004), α2 (Krashia et al., 2011), α3 (Marabelli et al., 2013). It was also 
used for describing the action of partial agonists on both glycine and muscle ACh nicotinic 
receptors (Lape et al., 2008). 
Analysis with these mechanisms has proven useful to understand why a partial agonist is less 
effective than the full agonist.  In the del Castillo-Katz mechanism, it is simply because 
partial agonists have small open-shut equilibrium constant E. In the flip model, the overall 
agonist efficacy depends on two parameters, the equilibrium constant for flipping (F) and the 
equilibrium constant for the open-shut reaction (E). The effective efficacy (Eeff) for the fully 
liganded receptor is  
 
 
So the partial agonist could be partial either because it is poor at producing the initial change 
(flipping) (low F), or because it is poor at opening the channel (low E) or both.  Analysis of 
the effects of glycine and taurine on the heteromeric GlyR by Lape et al. (2008) showed that 
the gating equilibrium constant (E) is similar for glycine (full agonist) and taurine (partial 
Equation 3 
Equation 4 
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agonist; about 50% maximum open probability).  The difference is therefore in the flipping 
equilibrium constant (F). Similar results were obtained for the effects of ACh, TMA and 
choline on the muscle nicotinic receptor (Lape et al., 2008; Lape et al., 2009).  
 
 
Scheme 1 
Scheme 1: “Flip” mechanism. The single-channel activity of several glycine receptor 
isoforms are describes well by the Flip mechanism (Burzomato et al., 2004; Lape et al., 
2008; Krashia et al., 2011; Marabelli et al., 2013; Lape et al., 2008). The scheme postulates 
the existence of additional shut states (‘flipped’) in addition to the open and closed states. 
Flip represents a conformational change that precede channel opening (Burzomato et al., 
2004). The scheme has 3 binding sites. An agonist molecule is presented as letter A. The 
number of agonist molecules that are bound to the receptor are indicated by letter A subscript. 
The resting closed-channel state is presented as R. The letter F denotes flip conformation in 
which the channel is closed but with higher binding affinity than in the rest state. F* denote 
open-channel state of the receptor. 
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1.12 Statement of purpose: 
My work aims to expand our knowledge of the structure function relation of the GlyR. The 
data presented includes the study of several human hyperekplexia mutations. Whole-cell 
recordings and single-channel recordings were used with different agonists to understand the 
function of the hyperekplexia mutated residues. The knowledge obtained here can be 
expanded to other Cys-loop family members. 
Aim 1 
Initial screening of several known human hyperekplexia mutations were conducted on both 
homomeric and heteromeric GlyRs by whole-cell patch-clamp to obtain macroscopic 
concentration-response curves for glycine. The purpose of this was to establish which of the 
mutations could be further studied by single channel recording. Mutants with low levels of 
expression or extreme loss of function, could not be further characterised.  Where possible I 
obtained single channel measurements of the maximum open probability in the presence of 
saturating glycine, in order to establish which mutants impaired channel gating.   
Aim 2 
When a mutation impairs gating, it is possible that allosteric modulators that enhance gating 
can offset the effect of the mutation and rescue the reduction of the GlyR gating function. 
The general anaesthetic, propofol, was selected as a modulator. Indeed we found that the 
reduction in glycine gating can be improved in α1(S267N)β heteromeric GlyR mutation by 
propofol.   
Aim 3 
From an homology model based on the structure of GluCl, two residues at the back of the 
binding site, a negatively charged glutamate at 103 (α1 E103) position and an arginine at 131 
(α1 R131) position were postulated to form a salt bridge. The effect on agonist sensitivity of 
of mutating these residues singly, or together, was assessed.  
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Chapter 2: Methods 
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2.1 Plasmid cDNA 
Human GlyR subunits α1 (UniProt accession number P23415) and β (UniProt Accession 
number P48167) were contained as cDNA in the vector pcDNA3.1 (Invitrogen, The 
Netherlands) and were kindly provided by Heinrich Betz, Frankfurt. The vector has a total 
size of 5.4 kb and contains the following elements (Figure 2.1, 2.2): human cytomegalovirus 
(CMV) promoter, T7 promoter, multiple cloning sites, bovine growth hormone (BGH) 
polyadenylation signal sequence, a neomycin and ampicillin resistance genes.   
For the identification of transfected cells the enhanced Green Fluorescent Protein (eGFP) was 
expressed with the plasmid peGFP (Clontech, UK). 
 
 
Figure  2.1 The human glycine receptor α1 (hGlyR α1)/pcDNA3 plasmid. 
Cytomegalovirus (CMV) promotes high-level expression of the α1 receptor in the expression 
system (HEK293 cells). There is also the T7 promoter which is followed by multiple cloning 
sites in the forward, or reverse orientation, that permit insertion of the selected gene. The 
prokaryotic promoter Sp6 is also indicated. Ampicillin and neomycin coding sequence 
resistance genes are shown. 
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Figure  2.2 The human glycine receptor β (hGlyR β)/pcDNA3 plasmid. 
Cytomegalovirus (CMV) promotes high-level expression of the β subunit in the expression 
system (HEK293 cells). There is also the T7 promoter which is followed by multiple cloning 
sites in the forward, or reverse, orientation that permit insertion of the selected gene. The 
prokaryotic promoter Sp6 is also indicated. Ampicillin and neomycin coding sequence 
resistance genes are shown. 
2.2 Mutagenesis 
Single point mutations were introduced into the wild-type human GlyR α1 subunit using the 
site-directed mutagenesis protocol (QuikChange™ Site-Directed Mutagenesis Kit, 
Stratagene). Vector with insert of interest and two oligonucleotides primers containing the 
desired mutation (see primer design) were used. The PCR reaction was divided into two 
steps. In first step the forward and the reverse primers were in separated PCR tubes. After 
five cycles of PCR run, the two reaction mixtures were combined and the PCR was 
continued.  The PCR reaction included the following with the final concentration distilled 
water (dH2O), 10x PCR buffer, deoxynucleoside triphosphates (dNTP; 200 μM each, DNA 
template (α1 GlyR vector at 100 ng), forward and reverse primers (each 0.5 μM), and 
PfuTurbo® DNA polymerase (1.25 U). The PCR amplification reaction was repeated for 30 
cycles. For double mutations, one mutation was inserted first and then this was used as 
template for the double mutant. Temperature cycling was done using a thermocycler 
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(PcrExpress HYBAID). The DNA template denatured at 95°C followed by annealing of the 
oligonucleotide primers containing the desired mutation at 55°C. PfuTurbo® DNA 
polymerase (Stratagene) extended the primers at 68°C. This produced a mutated plasmid with 
staggered nicks. Parental wild-type plasmid was removed by digestion with Dpn I (New 
England Biolabs) as it is specific for methylated and hemimethylated DNA. The nicked 
circular vector DNA is transformed to E.coli where the nicks were repaired and the plasmid 
was amplified.  
2.3 Primer design 
Primers for site-directed mutagenesis were designed with the desired mutation in the middle 
and each primer was complementary to opposite strands of the vector. They were 25- 45 
bases in sequence length and their melting temperature (Tm) was greater than, or equal to, 
78ºC. Also, the primers ended with at least one C or G bases and they had a minimal GC 
content of 40%. The PCR primers were designed by using PrimerX web-based program: 
http://bioinformatics.org/primerx/. Primers were synthesized by Eurofins (Ebersberg, 
Germany). A list of used primers in this study is shown in Table 2.1.   
Table  2.1 Sets of primers used in this study 
α1 GlyR 
Mutation  
Forward primer Reverse primer 
R72H GCAGCAATGGAACGACCCCC
ACCTGGCCTATAATGAATACC 
GGTATTCATTATAGGCCAGGTGGG
GGTCGTTCCATTGCTGC 
E103K CCTGTTCTTTGCCAACAAGAA
GGGGGCCCACTTCC 
GGAAGTGGGCCCCCTTCTTGTTGGC
AAAGAACAGG 
E103R CTGTTCTTTGCCAACCGGAAG 
GGGGCCCACTTC 
GAAGTGGGCCCCCTTCCG GTT 
GGCAAAGAACAG 
E103A CTGTTCTTTGCCAACGCGAAG 
GGG GCCCACTTC 
GAAGTGGGCCCCCTTCGCGTTGGC 
AAAGAACAG 
R131E GTCCTCTACAGCATCGAA ATC 
ACCCTGACACTG 
CAGTGTCAGGGTGATTTCGAT GCT 
GTAGAGGAC 
S231N CAGATGTATATTCCCAACCTG
CTCATTGTCATC 
GATGACAATGAGCAGGTTGGGAAT
ATACATCTG 
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Q266H GCTCACCATGACCACCCACAG
CTCCGGCTCTCGAG 
CTCGAGAGCCGGAGCTGTGGGTGG
TCATGGTGAGC 
S267N GCTCACCATGACCACCCAGAA
CTCCGGCTCTCGAGCATCTC 
GAGATGCTCGAGAGCCGGAGTTCT
GGGTGGTCATGGTGAGC 
Y279C CTGCCCAAGGTGTCCTGTGTG
AAAGCCATTGAC 
GTCAATGGCTTTCACACAGGACAC
CTTGGGCAG 
 
2.4 Transformation of competent cells 
Luria Broth (LB) agar plates were used for overnight growth of the vector with the desired 
mutation. They were prepared by first dissolving 10 g of LB broth base and 10 g of Agar 
(Invitrogen, UK) in distilled water to a final volume of one liter. The solution was then 
autoclaved for 20 minutes at 121 °C. Once it cooled down to a temperature that permits to 
hold the container by hand, an antibiotic (50 μg/ml kanamycin for peGFP plasmids or 100 
μg/ml ampicillin for pcDNA3.1 plasmids) was added and the solution was poured into 100 x 
15 mm petri dishes with lid (Nunclon™ Delta Surface) (~20). Plates were allowed to stand to 
cool down at room temperature and then stored in upside down position at 4ºC until use. 
Competent E.coli cells were thawed on ice for 15 minutes after being stored at −80ºC. 60 μl 
of the competent cells were transferred into a 1.5 ml Eppendorf tube and plasmid DNA (1 ng 
in case of retransformation of a plasmid or about 10 µl of PCR product after mutagenesis 
PCR) was added and incubated on ice for 30 minutes. After heat shock (45 seconds at 42ºC), 
the cells were immediately transferred into ice and kept on ice for 2 minutes. Then, 900 μl of 
super optimal broth (S.O.C, Invitrogen) medium was added and the cells were grown shaking 
for one hour (300 r.p.m) at 37ºC in a thermomixer (Eppendorf, UK). Meanwhile, plates were 
warmed in the incubator at 37  C. On each plate 100 μl of transformant cells were plated and 
incubated in the upside down position overnight at 37   C. 
The next day, one to three colonies per plate were selected, touched with Eppendorf pipette 
tip and allowed to grow overnight at 37ºC shaking at 220 rpm in a tube containing 2 ml (or 
250 ml in case of large scale preparation) of LB medium with 100 μg/ml ampicillin. After 
that, purification of high yields of plasmid DNA was done by using the Miniprep kits 
(QIAGEN Plasmid Mini Kit) according to their respective protocols. After checking DNA 
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purity and concentration, a sample was sent for sequencing of the full open frame (Wolfson 
Institute for Biomedical Research, London UK) to make sure that only the desired mutation 
was introduced. Then, if the mutagenesis had worked well, large scale preparation was 
carried out (QIAGEN Plasmid Maxi Kit).  
2.5 Culture and transfection of HEK293 cells  
2.5.1 Cell culture maintenance 
Human embryonic kidney 293 cells (HEK293) (American Type Culture Collection (ATCC)) 
were grown at 37 °C in a humidified 95 % air/5 % CO2 incubator in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10 % v/v heat-inactivated fetal bovine serum, 
100 U/ml penicillin G, 100 μg/ml streptomycin sulfate and 2 mM L-glutamine (all from 
Invitrogen). Cells were passaged every 2-3 days, up to 20 times. For this, the cells were first 
washed with Hank’s balanced salt solution (HBSS) and then exposed to 1 ml of 0.05% (w/v) 
trypsin (Invitrogen) for a brief time (30-40 s) at 37°C to detach them from the flask surface. 
Cells were then collected in 4 ml of fresh DMEM and centrifuged for 2-4 min (1000 rpm, 
157g). The supernatant was discarded and the pellet was resuspended with 1 ml of DMEM by 
gentle pipetting. A small volume of the cell suspension, according to the required dilution, 
was added to a new flask containing 5 ml growth medium.  
2.5.2 Transfection 
Cells were grown on glass coverslips coated with poly-L-lysine (Sigma-Aldrich). Coating of 
the coverslips (13 mm) was accomplished by incubating the coverslips for ~30 minutes with 
0.01% (w/v) poly-L-lysine (Sigma-Aldrich, UK), washing with distilled water and then 
autoclaving for 20 minutes at 121˚C. On the day of transfection, HEK293 cells were plated 
onto the coverslips and placed in 35 mm culture dishes with 2 ml growth medium. The 
plating density for whole cell experiments was lower than for single channel recording. 
Expression of the ion channel of interest was achieved by transfection of HEK293 cells using 
the Ca
2+ 
-phosphate co-precipitation method (Groot-Kormelink et al., 2002). In order to 
promote heteromeric formation of GlyR α1β, the transfection was made at a plasmid DNA 
ratio of 40- fold excess of β to α (Burzomato et al., 2003). Enhanced green fluorescent 
protein (eGFP) (Clontech, UK) was used as transfection marker. A mixture of plasmids was 
prepared for transfection containing pcDNA3.1 with α1 or β GlyR coding sequence, pEGFP-
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c1 and empty pcDNA3.1 vector. The purpose of adding empty vector is to obtain optimal 
level of receptor expression in each cell, while maintaining a high proportion of transfected 
cells.  A total of 3 μg complementary DNA (cDNA) (72 μl, DNA concentration 500 ng/ μl) 
was used per dish (Groot-Kormelink et al., 2002). In order to achieve best results, the 
proportion of the different plasmids within this total DNA was adjusted empirically. Details 
of the plasmid ratio used for optimal expression are shown in Table 2.2. CaCl2 solution (340 
mM in sterile water) was added to the DNA mix at a 1: 5 volume ratio. Precipitation of 
calcium phosphate was induced by adding an equal volume of 2x HBSS (280 mM NaCl; 2.8 
mM Na2HPO4; 50 mM HEPES, pH adjusted to 7.2 with NaOH) to the DNA/CaCl2 solution. 
The DNA mix solution was added dropwise to the petri dishes containing plated coverslips. 
Cells were then incubated overnight at 37°C in an 95% /air 5% CO2 atmosphere. They were 
then washed with HBSS (to remove the precipitate) and incubated in 2 ml of DMEM. Whole-
cell, or single-channel, recordings were performed at least 24 hours after the transfection. 
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Table  2.2 DNA mix used for patch clamp recordings. 
Receptor  α1 cDNA (%) β cDNA(%) EGFP (%) Empty Vector 
(%) 
Wild-type α1 5 - 25 70 
Wild-type α1β 2 80 18 0 
α1(R72H)  55 - 82 - 18-25 0 - 20 
α1(R72H)β 2 - 20 62 - 80 18  0 
α1(E103K)  55 - 25 20 
α1(E103K)β 2 80 0 18 
α1(E103A)  55 - 25 20 
α1(E103R) 55 - 25 20 
α1(E103R/R131E)  55 - 25 20 
α1(S231N)  55 - 25 20 
α1(S231N)β 2 80 18 0 
α1(Q266H)  55 - 25 20 
α1(Q266H)β 2 80 18 0 
α1(S267N)  55 - 25 20 
α1(S267N)β 2 80 18 0 
α1(Y279C)  55 - 82 - 18 - 25 0 - 20 
α1(Y279C)β 2 80 18 0 
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2.6 Whole-cell patch-clamp recording and analysis  
Whole-cell patch-clamp recordings were performed to obtain macroscopic current 
concentration-response curves for wild type or mutant GlyRs. For the recording a coverslip 
with transfected cells was placed in a chamber under an inverted microscope (Axiovert 135, 
Zeiss, Germany). The transfected cells were identified by their expression of eGFP; this was 
detected by exciting the fluorophor EXFO X-cite 120 light source, X-cite ®;  light with 
excitation 457 – 487 nm and bandpass filter 472 nm. Cells were continuously superfused with 
extracellular solution containing (in mM):  20 Na-gluconate, 112.7 NaCl, 2 KCl, 2 CaCl2, 1.2 
MgCl2, 10 HEPES, 10 tetraethylammonium-Cl (TEA-Cl), and 40 glucose. The pH of the 
solution was adjusted to 7.4 with NaOH; the osmolarity was ~320 mOsm/L. Borosilicate 
glass patch pipettes (with filament; outer diameter 1.5 mm; inner diameter 0.86 mm; Harvard 
Apparatus) were pulled on a Flaming-Brown type puller (Sutter Instrument, model P-97) and 
fire-polished with a microforge just before the recording to ensure gigaohm seal formation. 
Pipettes had a final resistance of 3-6 MΩ when filled with intracellular solution containing (in 
mM): 101.1 K gluconate, 11 EGTA, 1 CaCl2, 1 MgCl2, 10 HEPES, 20 TEA-Cl, 2 Mg ATP 
and 40 sucrose. Both the intracellular and extracellular solutions were filtered before use 
through 0.2 µm Whatman
TM
 cellulose nitrate membrane filters (GE Healthcare life sciences, 
Buckinghamshire, UK). The liquid junction potential was calculated to be 9 mV (Calculated 
using pClamp10; Molecular Devices) and no correction was done for it. Recordings were 
made at 19-21 °C with an Axopatch 200B amplifier (MDS Analytical Technologies, 
Molecular Devices, Sunnyvale, CA, USA). After achieving a strong seal, gentle suction was 
applied to rupture the cell membrane under the tip of the pipette. In the whole-cell 
configuration cells were voltage clamped at 50 mV pipette holding potential. Both series 
resistance (Rs) and cell membrane capacitance, Cm, were measured and were 7.26 ± 0.36 
MΩ and 22.85 ± 1.42 pF, respectively. Then, series resistance compensation was applied (60-
90%). Throughout the recording the Rs was monitored and if its value changed over than 
25% the recording was discarded. 
The drugs were applied onto the cells via a custom built ‘U-tube’ application system (Figure 
2.3; Krishtal and Pidoplichko, 1980). A thick-walled borosilicate glass capillary (Drummond) 
was used to prepare the U-tube. First, the capillary was bent to a U-shape while holding it 
over a flame. At the tip of the U-tube, a hole was made by applying positive pressure to the 
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inside of the tube, while heating the tip near a flame. The hole was polished using a Bunsen 
burner, to obtain smooth edges and a final diameter of 10-30 μm.   
During the experiment (see Figure 2.3), one end of the ‘U-tube’ was connected via a plastic 
tube to a vacuum pump, and the other end was connected to a tube immersed into a solution 
containing the drug. The pump was continuously sucking the drug solution into a collection 
jar. The cells were superfused at a rate of 2 ml/min by an independent bath perfusion system. 
In order to produce drug applications, the connection between the U-tube and the vacuum 
pump was interrupted, so that the drug solution was forced to flow into the bath. The ‘U-tube’ 
was positioned so that the flow from the hole was directed onto the patch-clamped cell. 
Before the start of each experiment, the rate of onset of the agonist application (exchange 
rate) was tested by applying 50% diluted extracellular solution. Applying the diluted solution 
to the open-tip pipette, changed the liquid junction potential at the pipette tip. The rate of 
these changes reflects the solution exchange rate at the recording pipette tip. The ‘U-tube’ 
was discarded if the 0-100% current onset was longer than 100 ms. 
Agonist was applied to the patched cells at 30-60 second time intervals. At the beginning of 
the experiment, the stability of the agonist response was checked by applying as a standard a 
saturating agonist concentration (Table 2.3) until a stable response was established. Then, 
different concentrations of agonist were applied in random order in order to obtain a full 
concentration-response curve. The standard saturating agonist concentration was applied 
every third response to check the stability of the responses. Recordings were discarded if 
there was run up, or run down, greater than 30%.   
Recordings were filtered using four-pole low-pass Bessel filter of the amplifier set at 5 kHz,  
digitized at sampling rate of 20 kHz (Digidata 1332A, Molecular devices) and acquired on a 
PC (Clampex 10.2, MDS Analytical technologies). Recorded current amplitudes were 
measured with Clampfit 10.2 software.  
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Figure  2.3 Dual application system used for the whole-cell experiments. 
For whole-cell recordings, U-tube application of different concentrations of ligands to the cell 
was used (not to scale). The perfusion system consisted of three tubes.  One provided 
continues flow of the extracellular solution to the recording chamber and other immediately 
sucked the solution to a waste compartment. The third was an U-tube application system and 
it was controlled manually. It provided continuous suction of the ligand solution but once the 
suction of the U-tube is switched off briefly (1-2 seconds), the solution will leak through a 
hole in the U-tube, applying the ligand solution onto the cells.  
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Table  2.3 Standard saturating concentrations of agonists used for whole-cell 
experiments. 
Receptor Glycine (mM) β-alanine (mM) Sarcosine (mM) 
Wild-type α1 10 - - 
Wild-type α1β 5, 10 50 - 
α1(R72H)  20 - - 
α1(R72H)β 20, 100 - - 
α1(E103K)  20 100, 300 300 
α1(E103K)β 50, 100 100, 200 - 
α1(E103R)  100, 200 - 200 
α1(E103A)  100 - 100 
α1(S231N)  20, 50 - - 
α1(S231N)β 20, 50 100 - 
α1(Q266H)  20, 50 - - 
α1(Q266H)β 20, 50 - - 
α1(S267N)  20, 50 - - 
Α1(S267N)β 20, 50 - - 
α1(E103R/R131E)  50 - 300 
α1(Y279C)  50 - - 
Α1(Y279C)β 20 - - 
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2.6.1 Concentration-response curves  
For each cell, the first task in the analysis was to assess the stability of agonist responses 
during recording (run up/down).  Cells were accepted for analysis only if there was minimal 
change in the amplitude of responses to a standard concentration of agonist.  Typically, a 
saturating concentration of ligand was used as a standard. This was applied two, or three, 
times at the start of the recording and then every third application (see Figure 2.4). A typical 
concentration-response curve took approximate ten minutes length..  The cell was discarded 
if its response to the standard changed more than 30 % during 10 minutes from the stable 
standard during the experiment.  Figure 2.4 shows a typical run of standard responses (in this 
example 20 mM glycine) in a cell expressing α1(S267N)β heteromeric GlyR.   
 
 
Figure  2.4 Representative example of run up/down in the α1(S267N)β heteromeric GlyR 
mutation. 
The plot is showing almost stable standard glycine responses over nine minutes of recording.  
The dimonds are representing only the responses to the standard saturating agonist 
concentration (in this case 20 mM glycine). The standard was applied twice in the beginning 
then applied every third application of different concentrations of glycine (not shown).  
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After checking the stability of the current response, data from each cell was fitted separately 
with the Hill equation: 
       
[ ]  
([ ]       
    )
 
This is a high ‘co-operativity’ model.  I is the measured current, Imax is the maximum current, 
[A] is the agonist concentration, nH is the Hill coefficient, and EC50 is the agonist 
concentration needed to achieve 50% of the maximum response. The CVFIT program 
(http://www.ucl.ac.uk/Pharmacology/dcpr95.html) was used to estimate Imax, EC50 and nH 
values. Curves were only accepted if a “poorly defined data” message does not show. This 
occurs when the estimates are highly correlated (> 0.9) or if the coefficient of variation (CV) 
is less than 33%.   
The accepted concentration-response curves from each cell were normalised to their fitted 
maximum. Then, the normalized data sets were pooled and refitted as one set for each 
receptor, wild-type, or mutant. Figure 2.5 shows an example of the analysis process, in four 
cells expressing α1 (S231N) β GlyR. In the tables data are presented as mean (of estimates 
from fitting each cell) ± standard error of the mean (SEM).   
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Figure  2.5 Example of the whole-cell recording analysis using CVFIT. 
α1 (S231N) β heteromeric GlyR, EC
50
 = 3.81 ± 0.42 mM, n
H
 = 1.12 ± 0.06, n = 4 for 
normalized, pooled data. A) Each concentration-response curve was fitted to the Hill 
equation. B) Normalisation of glycine gated currents to the fitted maximum in each cell. C) 
Pooled normalized data (error bars show ± SEM). 
 
 
2.6.2 Propofol application 
In order to determine if propofol, an intravenous anaesthetic, can rescue the function of the 
heteromeric GlyR hyperekplexia mutants, maximal, or submaximal (EC20), glycine 
concentrations were applied via U-tube in the absence, or presence, of propofol. One molar 
stock of propofol (2, 6-diisopropylphenol) was dissolved in dimethyl sulfoxide (DMSO, both 
from Sigma-Aldrich). Stocks were stored at −20 °C and the desired concentrations were 
prepared fresh on the day of experiment. U-tube application of maximal and then submaximal 
glycine concentration was followed by propofol application. Two protocols of propofol 
application were tested. For the initial experiments propofol was co-applied via the U-tube 
with the submaximal, or maximal, glycine concentration. This method will be referred as co-
application method. The other protocol was propofol pre-application in the extracellular 
solution for around 30 seconds followed by the co-application protocol. This method will be 
referred as “pre-application followed by co-application” method. The second propofol 
application protocol was selected when applying propofol concentrations of 50 μM. There 
was no glycine receptor activation during the propofol pre-application period as there was no 
observed change in the holding current. Peak currents were measured for the applications 
with, or without, propofol. Fold change [(response to glycine + propofol) / response to 
glycine] was calculated for each cell. Average fold change ± SEM is displayed where 
relevant.  
70 
 
2.7 Single-channel recording  
Single-channel recordings were performed in the cell-attached configuration using an 
Axopatch 200B amplifier (MDS Analytical technologies, Molecular Devices, Sunnyvale, 
CA, USA). Borosilicate glass pipettes (thick-walled, with filament; Harvard Apparatus Ltd, 
USA) were pulled to a resistance of 7- 10 MΩ, when filled with the pipette solution (see 
below), and coated near the tip with Sylgard (Dow Corning, Midland MI, USA) to lower the 
noise level. Electrodes were also fire-polished before the experiment to enable the formation 
of giga-ohm pipette seals. Recordings were made at 19-21 C°. Pipette potential was held at 
+100 mV. The extracellular solution contained (in mM): 20 Na gluconate, 102.7 NaCl, 2 
KCl, 2 CaCl2, 1.2 MgCl2, 10 HEPES, 14 glucose, 20 TEA-Cl, and  15 sucrose, pH 7.4 with 
NaOH and osmolarity 320 mOsmol /L. Pipette solutions were freshly prepared by adding 
glycine to the extracellular solution to have the required concentration (0.1-100 mM).  In 
order to reduce contamination by ambient glycine, all solutions were prepared with high 
performance liquid chromatography (HPLC)-grade water (VWR international, France).  
Solutions were then filtered through 0.2 µm Whatman
TM
 cellulose nitrate membrane filters 
(GE Healthcare life sciences, UK) to remove impurities that may block the electrodes.  The 
bath level was kept as low as possible in order to maintain a high signal-to-noise ratio. After 
successful seal, noise level was monitored by checking the meter on the amplifier (IRMS, the 
noise is measured at 5 kHz bandwidth). The record was kept for analysis only if the patch had 
a noise level of 0.25 pA rms or lower.  
Currents were digitised directly to a computer hard drive, using 10 kHz prefiltering (by the 
amplifier’s 4-pole low-pass Bessel filter), a Digidata 1404A and Clampex 10.2 software 
(sampling rate 100 kHz, MDS Analytical Technologies, CA, USA).  In order to display data 
off-line, currents were low-pass filtered with the Gaussian filter in Clampfit 10.2 (MDS 
Analytical Technologies, CA, USA) at a cut-off frequency of 3 kHz. 
2.7.1 Single-channel analysis 
2.7.1.1 Amplitude measurements 
Amplitudes of single -channel currents were measured in order to characterise the 
conductance of the channel as both mutations and subunit composition may affect it. For each 
selected cluster the amplitude was measured using Clampfit 10.2 (MDS Analytical 
Technologies, CA, USA). After 3 kHz filtering, the mean baseline was selected by placing 
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two cursors apart from each other just before the cluster of interest (Figure 2.6.A) in order to 
subtract it from the cluster signal. The cluster of interest was then selected by placing one 
cursor before the beginning of the cluster and another cursor at the baseline after the end of 
the cluster (Figure 2.6.B). All point amplitude histograms for both the baseline and the open 
level were established and fitted with a Gaussian. An example of the baseline and the main 
amplitude histogram is illustrated in (Figure 2. 6. C). The final amplitude measurement for 
each cluster was established by subtracting the baseline value from the open level value. 
Average current amplitude for each group is displayed ± SEM.  
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Figure  2.6 Amplitude current measurement using Clampfit 10.2. 
A) Baseline adjustment. B) Defining area for current amplitude measurement. C) Amplitude 
histogram for the selected cluster. 
  
73 
 
2.7.1.2 Popen measurement 
At high agonist concentration unbound shut times are at their shortest and channel openings 
occur in clusters separated by long closed (desensitized) intervals. If the open probability is 
sufficiently high (greater than 30%), clusters without double openings probably originate 
from the same channel ion molecule (Sivilotti, 2010). For that reason all of the single-channel 
recordings were conducted using saturating concentrations of the indicated agonist and were 
used for Popen measurements. First, channel activity in the selected clusters was idealized by 
half-amplitude threshold method (Clampfit 10.2, Molecular Devices). Popen was calculated as 
the ratio of cluster open time over total cluster length. Clusters longer than 10 ms were 
selected. The single-channel current amplitude was calculated as a difference between the full 
open level (at the beginning of each cluster) and the baseline (just before each cluster). 
 
Detection and analysis of single channel data was performed by using Clampfit 10.2. In order 
to measure the Popen the record was first low pass filtered at 3 kHz. Then, the cluster of 
interest was defined by placing one cursor at the beginning and another at its end (Figure 
2.7.A). For event detection a single-channel search tool was used. The zero level cursor was 
placed over the baseline (closed state) and level one placed close to open channel level 
(Figure 2.7.B). Levels and baseline were allowed to be updated automatically. Measured 
events were listed in a table format (Figure 2.7.C). By selecting Popen event analysis tool in 
the program the graph shows the probability of channel being open (Figure 2.7.D). Several 
records were used to calculate the average Popen. 
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Figure  2.7 Measurement of single-channel cluster P
open 
using Clampfit 10.2. 
A) Identification of the cluster. B) Results measurements. C) Graph showing the probability 
of channel being open graph. D) P
open
 measurement and statistics. 
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2.8 Reagents 
A summary of the whole-cell and single-channel recordings solutions is givin in Table 2.4.  
2.8.1 Whole-cell recordings experiments 
 Glycine, β-alanine, and sarcosine stock solutions were prepared by dissolving the desired 
amount into (HPLC)-grade water (VWR international, France). Stock solutions were kept at 4 
°C and used within a week. The desired concentrations were prepared on the day of 
experiment by dissolving the stock solution in the whole-cell extracellular solution. 
Propofol (2, 6-diisopropylphenol) was dissolved in DMSO. Stocks were stored at −20 °C and 
the desired concentrations were prepared on the day of experiment by diluting the stock 
solution with the whole-cell extracellular solution. 
2.8.2 Single-channel recordings experiments  
Glycine and sarcosine solutions were made by diluting the desired amount into the prepared 
singe-channel extracellular solution. These solutions were used on the day of experiment. 
To obtain the desired propofol concentration, propofol stock was dissolved with the single-
channel extracellular solution. 
Table  2.4 Solutions used for electrophysiological recordings. 
Extracellular solution 
single-channel (mM) 
Extracellular solution 
whole-cell (mM) 
Intracellular solution 
whole-cell (mM) 
20 Na gluconate 20 Na-gluconate  
  101.1 K-gluconate 
  11 EGTA 
102.7 NaCl 112.7 NaCl  
2 KCl 2 KCl  
2 CaCl2 2 CaCl2 1 CaCl2 
1.2 MgCl2 1.2 MgCl2 1 MgCl2 
10 HEPES 10 HEPES 10 HEPES 
20 TEA-Cl 10 TEA-Cl 20 TEA-Cl 
14 glucose 40 glucose  
  2 Mg ATP 
15 sucrose  40 sucrose 
pH 7.4 with NaOH pH 7.4 with NaOH pH 7.4 with NaOH 
osmolarity 320 mOsmol /L osmolarity 320 mOsmol /L osmolarity 325.2 mOsmol/L 
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2.9 Statistics 
Statistical comparisons were performed suing IBM SPSS software (IBM Analytics, USA). 
For single comparisons between groups unpaired t-test was used. For Chapter Four, paired t-
test was used for the comparison of the measured whole-cell current before and after propofol 
application on the same cell. The level of significant was set to be p < 0.05. Data are 
presented as mean ± S.E.M and n numbers are indicated in the text.  
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3 Chapter 3: Effects of human 
hyperekplexia mutations on glycine 
receptor single-channel activity  
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3.1 Introduction 
3.1.1 Hyperekplexia 
Hyperekplexia (OMIM # 149400) is a rare neuromotor disorder that is mainly caused by 
malfunction of glycinergic neurotransmission and is characterized by a non-habituating 
exaggerated startle response, muscle stiffness and hypertonia in response to unexpected 
tactile, auditory, or visual stimuli (Bakker et al., 2006; Harvey et al., 2008; Davies et al., 
2010). The startle reflex is a normal physiological reaction to unexpected stimuli and consists 
of an involuntary motor response including closure of the eyes, abduction of the arms, flexion 
of the neck, trunk, elbows, hips and knees (Dreissen et al., 2012).  Patients with 
hyperekplexia might have linguistic and cognitive defects (Thomas et al., 2013). The disease 
was first described in 1958 in four members of a Swedish family, who suffered from sudden 
falls as a consequence of unexpected visual, or auditory, stimuli (Kirstein and Silfverskiold, 
1958). Approximately one in 40,000 people in the United States are affected by 
hyperekplexia. Hyperekplexia is rare, but families with hyperekplexia have been reported 
from the entire world, including USA (Shiang et al., 1993), Japan (Mine et al., 2014), UK 
(Rees et al., 1994), Italy (Seri et al., 1997), Saudi Arabia (Seidahmed et al., 2012), Oman 
(Al-Futaisi et a.l, 2012) and Taiwan (Tsai et al., 2004). In addition Australian, Irish, 
Jordanian, Turkish and Pakistani cases were also identified (Chung et al., 2010). The 
condition is not sex-linked i.e. autosomal and both males and females are affected by 
hyperekplexia. Hyperekplexia is also found in other species like cow, goat, mouse, and 
zebrafish (see below, Harvey et al., 2008). 
3.1.2 Genetic Causes 
In most patients hyperekplexia is due to loss-of-function mutations in the key synaptic 
proteins involved in glycinergic neurotransmission and therefore impairment of the normal 
inhibitory neurotransmission (Harvey et al., 2008; Thomas et al., 2013). Human 
hyperekplexia is mainly caused by missense, nonsense and frameshift mutations in the 
postsynaptic human glycine receptor (hGlyR) α1 gene (GLRA1) (Shiang, 1993; Chung et al., 
2010; Davis et al., 2010; Bode et al., 2013). Around 60 α1 hGlyR mutations have been 
reported to date (survey conducted in April 2018; Table 3.1). Many of the missense mutations 
are found in the ECD (17 mutations) followed by the TM2 (11 mutations), TM1 (7 mutations, 
and TM2-TM3 (6 mutations).  
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The disease can be inherited in either an autosomal dominant, or an autosomal recessive, 
pattern. Most of the hyperekplexia caused by α1 hGlyR mutations are inherited in an 
autosomal recessive pattern (36 vs 19). Most mutations that cause dominant hyperekplexia 
are found in the second transmembrane domain (TM2) and in the region between the TM2 
and TM3 domain, whereas the recessive mutations are found throughout the GlyR α1 subunit 
(Chung et al., 2010; James et al., 2013). The second most common cause of hyperekplexia is 
mutations in the presynaptic glycine transporter-2 GlyT2 gene (SLC6A5) (Rees et al., 2006; 
Harvey et al., 2008; Carta et al., 2012), followed by mutations in the β subunit of glycine 
receptor (GLRB) (James et al., 2013; Chung et al., 2013). In addition, mutations in the genes 
encoding the GlyR cytoskeletal anchoring protein gephyrin (Rees et al., 2003) and collybistin 
(Harvey et al., 2004) have been reported. Also, some hyperekplexia cases that are familial but 
do not have an identified genetic cause (de novo) have been reported (Seidahmed et al., 2012; 
Thomas et al., 2013). 
Gain-of-function GlyR α1 mutations can also cause hyperekplexia (Chung et al., 2010; Bode 
et al., 2013; Zhou et al., 2013), yet the mechanism behind this is not clear. The GlyR 
mutations α1(I43F), α1(W170S), α1(Q226E), α1(V280M and α1(R414H) were found to 
prolong the decay of IPSCs and induce spontaneous GlyR activation (Bode et al., 2013; 
Zhang et al., 2016). It is suggested that spontaneous channel opening results in increased 
intracellular Cl
− 
concentration (normally low) in adult spinal motor neurons and this 
intracellular Cl
−
 accumulation in turn might cause impairments of glycinergic synaptic 
inhibition (Zhang et al., 2016).  
 
3.1.3 Symptoms 
The main characteristics of hyperekplexia are generalized stiffness, which appears soon after 
birth, exaggerated startle reflex and stiffness after the reflex. Hypertonia predominantly 
occurs in the trunk, or lower limbs. The hypertonia is impermanent and usually diminishes 
after the first years of life (1 - 5 years) (Gordon et al., 1993; Bakker et al., 2006; Mine et al., 
2014). This might suggest a compensatory mechanism by the other inhibitory receptor 
GABAA. The syndrome produces continuous non-habituating exaggerated startle reactions in 
response to unexpected stimuli. For instance, tapping the bridge of the nose induces startle 
attacks that persist when the stimulus is repeated (Zhou et al., 2002; Bakker et al., 2006). 
During the exaggerated startle reflexes, consciousness is maintained, but afterwards 
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temporary generalized stiffness can lead to injuries from unprotected falls, as the arms 
abducted the sides cannot be used to prevent the fall. The excessive startle reflexes to 
unexpected stimuli persist throughout life although the severity varies from one patient to 
another (Zhou et al., 2002; Bakker et al., 2006; Thomas et al., 2013).  
Symptoms of this disease may appear even before birth, manifesting as increased foetal 
movements (Hussain et al., 2012). After birth, affected neonates show hypertonia and this 
increases with handling and diminishes during sleep (Bakker et al., 2006; Mine et al., 2014). 
Umbilical hernia and hip dislocation are more frequent than in unaffected siblings.  Muscle 
stiffness may start immediately after birth and decline during the first years, or appear in 
adult life (Gordon, 1993; Hussain et al., 2012;  Mine et al., 2014). Another manifestation is 
motor delay, which is seen in the first year with subsequent catch up. Learning difficulties, 
developmental delay, and delayed speech acquisition are also reported (Chung et al., 2010; 
Thomas et al., 2013). 
The disease is not in itself lethal, but increases the risk of sudden infant death as a result of 
strong muscle spasm and apnoea attacks are commonly reported (Seidahmed et al., 2012; 
Hussain et al., 2012; Thomas et al., 2013; Mine et al., 2014). Other consequences are injuries 
from unprotected falls, and these can be serious, leading to traumatic subarachnoid 
haemorrhage, and skull fractures (Bakker et al., 2006; Thomas et al., 2013; Mine et al., 
2014).  Untreated patients can become dependent on wheelchairs due to their fear of sudden 
falls elicited by the exaggerated startle reflex (Zhou et al., 2003).  
3.1.4 Diagnosis 
The diagnosis of hyperekplexia is mainly clinical. For early diagnosis, the most important 
symptoms are neonatal muscle stiffness, startle responses and a positive nose-tapping test 
(Bakker et al., 2006; Mine et al., 2014). Hyperekplexia can be confused with other disorders 
like epilepsy, dystonia, or cerebral palsy. In a study of a cohort of 17 Japanese hyperekplexia 
patients aged from neonates to 45 years only seven patients were diagnosed with 
hyperekplexia in their first year of life, even though all the patients had hyperekplexia 
symptoms.  The remaining patients were misdiagnosed for a period reaching up to 45 years of 
age (Mine et al., 2014). 
No abnormalities are detected with standard blood, urine, or cerebrospinal fluid tests, or 
imaging studies such as computer-aided tomography (CT) and magnetic resonance imaging 
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(MRI), or on physiological examinations like electroencephalography (EEG) (Bakker et al., 
2006).  
3.1.5 Treatment of manifestations 
Based on case reports, or open studies, the symptoms of the disease can be effectively 
alleviated in humans by the administration of the benzodiazepine clonazepam, which 
improves stiffness by enhancing γ-aminobutyric acid (GABA) - gated chloride channel 
function. Patients treated with clonazepam (0.1-0.2 mg/kg/day) had reduced muscle stiffness 
and/or reduced startle responses (Zhou et al., 2002; Bakker et al., 2006; Thomas et al., 2013). 
Clonazepam has adverse effects such as sleepiness and light headedness in some cases. 
Alternative medications including valproate, clobazam and levetiracetam are effective in 
some cases (Bakker et al., 2006; Hussain et al., 2012; Mine et al., 2014).  
In addition to that, life-threatening hypertonia may be acutely reduced by the Vigevano 
manoeuvre (forced flexion of the head and limbs toward the trunk, (Vigevano et al., 1989).  
 
3.1.6 Animal models 
Hyperekplexia phenotypes are also found in rodents. Analogous to genetic defects in hGlyR, 
recessively inherited mutations in the Glra1 gene and the Glrb gene were found to cause 
hyperekplexia in mice. Four mouse models with mutations in the α1 subunit of GlyR have 
been identified: spasmodic (spd), oscillator (spd
ot
), Cincinnati, and Nmf11. One model in the 
β subunit of GlyR, spastic (spa) was described (Buckwalter et al., 1994; Kingsmore et al., 
1994; Mulhardt et al., 1994; Ryan et al., 1994; Holland et al., 2006; Traka et al., 2006). All 
of these strains arose from spontaneous mutations, except the Nmf11 was chemically induced 
by ENU (N-ethyl-N-nitrosourea), which is a chemical supermutagen used to induce point 
mutations through the mouse genome (Balling, 2001). Both the Nmf11mouse and spasmodic 
mouse, carry a missense mutation at the N-terminus of the α1GlyR, N46K and A52S, 
respectively (Ryan et al., 1994; Traka et al., 2006). In the oscillator model a null mutation 
(P327X) in the α1 subunit of GlyR leads incomplete 1 subunits, without the TM3-TM4 loop 
and the TM4 domain (Kling et al., 1997). The Cincinnati mouse also harbours a null 
mutation in α1, F159X (Holland et al., 2006). Truncated oscillator and Cincinnati α1 
subunits cannot assemble into functional receptors. 
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The only spontaneous mouse mutant in GlyR β subunit is the spastic mouse mutant, where an 
insertion of the LINE-1 element within intron 6 of Glrb gene leads to a reduction in the β 
mRNA levels and impairs the normal expression of the GlyR complex (Kingsmore et al., 
1994).  
The mouse models have similar phenotypes to human hyperekplexia, including the 
exaggerated startle reflex, increased tremor, and muscle rigidity (Zhou et al., 2002). As 
indicated earlier, human patients with hyperekplexia exhibit symptoms postnataly, or even in 
utero. In contrast to human patients, mouse models show symptoms later, usually by the 
second postnatal week or even, in the case of spasmodic, in the third postnatal week. Except 
for the spasmodic mouse, all mice homozygous for the oscillator, spastic, Cincinnati, and 
Nmf11 trait die about three weeks after birth. This is in contrast with, human patients with 
GLRA1 null mutations, who do survive. This suggests that compensatory mechanisms may be 
more effective in humans than in mice (Tsai et al., 2004; Becker et al., 2006).   
In addition to naturally arising mutations, transgenic mouse models of hyperekplexia have 
been generated to evaluate the physiological effects of specific mutations in vivo (Becker et 
al., 2000; Becker et al., 2002).  Knock-in of the tgR271Q GlyR α1 mutation produced 
hyperekplexia phenotypes such as exaggerated startle responses to visual, or tactile, stimuli 
(Becker et al., 2002). In another study, transgenic expression of rat wild-type GlyR β subunit 
in spastic mouse reduced the hyperekplexia symptoms completely (Hartenstein et al., 1996). 
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Table  3.1 Hyperekplexia mutations in the α1 subunit of the hGlyR. 
Mutation Type 
Mode of 
inheritance 
Position Notes References 
del Ex1-7 deletion recessive n.a 
 
Brune et al. 
(1996); Bode 
et al. (2013) 
del Ex4-7 deletion recessive n.a 
compound 
heterozygous 
with R65L 
Chung et al. 
(2010) 
I43F missence de novo ECD  
Horváth et 
al. (2014); 
 Zhang et al. 
(2016) 
R65L missense recessive ECD 
compound 
heterozygous 
with ΔEx4-7 
Chung et al. 
(2010) 
R65W missense recessive ECD 
compound 
heterozygous 
with P230S 
Chung et al. 
(2010) 
W68C missense recessive ECD 
compound 
heterozygous 
with R316X 
Tsai et al. 
(2004); 
Schaefer et 
al. (2015) 
D70N missense recessive ECD 
compound 
heterozygous 
with W407R 
Schaefer et 
al. (2015) 
R72fsX47 deletion recessive ECD 
 
Rees et al. 
(2001) 
R72H missense recessive ECD 
 
Coto et al. 
(2005); 
Schaefer et 
al. (2015) 
R72C missense recessive ECD 
 
Bode et al. 
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(2013) 
E103K missense recessive ECD 
compound 
heterozygous 
with 
L184fs21X 
Chung et al. 
(2010); 
Thomas et al. 
(2013) 
Y128C missense dominant ECD 
 
Chung et al. 
(2010) 
K132fsRX15 deletion recessive ECD 
 
Zoons et al. 
(2012) 
C138S missense recessive ECD 
compound 
heterozygous 
with 
D148fsX16 
Chan et al. 
(2012) 
M147V missense recessive ECD 
 
Rees et al. 
(2001); 
Thomas et al. 
(2013) 
D148fsX16 deletion recessive ECD 
compound 
heterozygous 
with C138S 
Chan et al. 
(2012) 
G160R missense dominant ECD 
 
Schaefer et 
al. (2015) 
T162M missense recessive ECD 
 
Schaefer et 
al. (2015) 
D165G missense recessive ECD 
 
Chung et al. 
(2010); 
Thomas et al. 
(2013) 
W170S missense recessive ECD 
 
Al-Futaisi et 
al. (2012); 
Zhou et al. 
(2013); 
Zhang et al. 
(2016)  
L184fs21X deletion recessive ECD compound Chung et al. 
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heterozygous 
with E103K 
(2010) 
T190M missense recessive ECD 
compound 
heterozygous 
with D424N 
Yang et al. 
(2017) 
 
Y197X nonsense recessive ECD 
compound 
heterozygous 
with Y202X 
Chung et al. 
(2010) 
Y202X nonsense recessive ECD 
compound 
heterozygous 
with Y197X 
Rees et al.   
(2001); 
Thomas et al. 
(2013) 
R218Q missense de novo ECD 
compound 
heterozygous 
with S296X 
Miraglia et 
al. (2003); 
Castaldo et 
al. (2004) 
R218W missense recessive ECD 
 
Bode et al. 
(2013) 
Q226E missense dominant TM1 
 
Bode et al. 
(2013); Scott 
et al. (2015); 
Zhang et al. 
(2016) 
Y228C missense recessive TM1 
 
Forsyth et al. 
(2007) 
P230S missense recessive TM1 
compound 
heterozygous 
with R65W 
Bode et al. 
(2013) 
S231R missense recessive TM1 
 
Humeny et 
al. (2002); 
Villmann et 
al. (2009) 
S231N missense recessive TM1 compound Chung et al. 
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heterozygous 
with S296X 
(2010); 
Thomas et al. 
(2013) 
W239C missense dominant TM1 
 
Gilbert et al. 
(2004) 
I244N missense recessive TM1 
 
Rees et al. 
(1994); 
Lynch et al. 
(1997); 
Villmann et 
al. (2009) 
P250T missense dominant 
TM1-TM2 
loop  
Saul et al. 
(1999) 
R252H missense recessive TM2 (0') 
compound 
heterozygous 
with R392H 
Vergouwe et 
al. (1999); 
Rea et al 
(2002); 
Villmann et 
al. (2009) 
R252C missense recessive TM2 (0') 
 
Chung et al. 
(2010); 
Thomas et al. 
(2013) 
G254D missense recessive TM2 (2') 
 
Chung et al. 
(2010); 
Thomas et al. 
(2013) 
V260M missense dominant TM2 (8') 
 
del Giudice 
et al. (2001); 
Castaldo et 
al. (2004) 
T265I missense dominant TM2 (13') 
 
Chung et al. 
(2010) 
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Q266H missense dominant TM2 (14') 
 
Milani et al. 
(1996); 
Moorhouse 
et al. (1999), 
Castaldo et 
al. (2004) 
S267N missense dominant TM2 (15') 
 
Becker et al. 
(2008) 
S270T missense recessive TM2 (18') 
 
Lapunzina et 
al. (2003) 
R271L missense dominant TM2 (19') 
 
Shiang et al. 
(1993); 
Langosch et 
al. (1994); 
Lynch et al. 
(1997); Rees 
et al. (2001); 
Kwok et al. 
(2001) 
R271Q missense dominant TM2 (19') 
 
Shiang et al. 
(1993), 
Langosch et 
al. (1994); 
Rees et al. 
(1994); 
Lynch et al. 
(1997); 
Kwok et al. 
(2001); 
Thomas et al. 
(2013); Mine 
et al. (2014); 
Scott et al. 
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(2015) 
R271P missense dominant TM2 (19') 
 
Gregory et 
al. (2008) 
R271X nonsense dominant TM2 (19') 
 
Lee et al. 
(2013) 
A272P missense dominant 
TM2-TM3 
loop  
Mine et al. 
(2015) 
K276E missense dominant 
TM2-TM3 
loop  
Elmslie et al. 
(1996), Seri 
et al. (1997); 
Lewis et al. 
(1998); Doria 
et al. (2007); 
Lape et al. 
(2012); Mine 
et al. (2014); 
Scott et al. 
(2015) 
K276Q missense de novo 
TM2-TM3 
loop  
Kang et al. 
(2008) 
Y279C missense dominant 
TM2-TM3 
loop  
Shiang et al. 
(1995); 
Lynch et al. 
(1997); 
Kwok et al. 
(2001); 
Thomas et al. 
(2013) 
Y279S missense dominant 
TM2-TM3 
loop  
Poon et al. 
(2006) 
V280M missense dominant 
TM2-TM3 
loop  
Bode et al. 
(2013); 
Zhang et al. 
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(2016) 
L291P missense recessive TM3 
compound 
heterozygous 
with D388A 
Bode et al. 
(2013); 
Thomas et al. 
2013 
S296X nonsense recessive TM3 
compound 
heterozygous 
with S231N 
and R218Q 
Bellini et al. 
(2007); 
Chung et al. 
(2010); Bode 
et al. (2013) 
R316X nonsense recessive 
TM3-TM4 
loop 
compound 
heterozygous 
with W68C 
Tsai et al. 
(2004); 
Schaefer et 
al. (2015) 
G342S missense recessive 
TM3-TM4 
loop  
Jungbluth et 
al. (2000); 
Rees et al. 
(2001); 
Chung et al. 
(2010) 
E375X nonsense recessive 
TM3-TM4 
loop  
Bode et al. 
(2013) 
A384P missense recessive 
TM3-TM4 
loop 
compound 
heterozygous 
with R392H 
Mine et al. 
(2014); 
Wang et al. 
2018 
D388A missense recessive 
TM3-TM4 
loop 
compound 
heterozygous 
with L291P 
Bode et al. 
(2013) 
R392H missense recessive TM4 
compound 
heterozygous 
with R252H/ 
compound 
Vergouwe et 
al. (1999); 
Rea et al. 
(2002); 
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homozygous Villmann et 
al. (2009); 
Chung et al. 
(2010) 
W407R missense recessive TM4 
compound 
heterozygous 
with D70N 
Schaefer et 
al. (2015) 
R414H missense dominant TM4 
 
Bode et al. 
(2013); 
Zhang et al. 
(2016) 
D424N missense recessive TM4 
compound 
heterozygous 
with T190M 
Yang et al. 
(2017) 
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3.2 Results 
Human hyperekplexia is caused by the malfunction of glycinergic synaptic transmission, 
most commonly because of mutations in the GlyRα1 subunit. As in other channelopathies, 
every disease causing mutation identifies a residue that is essential for the function of the 
channel, and thus is worth investigating (Bode and Lynch, 2014).   For instance, thorough 
kinetic analysis of the  (K276E) mutation has allowed our lab to identify the crucial role of 
the M2-M3 domain in signal transduction in GlyRs (Lewis et al., 1998; Lape et al., 2012). 
The first level of this investigation is to characterise the main effects of known human 
hyperekplexia mutations by electrophysiological recording.  This means, for example 
establishing glycine and/or partial agonist concentration-response curves, and measuring the 
single channel conductance and maximum open probability of mutant channels.   
The aim of my work was to perform an initial screening of several known human 
hyperekplexia mutations to understand their effect on both homomeric and heteromeric 
glycine receptors.  It was very important to begin with this step as single channel kinetic 
analysis can be performed only in receptor variants with favourable properties. Six human 
hyperekplexia mutations in the α1 subunit R72H, E103K, S231N, Q266H, S267N and 
Y279C were selected for screening. In choosing these mutations, we tried to sample different 
channel domains and to avoid extreme loss of function mutations, which we know could not 
be analysed as such with single channel kinetics. 
3.2.1 Expression of the wild-type human homomeric and heteromeric 
GlyR in HEK293 cells 
The first set of experiments is obviously to characterise wild type α1 and α1β receptors. 
Previous work of my lab was carried out on the rat subunit (Beato et al., 2002; Burzomato et 
al., 2003; Lape et al., 2012). 
Sequence alignment of human versus rat α1 glycine receptor shows 98.5% identity and the 
alignment of the β subunit from these two species shows 97.2% identity.  Indeed the human 
α1 subunit differs from the rat subunit only in 7 amino acid residues and the human β subunit 
differs from rat in 14 amino acids residues.  While the receptors obviously perform the same 
function in the two species, it cannot be taken for granted that these sequence differences are 
unimportant.  We therefore thought it essential to establish channel properties of the wild-
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type human glycine receptor in order to be able to compare them with those of the human 
hyperekplexia mutant channels. 
In order to compare the effect of different GlyR mutations on glycine channel sensitivity, I 
obtained glycine concentration-response curves for the wild-type receptors first for both 
homomeric α1 and heteromeric α1β human GlyR. Representative responses to different 
concentrations of glycine to wild-type α1, or α1β, receptors in cells voltage-clamped at −50 
mV in asymmetrical chloride are shown in Figure 3.1 and 3.2, respectively. For the 
homomeric GlyR, I applied a range of different concentrations of glycine between 0.025 and 
10 mM by a U-tube. The traces show that as glycine concentration increases, the risetime of 
the response speeds up and the amplitude of the inward current increases until it reaches 
saturation below 10 mM. Desensitization was clearly starting from 0.2 mM glycine 
concentration (e.g. approximately EC30).  
Whole-cell peak current amplitudes were measured, plotted and fitted with the Hill equation 
(see Methods 2.6.1). The fitted concentration-response curve for homomeric GlyRs is shown 
in Figure 3.1. Fits with the Hill equation gave estimates of EC50 of 0.25 ± 0.03 mM and a Hill 
slope of 1.87 ± 0.37 (n = 6). Similar results were obtained for heteromeric GlyRs, expressed 
with a cDNA  ratio of 1:40 (Burzomato et al., 2003). As the concentration of glycine was 
increased faster activation was observed for the heteromeric GlyR. The lowest concentration 
for which clear desensitisation was observed was 0.1 mM, i.e. approximately EC60 as shown 
in the sample trace in Figure 3.2. The EC50 of the human heteromeric GlyR was 0.10 ± 0.03 
mM and a Hill slope 1.48 ± 0.09 (n = 6).  
These values should be compared with those obtained with an identical technique for rat 
homomeric and heteromeric GlyRs.  These have similar EC50 values: the EC50 of wild-type 
rat α1 was 0.08 ± 0.01 mM and of α1β = 0.09 ± 0.004 mM, and Hill slope of 3.3 ± 0.2 and 
2.0 ± 0.2, respectively (Beato et al., 2002; Burzomato et al., 2003). 
The human wild type GlyR homomers have a significant higher EC50 than heteromers. It is 
not clear why coexpression with the β subunit should reduce the potency of glycine in human 
(p < 0.01), but not in rat receptors.  
The Hill coefficient values were not significantly different for homomeric versus heteromeric 
GlyRs (1.87 ± 0.37 and 1.48 ± 0.09, p > 0.05), but note the large scatter of the homomeric 
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data.  It is worth noting that both homomeric and heteromeric channels are thought to be 
maximally activated when three glycine molecules are bound. 
The expression level, judging from the maximum current recorded, was comparable (10.34 ± 
2.47 vs 4.43 ± 1.83 nA, for α1 and α1β respectively, p > 0.05).                                       
3.2.2 Single-channel recordings of homomeric and heteromeric wild-type 
GlyR 
Single channel recordings of homomeric or heteromeric wild-type human GlyR expressed in 
HEK293 cells were obtained in cell-attached configuration (pipette potential +100 mV). 
Activation of homomeric channels with saturating glycine concentration (10 mM) is 
illustrated Figure 3.3. Clear clusters of openings of channels between long silent channel 
periods were observed. The channel closures are more likely to be desensitised intervals, a 
finding that was reported previously (Beato et al., 2004). The maximum Popen value was 
obtained for each individual cluster as the ratio between the total cluster open time and total 
cluster duration (see Methods). Human GlyR α1 opened with average maximum Popen of 0.99 
± 0.002 (n = 30 clusters from 4 records), a value similar to the homomeric rat GlyR with Popen 
of 0.96 ± 0.3, n = 45 clusters from 5 records (Beato et al., 2004).  Average amplitude of 
human homomeric GlyR was 5.77 ± 0.06 pA (n = 30 clusters from 4 records) slightly higher 
than average amplitude of rat homomeric receptors recorded previously in our lab 4.7 ± 0.1 
pA (n = 26) (Beato et al., 2004).  
Activation of wild-type α1β glycine channels with saturating concentration of glycine (1 
mM) resulted in long clusters of channel openings. A sample trace of a single channel record 
is shown in Figure 3.4. Average Popen of 0.98 ± 0.01 (n = 29 clusters from 6 patches) was 
measured. This value is very similar to the one reported previously in our lab for the rat 
heteromeric GlyR with average maximum Popen of 0.97 ± 0.0007, n = 91 clusters from 4 
patches (Burzomato et al., 2004). The long clusters were separated by long sojourns in 
desensitized intervals. The average current amplitude for the heteromeric wild-type receptors 
was 3.07 ± 0.06 pA, n = 29 clusters from 6 records, similar average current amplitude of 3.1± 
0.1 pA has been reported for the heteromeric rat GlyRs (Burzomato et al., 2004). 
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3.2.3 Conclusion human wild-type GlyR  
Human wild-type heteromeric GlyR has a lower EC50 than the homomeric GlyR. However, 
both homomeric and heteromeric GlyRs open with very high Popen when activated by 
saturating concentration of glycine (0.99 ± 0.002, 0.98 ± 0.01, respectively). Their single 
channel current amplitudes are different 5.77 ± 0.06 pA cf 3.07 ± 0.06 pA. 
 
 
  
95 
 
 
Figure  3.1 Sensitivity of the human wild-type α1 GlyRs to glycine.  
A) Representative whole cell current traces evoked by U-tube application of 0.1, 0.2, 0.5, 1, 
2, 5, and 10 mM glycine (black bars) to the recombinant HEK293 cells expressing wild-type 
α1 GlyR. Cells were held at – 50 mV. B) Average glycine concentration-response curve 
obtained from α1 wild-type GlyR. The solid curve is a fit to the Hill equation. EC50 = 0.25 ± 
0.03 mM, nH = 1.87 ± 0.37, Imax = 10.34 ± 2.47 nA, n = 6 cells. Error bars indicate mean ± 
SEM.  
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Figure  3.2 Glycine concentration-response curve of the human wild-type α1β GlyR. 
A) Sample whole-cell glycine activated current traces evoked by U-tube application of 
different concentrations to recombinant HEK293 cells expressing wild-type α1β GlyR (at – 
50 mV). Respective concentrations of glycine are shown in mM. B) Average glycine 
concentration-response curves obtained from wild-type α1β GlyR. Solid curve is a fit to the 
Hill equation. EC50 = 0.10 ± 0.03 mM, nH = 1.48 ± 0.09, Imax = 4.43 ± 1.08, n = 6 cells. Error 
bars indicate mean ± SEM. 
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Figure  3.3 Example of single channel activity of the human wild-type α1 GlyR in 
response to saturating concentration of glycine (10 mM).  
Openings of the channels were recorded in the cell attached configuration at a holding 
potential of + 100).  There is clear clustering of the openings between long desensitised 
closures. Homomeric glycine channels open with average maximum Popen of 0.99 ± 0.002 
and average amplitude of 5.77 ± 0.06 pA, n = 30. Channel open upward. (3 kHz low pass 
filtered for display). 
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Figure  3.4 Activation of human wild-type α1β GlyR by saturating glycine concentration. 
Sample cell-attached single channel trace with one cluster opening is shown (pipette potential 
+100 mV). The average maximum Popen = 0.98 ± 0.01 and the average amplitude = 3.07 ± 
0.06 pA, n = 29. Channel opening is upwards (3 kHz low pass filtered for display). 
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3.2.4 Choice of the human hyperekplexia mutations to characterise  
There are more than 30 human hyperekplexia mutations published for the α1 subunit of the 
glycine receptor (Bode and Lynch, 2014). With this huge number, screening is vital to 
exclude channel mutants with severe, or complete loss, of function. Several human 
hyperekplexia mutations were selected for characterization in both homomeric and 
heteromeric glycine receptors. The selection of the mutations aimed to include residues in 
different regions of the GlyR α1 subunit, namely parts of the ECD, TM1, TM2 and the TM1-
TM2 loop. Also, those mutations have different modes of inheritance and both recessive and 
dominant forms were included. Figure 3.5 shows a homology model of a single subunit of 
GlyR and the location of the selected human hyperekplexia mutations. 
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Figure  3.5 A homology model for the α1 subunit of the glycine receptor. 
The model is presented as a side view from the inside of the channel pore towards the 
periphery of the receptor. The TM2 line the inner pore. The locations of the tested human 
hyperekplexia GlyR mutations are indicated. The middle part represents the overall view of a 
single GlyR α1 subunit with the extracellular domain and the transmembrane domain. This 
homology model is based on C.elegans GluCl channel (PBD ID 3WI5) and was provided by 
collaborators from Oxford University (Biggin and Yu, see Yu et al., 2014). The mutations are 
highlighted in orange. 
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3.2.5 The effect of the human hyperekplexia mutations on glycine receptor 
sensitivity and efficacy 
 
3.2.6 ECD or binding site domain: the E103K mutation 
3.2.6.1 Location 
E103 is in loop A on the principal side of the agonist binding site, in the cleft between two 
adjacent subunits see Figure 3.5 (a full description of the interaction of this GlyR mutation 
with other residues will follow in Chapter five). 
Glycine receptor α1 E103 is conserved in many subunits from different receptors and species 
(Figure 3.6). It is conserved in the human glycine receptor subunits α2, α3, α4, and β. It is 
also conserved in the bovine glycine receptor α1 and β subunits. Glycine receptor α1 subunit 
of Danio rerio (zebrafish) has the same amino acid. Furthermore, rat glycine receptor 
subunits α1, α2, α3, and β have a conserved glutamic acid in the indicated position. All the 
subunits (α1, α2, α3, α4, and β) of the mouse glycine receptor have a conserved amino acid in 
the region of interest. Both GluCl receptor α and β subunits from Caenorhabditis elegans 
have a conserved glutamic acid in the indicated position. Drosophila melanogaster (fruit fly) 
and Haemonchus contortus (Barber pole worm) GluCl channel α and β subunit, respectively, 
includes the conserved amino acid of interest.  
 
3.2.6.2 Reported hyperekplexia case 
The E103K mutation was first reported to cause hyperekplexia in human by Chung et al. 
(2010). The index case, a Caucasian male patient did not have a family history of 
hyperekplexia as his parents were asymptomatic. He had stiffness and non-habituating startle 
response. The patient responded positively to clonazepam. DNA sequencing screening of the 
GLRA1 identified the maternal hemizygous recessive missense E103K mutation in the N-
terminal of GlyR α1. The patient happened to be a compound heterozygote, having inherited 
this mutation with the paternal frameshift mutation L184fs21X. This deletion produces a 
premature stop codon at amino acid position 205 (Chung et al., 2010).  The lack of symptoms 
in the mother suggests that this mutation is relatively mild and receptors containing wild-type 
and mutant subunits would function reasonably well. 
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Although when the deletion L184fs21X GlyR mutation was expressed in HEK293 cells as 
homomeric, or heteromeric with the β subunit, the GlyR channels were not functional. Co-
expression with the E103K mutation resulted in higher level of functional channels 
expression. Also, the number of the functional GlyRs of the homomeric, or heteromeric, 
GlyR E103K mutation alone was similar to the corresponding wild-type. Since the frameshift 
mutation produced a non-functional allele, it is predicted that the patient’s functional α1 
GlyR in vivo contained only mutant α1 E103K subunits (Chung et al., 2010).   
Whole cell analysis of the homomeric α1 (E103K) or heteromeric α1 (E103K) β GlyR 
expressed in HEK293 cells indicated a 26, 33 fold change in glycine EC50, respectively 
(Chung et al., 2010).  A slight disruption of the glycine binding site was predicted by 
structural modelling of the α1(E103K) GlyR mutant on the Torpedo α1βγα2ε nicotinic ACh 
receptor (nAChR) (Chung et al., 2010). 
As there are only few published functional data for the Cys-loop receptors with mutations in 
this position, I checked whether there were reports of other GlyR mutations in nearby 
residues of loop A. Cysteine, alanine, or lysine substitution of the 102, 103, or 104 residues in 
the GlyR α1 are shown in Table 3.2 and will be discussed further in the following paragraphs. 
3.2.6.3 GlyR mutations in the proximity of E103K 
N102A, N102C 
The N102 residue is important for GlyR function: an alanine scan of GlyR α1 loop A residues 
showed that N102A GlyRs had higher EC50 for glycine, β-alanine and taurine (44, 32 and 14 
fold greater, respectively) without a change in strychnine sensitivity (Table 3.2) (Vafa et al., 
1999). This finding was supported by another study, where the N102C α1 GlyR mutation was 
examined (Han et al., 2001). The latter study reported an even greater loss of agonist 
sensitivity, for both glycine and taurine, by 142 and 346 fold respectively (for ease of 
comparison these published results are summarised in Table 3.2). The same paper reported 
also a significant decrease in taurine maximum response relative to glycine (from 1.03 to 
0.29) 
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E103C, E103A 
E103C GlyR α1expressed in HEK293 cells shifts glycine sensitivity by 44 fold from 19 to 
850 M. It also shifts taurine EC50 by 35 fold from 120 to 4200 M, with a slight reduction 
of taurine relative efficacy from 1 to 0.9 (Table 3.2) (Han et al., 2001). However, E103A did 
not produce a significant reduction of the glycine EC50   (0.7 fold change; Table 3.2) (Vafa et 
al., 1999).  
K104A, K104C  
While α1(K104A) GlyR causes a slight decrease of the glycine sensitivity by 1.7 fold when 
expressed in HEK293 cells (Vafa et al., 1999), the same mutation was found to increase 
glycine sensitivity by 0.75 fold when expressed in oocytes (Schmieden et al., 1999). In the 
same study, this α1(K104A) GlyR mutation was found to enhance the potency of several 
partial agonists including taurine and β-aminoisobutyric acid and to increase the relative 
efficacy of taurine (see Table 3.2).  
On the other hand, α1(K104C) GlyR expressed in HEK293 cells reduced both glycine and 
taurine EC50 by 0.38 and 0.31 fold, respectively.  No significant change in taurine relative 
efficacy was detected (Table 3.2) (Han et al., 2001).  
3.2.6.4 Whole-cell recordings of α1(E103K)  
Different amounts of plasmid were used to have suffiecient expression of α1(E103K) mutant 
GlyR in HEK293 cells. The E103K GlyR barely expressed in HEK293 cells when 5 % of 
DNA was used so in order to study this receptor the DNA percentage of the α1(E103K) GlyR 
was increased from 5 to 55% (see Methods). Sample traces of glycine responses recorded 
from homomeric E103K GlyRs are shown in Figure 3.7.A. Higher agonist concentrations 
were needed to evoke current responses than in wild-type channels. As in wild-type, the 
risetime of the current response became faster with higher glycine concentrations, up to the 
maximum concentration of 20 mM glycine, where the glycine response was saturated. The 
glycine EC50 was significantly decreased by 2.8 fold from its wild-type value of 0.25 ± 0.03 
(n = 6) to 0.71 ± 0.11 mM (n = 3; p < 0.001, unpaired t-test). Hill slope was comparable with 
those of wild-type GlyR of 1.87 ± 0.37 (n = 6) vs 1.32 ± 0.07 for α1(E103K) (n = 3; p > 0.05, 
unpaired t-test). The maximal current was decreased insignificantly from 10.34 ± 2.47 nA for 
wild-type (n = 6) to 2.73 ± 1.41 nA for α1(E103K) GlyRs (n = 3, p > 0.05) (Figure 3.7.B, 
Table 3.3).  
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3.2.7 Whole-cell recordings of α1(E103K)β  
Co-expression of the human wild-type GlyRβ with the α1E103K GlyR mutant at an  
cDNA ratio of 1:40 resulted in functional GlyR with enough glycine current to proceed with 
whole-cell recordings. The average maximum glycine current elicited was similar to the one 
obtained with wild-type GlyRs:  4.43 ± 1.08 nA (WT, n = 6) and 3.62 ± 0.89 nA 
(α1(E103K)β, n = 6; p > 0.05, unpaired t-test ). As shown in (Figure 3.8), 1 mM of glycine 
elicited currents with approximately an EC10 and a very high concentration of 100 mM 
glycine was needed to produce a saturating response. Glycine gated currents showed 
desensitization with the all of the tested glycine concentrations starting at 1 mM glycine until 
100 mM glycine (Figure 3.8.A). The α1(E103K)β GlyR mutation caused a significant ~ 70 
fold increase of the glycine EC50 with a value of 7.27 ± 0.58 mM, n = 6 (cf.. for wild-type 
heteromeric GlyR = 0.10 ± 0.03 mM, n = 6;  p < 0.001, unpaired t-test). The Hill slope was 
similar for wild-type and the mutant GlyR 1.48 ± 0.09 vs 1.22 ± 0.08 (n = 6 for both; p > 
0.05, unpaired t-test; Figure 3.8.B, Table 3.4). 
 
3.2.8 Single-channel recordings of homomeric and heteromeric GlyR 
bearing the E103K α1 mutation  
Single-channel recordings of the homomeric E103K GlyR were obtained in the cell-attached 
configuration (pipette potential +100 mV) in the presence of 50 mM glycine, a concentration 
that was found to be saturating in whole cell recordings (see Figure 3.7).  Mutant channels 
opened in clusters, separated by long desensitised periods.  The clusters had a significantly 
reduced maximum Popen from 0.99 ± 0.002 to 0.71 ± 0.09 (n = 30, 13, respectively, p < 0.01, 
unpaired t-test).  Measurements of approximate Popen were carried for each cluster; however, 
for some clusters it was difficult to judge whether two subsequent channel openings are from 
one or two channels (see upper trace Figure 3.9). For the illustrated example Popen of 0.40 was 
selected instead of two openings with 0.78 and 0.68 Popen. For the second cluster shut time 
intervals (0.004 – 0.06 seconds) in addition to the apparent short open times contributed to 
the reduced Popen ~ 0.8 seconds. The labelled apparent shut times are approximately measured 
by Clampfit 10 (Figure 3.9, last trace).  
The single-channel current amplitude was estimated for each cluster separately using all point 
histograms and also was checked visually (see Methods). The main amplitude of mutant 
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receptor single channel currents was 5.22 ± 0.11 pA very similar to the one measured for wild 
type receptor (cf. 5.77 ± 0.06, n = 13, 30 clusters, respectively, Figure 3.9). However, in the 
single-channel record from mutant receptor it was observed that the mutant receptor can open 
to a lower conductance level, an example of which is indicated with the arrow in the Figure 
3.9. This sublevel is measured by the all point amplitude histogram as separate peak with 
amplitude of 4.6 pA.  As seen in the indicated figure there seems to be a transition from one 
level to another 20% lower level. It is also observed that the open channel noise level is much 
higher than closed channel. This might be due to many very short channel closings which are 
not resolved.  
These results were consistent with different patches tried on different days. It is worth 
mentioning that for single channel recordings I tested on the same day a wild-type GlyR to 
make sure that the transfection went well. For HEK293 cells expressing mutant homomeric 
GlyRs only 2 records out of 21 patches were suitable for analysis. The expression level of 
this mutation was poor as 55% of DNA was needed to have transfected cells compared to 2 
% in wild-type GlyRs.  
Similar results were obtained for single-channel recordings of heteromeric GlyR with 
saturating glycine concentration (50 mM, Figure 3.10). The average maximum Popen was 
reduced without change in the current amplitude. As indicated earlier, measurement of 
current amplitude and Popen was done for each cluster separately. Possible heterogeneity of 
activity was observed with the openings within the cluster (Figure 3.10). The average 
approximate Popen is 0.67 ± 0.06 (n = 5) a value that significantly lower of the corresponding 
wild-type with a Popen of 0.98 ± 0.01 (n = 29; p < 0.01, unpaired t-test). The current amplitude 
was similar to that of the corresponding wild-type 3.10 ± 0.16 pA vs 3.07 ± 0.06 (n = 5, 29, 
respectively). Note that there was no clear stable open level as seen in wild-type. These 
results were consistent among different patches tested on different days using HEK293 cells. 
Out of twenty records, only four were suitable for analysis. Please note that on the same day 
of recording HEK293 cells expressing wild-type were used as a control to make sure there is 
no artefact and to exclude transfection error. 
3.2.8.1 Conclusion- the E103K GlyR mutants.  
This hyperekplexia mutation causes a decrease in the potency of the agonist glycine, and this 
effect is much more pronounced in the heteromeric channel (2.8 cf ~70-fold change in EC50).   
This decrease is associated with a significsnt reduction in the maximum Popen recorded in the 
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cell-attached configuration, from 0.99 ± 0.002 to 0.73 ± 0.07 and 0.98 ± 0.01 to 0.67 ± 0.06 
homomeric, heteromeric E103K GlyR, respectively.     
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Figure  3.6 Partial sequence alignment of GlyR with other pLGICs and proteins. 
A) The E103 human hyperekplexia mutation residue in the ECD of the GlyR α1 is 
highlighted in blue along with the aligned residues in other receptors. Glutamate is conserved 
in 21 receptors (see text). Uniprot accession numbers are indicated at the left side for each 
receptor,  human glycine α1 (P23415), human glycine α2 (P23416), human glycine α3 
(O75311), human glycine α4 (Q5JXX5), human glycine β (P48167), bovine glycine α1 
(P57695), bovine glycine β (Q9GJS9), zebrafish glycine α1 (O93430), rat glycine α1 
(P07727), rat glycine α2 (P22771), rat glycine α3 (P24524), rat glycine α4 (P28471), rat 
glycine β (P20781), mouse glycine α1(Q64018), mouse glycine α2 (Q7TNC8), mouse 
glycine α3 (Q91XP5), mouse glycine α4 (Q61603), mouse glycine β (P48168), C. elegans 
GluCl α (G5EBR3), C. elegans GluCl β (Q17328), D. melanogaster GluCl α (Q94900), H. 
contortus GluCl β (P91730), human GABAA α1(P14867), human GABAA β3 (P28472), 
human α7 nAChR (P36544), L. stagnalis AChBP (P58154), human 5-HT3A (P46098), 
mouse 5-HT3A (P23979), GLIC (Q7NDN8), and ELIC (P0C7B7). B) Homology model for 
GlyR α1 subunit based on C.elegans GluCl channel showing one GlyR subunit and the 
location of the indicated residue (see Yu et al., 2014). 
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Table  3.2  Literature review of the sensitivity of the human α1 GlyR to N102X, E103X, 
or K104X mutations, where X = ʻotherʼ 
 
GlyR 
Mutation 
EC50 Glycine 
(fold change) 
EC50 
β-alanine 
(fold change) 
EC50 Taurine 
(fold change) 
ITau/ImaxGly 
Expression 
System 
References 
α1(N102A) 44 32 14 - HEK293 Vafa et al.(1999) 
α1(N102C) 142 - 346 
0.29 ± 0.02 
WT:1.03 ±0.06 
HEK293 
Han et al. (2001) 
α1(E103K) 26 - - - HEK293 Chung et al. (2010) 
α1(E103C) 44 - 35 
0.90 ± 0.07 
WT: 1.03 ± 0.06 
HEK293 
Han et al. (2001) 
α1(E103A) 0.7 - - - HEK293 Vafa et al. (1999) 
α1(K104C) 0.38 - 0.31 
0.95 ± 0.08 
WT: 1.03 ± 0.06 
HEK293 
Han et al. (2001) 
α1(K104A) 1.7 - - - HEK293 Vafa et al. (1999) 
α1(K104A) 0.75 0.40 0.56 
73.2 ± 1.7 
WT: 31.9 ± 2.8 
Oocytes 
Schmieden et al. 
(1999) 
Fold change = increase from WT to mutant. ITau = current in response to taurine. ImaxGly =  
current in response to saturating concentration of glycine.  
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Figure  3.7 Human α1(E103K) mutant GlyR expressed in HEK293 cells has a reduced 
sensitivity to glycine. 
A) Example whole-cell current traces showing inward chloride current responses to the 
indicated glycine concentrations in mM (holding potential = –50 mV). Bars above the traces 
show the application of glycine. B) Average glycine concentration-response curve for the 
homomeric E103K GlyR is shifted to the right by ~ 3 fold. The curve is a fit to the Hill 
equation with EC50 = 0.71 ± 0.11 mM, nH = 1.32 ± 0.07, Imax = 1.32 ± 0.07, n = 3. Error bars 
represent SEM.  
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Figure  3.8 The α1(E103K) mutation reduces the sensitivity to glycine of the human α1β 
GlyR. 
A) Representative whole cell traces showing inward currents elicited by U-tube application of 
glycine to HEK293 cells expressing α1(E103K)β human hyperekplexia receptor. The lines 
over the tracing refer to application of glycine (in mM). Cells were held at 50 mV. B) 
Average glycine concentration-response curve fitted with the Hill equation EC50 = 7.27 ± 
0.58 mM, nH = 1.22 ± 0.08, Imax = 3.62 ± 0.89 nA, n = 6 cells. Error bars represent SEM. 
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Figure  3.9 α1(E103K) GlyR mutation reduces maximum Popen in response to 50 mM 
glycine, a saturating concentration of agonist for this receptor. 
These single-channel traces (cell-attached, pipette potential + 100 mV) show that the mutant 
receptor opens in clusters, but at lower maximum open probability. Average maximum Popen 
= 0.73 ± 0.07, average amplitude = 5.24 ±1.4 pA, n = 13 clusters.  Note the relative unstable 
opening level and existence of possible sublevels.  
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Figure  3.10 The human hyperekplexia α1(E103K)β GlyR mutation decreases 
maximum open probability in response to a saturating concentration of glycine.  
Cell-attached single channel traces recorded with saturating glycine concentration of 50 mM 
(pipette potential +100 mV, 3 kHz low pass filtered) show a profound disruption of the open 
state by the mutation. Average maximum Popen = 0.67 ± 0.06, average amplitude = 3.10 ± 
0.16 pA, n = 5 clusters. Expansion of the trace in the lower panel shows presence of 
different gating modes within the cluster. 
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3.2.9 TM1 domain: the S231N mutation  
3.2.9.1 Location 
The S231 residue is located in TM1 close to the extracellular side (Figure 3.5). Serine in this 
position is conserved in twenty two pLGICs. It is conserved in all of the human GlyR α 
subunits (α1, α2, α3, and α4). It is also conserved in bovine and Danio rerio (zebrafish) α1 
subunit of GlyR. Rat α1, α2, and α3 GlyR subunits have conserved serine in the indicated 
position. Residues equivalent to S231 GlyR α1 are conserved in mouse α1, α2, α3, and α4 
GlyRs. GluCl receptor α subunit from Caenorhabditis elegans has a conserved serine in the 
highlighted position. The amino acid of interest is also conserved in the human GABAA 
receptor α1, α2, α3, δ, ε, and π subunits. Sequence alignment of both mouse and human 5-
HT3A receptors shows a conserved residue equivalent to S231 GlyRα1 (Figure 3.11).  
The homology model obtained from the GluCl structure by our collaborators at Oxford 
University, Biggin and Yu,  showed that the side chain of S231 may interact with the facing 
TM2 Q226 residue (Figure 3.5), offering a possible explanation for loss of function produced 
by the hyperekplexia S231N mutation. As S231 and Q266 are very near to each other, a steric 
effects of the bigger N side chain could conceivably be disruptive the transmembrane domain 
and channel gating. The molecular modelling suggests that the wild-type residues S231 and 
the Q266 may interact by a H-bond.  Note that Q266H is also a startle disease mutation 
(Milani et al., 1996; Moorhouse et al., 1999). 
3.2.9.2 Hyperekplexia phenotype 
The S231N hyperekplexia GlyR mutation was first identified in a white Australian male 
patient with no family history of hyperekplexia. He had startle symptoms but responded well 
to clonazepam treatment. In this patient, the S231N missense mutation was found to be co-
inherited with the nonsense mutation S296X in TM3. The patient also had an asymptomatic 
sibling who carried the nonsense S296X mutation alone. Expression of the S296X nonsense 
mutation in HEK293 cells failed to produce functional channels, whereas both homomeric 
and heteromeric S231N GlyRs produced functional channels when expressed in HEK293 
cells. Glycine sensitivity was markedly decreased, as the glycine EC50 shifted by 13 fold for 
the S231N α1GlyR (from 20 to 262 µM) and 16 fold for heteromeric receptors (from 23 to 
383 µM); no change of the Hill slope was reported. The expression level of the mutant 
S231N GlyR was not affected as the number of cells expressing homomeric, or heteromeric, 
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S231N GlyRs were similar to the corresponding wild-type cells. This was tested by live cell 
imaging where quantification of HEK293 cells expression receptor of interest co-transfected 
with YFP enabled comparing the fluorescence intensity between different groups (Chung et 
al., 2010). There is no reported data regarding the influence of the S231N GlyR mutation on 
the relative maximal currents. The same study hypothesized that the S231N mutation was the 
only functional hemizygous allele of the α1GlyR in vivo as neither, homomeric nor 
heteromeric, S296X GlyR was functional. This was predicted because S296X is a nonsense 
mutation. The same study predicted that based on homology modelling of Torpedo α1βγα2ε 
nicotinic ACh receptor (nAChR) this mutation may produce some alteration in the 
transmembrane domain, (See Figure S3. A in Chung et al., 2010).  
3.2.9.3 Review of the literature reporting other mutations in the same residue: 
S231R 
S231R is another recessive homozygous hyperekplexia mutation found in a 6 years old boy 
of Iranian origin. Neither of his consanguineous parents displayed symptoms of 
hyperekplexia, nor his 8 years sister. Symptoms of hyperekplexia, like generalised jerks, were 
noticed in the patient since the third day after birth. Other symptoms of hyperekplexia, such 
as sudden falls caused by startle reaction, exaggerated head retraction, and increased muscle 
tone were also identified. Although treatment with clonazepam improved the patient’s 
condition, the patient was also deemed to have mild mental retardation and impairment in 
social behaviour. Immunoblotting and whole-cell recordings from HEK293 cells transfected 
with S231R α1 GlyR revealed reduced recptor expression and reduced channel function as 
glycine maximal current was reduced (Humeny et al., 2002). Another study (Villman et al., 
2009) confirmed that recombinant expression of homomeric, or heteromeric, α1 GlyR S231R 
resulted in reduced glycine-evoked whole-cell maximal current associated with reduced cell 
membrane integration.  So for the S231R mutation it is more likely that insufficient plasma 
membrane insertion has more effect on the reduced glycinergic inhibition than improper 
channel binding, or gating, by glycine. 
 
 
 
115 
 
S231A 
Another study evaluated the effect of alanine replacement of S231 in α1 GlyR and found that 
surface expression was unaffected when evaluated using [
35
S] methionine-protein labelling 
method (Haeger et al., 2010). 
 
3.2.10 Whole-cell recordings from human homomeric GlyR bearing the 
α1(S231N) hyperekplexia mutation 
To further characterize the α1(S231N) hyperekplexia mutation and determine if it has an 
effect on glycine efficacy as well as EC50, whole-cell experiments were conducted. Example 
whole-cell traces are shown in Figure 3.12. The mutation produced a significant decrease in 
glycine potency, with an increase in glycine EC50 of about four fold from 0.25 ± 0.03 to 1.16 
± 0.13 mM (n = 6, 4, respectively; p < 0.01, unpaired t-test; Table 3.3). The average Hill 
slope slope was comparable with that of wild-type GlyR 1.87 ± 0.37 (WT, n = 6), 1.11 ± 0.06 
(α1(S231N), n = 4; p > 0.05, unpaired t-test, Table 3.3). The maximum current was less than 
wild-type 10.34 ± 2.47 vs 2.05 ± 0.50 (p < 0.05, unpaired t-test; Table 3.3). The time course 
of the responses did not seem to be in any way different from those recorded from wild-type 
GlyR, but saturation was reached at about 20 mM.  Desensitisation was observed in responses 
to glycine concentrations greater than 0.2 mM, approximately EC10.   
3.2.11 Whole-cell recordings from human heteromeric GlyR expressing the 
α1(S231N) hyperekplexia mutation 
I next evaluated the effect of co-expression of the GlyR β subunit together with α1 S231N 
(α1: β ratio 1:40). Whole-cell recordings of the α1(S231N)β GlyRs showed a much greater 
reduction in glycine sensitivity than in homomeric channels bearing the same mutation.  
Glycine EC50 significantly increased by ~ 40 fold, from 0.10 ± 0.03 mM (wild-type) to 3.81 ± 
0.42 mM (α1(S231N)β, n = 6, 4, respectively; p < 0.01, unpaired t-test; Figure 3.13, Table 
3.4).  Desensitization was noticeable at glycine concentrations equal to or greater than 1 mM 
(EC20) and achieving maximum current response required a glycine concentration of 50 mM 
(Figure 3.13.A). The average Hill slope for α1(S231N)β was less than the corresponding 
wild-type, 1.12 ± 0.06 vs. 1.48 ± 0.09 (n = 4, 6, respectively;  p < 0.05, unpaired t-test; Table 
3.4). The expression level was sufficient to allow us to obtain recordings with average 
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maximal response of 3.84 ± 0.80 nA (n = 4) compared to 4.43 ± 1.08 nA (n = 6) for wild-type 
heteromeric GlyR (p = > 0.05, unpaired t-test; Table 3.4).  
Single-channel recordings of the homomeric channels were not tested as both homomeric and 
heteromeric wild-type GlyRs have similar maximal Popen. Also, the E103 α1 and α1β GlyR 
showed comparable glycine maximal Popen.  I decided to record from the heteromeric 
receptors as they represent the native form of synaptic GlyRs.  
3.2.12 Single-channel recordings of α1(S231N)β hGlyR 
Single channel recordings were done in the cell-attached configuration using a saturating 
glycine concentration of 100 mM. As sample single channel trace is illustrated in Figure 3.14. 
The trace clearly shows how the S231N α1 mutation profoundly changed the function of the 
heteromeric GlyR. Measurements of maximal Popen were done for each cluster separately and 
the maximum Popen was estimated as cluster open time/total cluster time (see Methods). The 
average maximum glycine Popen was found to be significantly reduced by the mutation, to 
0.38 ± 0.06 (n = 16 clusters, 3 patches; p < 0.0001, unpaired t-test), cf 0.98 ± 0.01 (n = 29 
clusters, 6 patches) in wild-type (Table 3.5).  
Different modes of openings were obvious within each cluster from three records. This 
phenomenon was not detected in wild-type heteromeric GlyR activated by saturating 
concentrations of glycine (Figure 3.4).  An attempt to measure the different modes of 
openings within the cluster is illustrated in Figure 3.14. Different parts of the cluster that 
seem to have similar mode of opening were first selected visually.  The beginning and the 
end of the area of interest was defined by using Clampfit 10.2 (see Methods) and Popen was 
measured for the selected part. It seems there are three modes of opening within the cluster 
(in this cluster) with approximate maximum Popen of 0.1, 0.4, and 0.8. All of these modes 
within the cluster contributed to a cluster approximate maximum Popen of 0.57.  The current 
amplitude was less than the corresponding wild-type GlyR with 2.01 ± 0.05 for α1(S231N)β 
(n = 29 clusters, 6 patches) and  3.07 ± 0.06 pA for (WT, n = 16 clusters, 3 patches; p < 
0.001, unpaired t-test; Table 3.5). The overall finding clearly indicates that the human 
hyperekplexia α1(S231N)β GlyR mutation impairs channel gating. 
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Figure  3.11 Partial sequence alignment of TM1 S231 GlyR with a selection of related 
pLGICs.  
A) Equivalent residues to the selected human α1 GlyR hyperekplexia mutation S231 are 
highlighted in green. Serine in this location is conserved in twenty two receptors. Uniprot 
accession numbers are indicated: human glycine α1 (P23415), human glycine α2 (P23416), 
human glycine α3 (O75311), human glycine α4 (Q5JXX5), human glycine β (P48167), 
bovine glycine α1 (P57695), bovine glycine β (Q9GJS9), zebrafish glycine α1 (O93430), rat 
glycine α1 (P07727), rat glycine α2 (P22771), rat glycine α3 (P24524), rat glycine α4 
(P28471), rat glycine β (P20781), mouse glycine α1(Q64018), mouse glycine α2 (Q7TNC8), 
mouse glycine α3 (Q91XP5), mouse glycine α4 (Q61603), mouse glycine β (P48168), C. 
elegans GluCl α (G5EBR3), C. elegans GluCl β (Q17328), D. melanogaster GluCl α 
(Q94900), H. contortus GluCl β (P91730), human GABAA α1 (P14867), human GABAA α2 
(P47869), human GABAA α3 (P34903), human GABAA α4 (P48169), human GABAA α5 
(P31644), human GABAA α6 (Q16445), human GABAA β1 (P18505), human GABAA β2 
(P47870), human GABAA β3 (P28472), human GABAA γ1 (Q8N1C3), human GABAA γ2 
(P18507), human GABAA γ3 (Q99928), human GABAA δ (O14764), human GABAA ε 
(P78334), human GABAA π (O00591), human GABAA θ (Q9UN88), human GABAA ρ1 
(P24046), human GABAA ρ2 (P28476), human GABAA ρ3 (A8MPY1), human α7 nAChR 
(P36544), human 5-HT3A (P46098), mouse 5-HT3A(P23979), GLIC (Q7NDN8), and ELIC 
(P0C7B7). B) Homology model based on C.elegans GluCl channel showing the location of 
the S231 residue in one subunit of GlyR α1 (see Yu et al., 2014).  
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Figure  3.12 Human α1(S231N) hyperekplexia mutation impaired the sensitivity of the 
homomeric hGlyR to glycine.  
A) Whole-cell current responses from HEK293 cells expressing human α1(S231N) GlyR. 
Glycine-evoked currents recorded at 50 mV. Glycine concentrations in mM are indicated 
above the traces; the bars show the duration of each application. B) Glycine concentration-
response curve (normalized to their maximal response) is shifted to the right by the mutation, 
with EC50 value of 1.16 ± 0.13 mM, n = 4. Data points in this figure represent mean values 
fitted to the Hill equation. nH = 1.11 ± 0.06, Imax = 2.05 ± 0.50 nA, n = 4 cells. Error bars 
indicate SEM.   
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Figure  3.13 The human heteromeric hyperekplexia α1(S231N)β GlyR mutation reduces 
the channel sensitivity to glycine.  
A) Whole-cell current responses from HEK293 cells expressing human α1(S231N)β GlyR. 
Glycine-evoked currents recorded at 50 mV. Glycine concentrations in mM are indicated 
above the traces; the bars show the duration of each application. B) Glycine concentration-
response curve (normalized to their maximal response) is shifted to the right by the mutation, 
with EC50 value of 3.81 ± 0.42 mM, n = 4. Data points in this figure represent mean values 
fitted to the Hill equation. nH = 1.12 ± 0.06, Imax = 3.84 ± 0.80 nA, n = 4 cells. Error bars 
indicate SEM. 
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Figure  3.14 The α1(S231N)β mutation decreases the maximum Popen of heteromeric 
GlyR in response to saturating concentration of glycine.    
Mutant GlyRs show different modes within a cluster. Representative single channel cell-
attached trace recorded at pipette potential +100 mV. Average maximal Popen was reduced to 
0.38 ± 0.06 in mutant GlyR (n = 16). Expanded view of the cluster is shown in the lower 
panel. Lines with different colours above the trace indicating different modes of Popen within 
the cluster (purple: 0.8, red: 0.4, blue: 0.1). Average amplitude = 2.01 ± 0.05 pA. 
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3.2.13 The Q266H mutation (14’TM2)   
3.2.13.1 Location   
The Q266 residue is part of the TM2 domain, which lines the channel pore (Figure 3.15). An 
alignment of the TM2 sequences (with the 14’ residue highlighted) of the human GlyR α1 
subunit with glycine receptor subunits from other species and with related pLGICs (obtained 
from Swiss-Prot, June, 2015) is shown in the same figure. There are 15 conserved glutamine 
residues homologous to the 266 glutamine located in 14’ TM2 in the human GlyR α1 subunit. 
These include human, rat and mouse α1, α2, α3, and α4, and bovine α1, whereas β subunits 
(in man, rat, mouse and cattle) have glutamate. Glutamine is conserved also in GlyR subunits 
of other species like α Z1 of Danio rerio (Zebrafish) and in GluCl α of both Caenorhabditis 
elegans and Drosophila melanogaster (fruit fly).      
The human hyperekplexia mutation Q266H induces a positive charge in the pore region 
which in theory might have beneficial effect for Clˉ ion flow through the transmembrane 
pore.  As indicated previously in this Chapter the Q266 residue might interact with the TM1 
S231 residue (Figure 3.5).  
3.2.13.2 Reported hyperekplexia family case 
Milani et al reported an Italian family with hyperekplexia caused by the α1(Q266H) GlyR 
mutation (Milani et al., 1996). The phenotype varied from one patient to another, but clearly 
became more severe with the third generation. Thus, in the family studied, no signs of 
hyperekplexia were observed in the adults of the first generation although the mutation was 
found in two members. This might be due to the disappearance of the symptoms in 
adulthood. All of the mutation carrier patients in the second and third generations had an 
exaggerated startle response. Hypertonia was found in one member of the second generation 
and in two members of the third generation. Apnoea attacks following myoclonic fits led to 
the death of a 45 days age infant, highlighting the severity of the symptoms in the third 
generation (Milani et al., 1996). 
3.2.13.3 Review of the literature reporting mutations in the same residue 
Q266H 
Glycine and taurine potency was found to be reduced by 6 fold in human homomeric α1 
Q266H GlyR expressed in HEK293 cells compared to WT GlyR (Moorhouse et al., 1999). 
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This mutation was also reported to reduce the sensitivity to glycine by 5 fold in another study 
using HEK293 cells (Castaldo et al., 2004). In the same study the whole-cell efficacy of β-
alanine, or taurine, relative to glycine was reduced compared to wild-type GlyRs (I β-alanine/I 
Glyine from 0.95 to 0.70, I Taurine/I Glycine from 0.90 to 0.50).  
Plasma membrane expression level of Q266H α1 GlyR in HEK293 cells was not affected as 
shown by western blot experiments for total lysates or streptavidin-purified biotinylated 
plasma membrane proteins. This indicated that the shift of the agonist sensitivity is due to 
modified channel function and not to alteration of insertion of the α1 Q266H subunit into the 
plasma membrane (Castaldo et al., 2004). 
It is likely that the Q266H α1 GlyR mutation changed efficacy by decreasing the open 
probability at high and low glycine concentrations (Moorhouse et al., 1999). Single channel 
recordings of α1 Q266H GlyR in outside-out patches showed that the mean channel open 
time  was shorter in mutant receptors than wild-type at different glycine concentrations (wild-
type: 1 - 50 µM; mutant 50 - 250 µM). The mean open time was calculated from individual 
time constants and their relative contributions. The single-channel conductance was similar 
between wild-type and Q266H glycine receptors. Although the ability of the channel to open 
with glycine was reduced, the displacement of strychnine binding by glycine was not affected 
(Moorhouse et al., 1999). 
This mutation was also reported to make the receptor less sensitive to zinc potentiation and 
more sensitive to zinc inhibition (Moorhouse et al., 1999). This will be explained further in 
the fourth Chapter  
Q266I 
Glycine sensitivity was reduced by nearly two fold in human homomeric α1(Q266I) GlyR 
expressed in HEK293 cells. In heteromeric Q266I GlyR the reduction in glycine sensitivity 
was somewhat smaller, less than two fold (Xiong et al., 2014). A reduction in glycine 
sensitivity was reported for the homomeric Q266I GlyR expressed in oocytes (Borghese et 
al., 2012). The same paper reported that ethanol (50 - 200 mM) enhancement of glycine 
submaximal current (EC5) was almost absent in oocytes expressing α1 Q266I GlyR. A 
reduced enhancement effect was also found for the following allosteric enhancers: 73 mM 
propanol, 11 mM butanol, 2.9 mM pentanol, and 0.57 mM hexanol. However, zinc 
modulation of glycine response was not changed (Borghese et al., 2012).  
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Furthermore, increased channel open time and decreased conductance was observed in 
outside-out single-channel recordings of HEK293 cells expressing α1(Q266I)β GlyR.  These 
data were obtained using 10 µM glycine and compared with the results obtained with 3 µM 
glycine in wild type channels (Borghese et al., 2012).  Note that these results contrast with 
those of Moorhouse et al., 1999). 
Homozygous Q266I knock-in mice displayed muscle tremor and motor control impairment. 
These mice usually died within three weeks (Borghese et al., 2012). Heterozygous α1 GlyR 
Q266I mice, however, survived and displayed increased startle response to sound stimuli (a 
hyperekplexia phenotype) (Blendnov et al., 2012; Borghese et al., 2012; Xiong et al., 2014).  
 
3.2.14 Whole-cell recordings from human homomeric GlyR bearing the 
α1(Q266H) hyperekplexia mutation 
Whole-cell concentration-response curves to glycine from HEK 293 cells expressing 
α1(Q266H) GlyR were obtained. Sample current responses to glycine are illustrated in Figure 
3.16.A. The risetime of the currents appeared to be faster with higher glycine concentrations 
and desensitization become clear at 0.5 mM (EC40).  The channel sensitivity to (0.1 – 50 mM) 
glycine was reduced significantly, as glycine EC50 was increased by 2.7 fold from 0.25 ± 0.03 
(wild-type) to 0.68 ± 0.17 mM (α1(Q266H)) GlyR, n = 6, 4, respectively (p < 0.01, unpaired 
t-test; Figure 3.16.B; Table 3.3). The Hill slope obtained was comparable with corresponding 
exhibited from wild-type GlyR 1.87 ± 0.37 (WT, n = 6) and 1.38 ± 0.40 (α1(Q266H),  n = 4;  
p > 0.05, unpaired t-test). The maximum currents were 10.34 ± 2.47 nA for the wild-type (n = 
6) and 5.27 ± 2.68 nA for α1(Q266H) GlyRs (n = 4;   p > 0.05, unpaired t-test, Table 3.3). In 
order to have sufficient expression of the Q266H GlyR in HEK293 cells, more plasmid was 
used than of wild-type GlyR (see Methods).   
 
3.2.15 Whole-cell recordings from human heteromeric GlyR expressing the 
α1(Q266H)β hyperekplexia mutation 
I investigated the effect of co-expression of the wild-type GlyR β subunit together with α1 
Q266H (α1: β ratio 1:40). Whole-cell concentration-response curves from HEK 293 cells 
expressing heteromeric GlyR were obtained (Figure 3.17).  Glycine-gated currents showed 
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desensitization with glycine concentrations of 0.5 mM (EC30) and above. Also, the risetime of 
the glycine current response was faster with increasing glycine concentration. A significant 
reduction in the channel sensitivity to glycine was observed in α1(Q266H)β GlyR, with 
glycine EC50 shifted from 0.10 ± 0.02 mM to 1.16 ± 0.19 mM for wild-type, Q266H GlyR 
respectively (n = 6, 5, respectively; p < 0.001, unpaired t-test, Table 3.4).  Thus the effect of 
the mutation was much larger in heteromeric GlyR, with a 10-11-fold decrease in glycine 
potency. 
The average maximal response to glycine for α1(Q266H)β GlyR was 9.07 ± 1.16 nA 
compared to average maximal response in wild-type 4.43 ± 1.08 (n = 5, 6, respectively, p > 
0.05, unpaired t-test). The Hill slope was similar for wild-type and the mutant GlyR with 1.48 
± 0.09 vs 1.35 ± 0.10 (n = 6, 5, respectively, p > 0.05, unpaired t-test; Table 3.4).  
 
3.2.16 Single-channel recordings of heteromeric α1(Q266H)β GlyR 
Single-channel currents in cell-attached configuration were investigated for the α1(Q266H)β 
GlyR using a saturating glycine concentration of 50 mM (Figure 3.18). Activation of the 
heteromeric Q266H glycine channels was detectable. However, reduced channel openings 
were observed, without obvious cluster type opening. After the short openings, the channel 
tended to desensitize.  
The lack of obvious clusters made it very difficult to estimate open probability with any 
degree of certainty. In the illustrated example, these were the only openings that were 
detected in the patch.  If we assume that the whole trace came from one channel, Popen could 
be measured from the first channel opening to the last opening as it was considered as one 
channel. In comparison to wild-type GlyRs, the average maximum Popen of human 
α1(Q266H)β GlyR was reduced significantly from 0.98 ± 0.01 ( n = 20 apparent clusters 
from 6 records) to 0.61 ± 0.06 (n = 29 clusters from 6 records; p < 0.001, unpaired t-test; 
Table 3.5). The average current amplitude of the mutant GlyR was 3.06 ± 0.08 pA (n = 20 
apparent cluster from 6 records) similar to the average current amplitude of wild-type 
receptors 3.07 ± 0.06 pA (n = 29 clusters from 6 records; p > 0.05, unpaired t-test; Table 3.5). 
The trace in the indicated figure shows that the Q266H mutation reduced the channel open 
probability. This effect suggests that the α1(Q266H)β mutation impaired the channel gating.   
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Conclusion- the Q266H GlyR mutants. This hyperekplexia mutation caused a significant 
reduction of the glycine potency and the effect is more marked in the heteromeric 
α1(Q266H)β GlyR  (2.7 cf ~ 12 fold change). This reduction is related to a significant 
reduction in the maximum open probability recorded in the cell-attached configuration from 
0.98 ± 0.01 to 0.61 ± 0.06. 
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Figure  3.15 Partial sequence alignment of TM2 Q266 GlyR with a selection of related 
pLGICs.  
A) Equivalent residues to the selected human α1 GlyR hyperekplexia mutation Q266 are 
highlighted in red. Glutamine in this location is conserved in fifteen subunits. Uniprot 
accession numbers are indicated: human glycine α1 (P23415), human glycine α2 (P23416), 
human glycine α3 (O75311), human glycine α4 (Q5JXX5), human glycine β (P48167), 
bovine glycine α1 (P57695), bovine glycine β (Q9GJS9), zebrafish glycine α1 (O93430), rat 
glycine α1 (P07727), rat glycine α2 (P22771), rat glycine α3 (P24524), rat glycine α4 
(P28471), rat glycine β (P20781), mouse glycine α1(Q64018), mouse glycine α2 (Q7TNC8), 
mouse glycine α3 (Q91XP5), mouse glycine α4 (Q61603), mouse glycine β (P48168), C. 
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elegans GluCl α (G5EBR3), C. elegans GluCl β (Q17328), D. melanogaster GluCl α 
(Q94900), H. contortus GluCl β (P91730), human GABAA α1 (P14867), human GABAA α2 
(P47869), human GABAA α3 (P34903), human GABAA α4 (P48169), human GABAA α5 
(P31644), human GABAA α6 (Q16445), human GABAA β1 (P18505), human GABAA β2 
(P47870), human GABAA β3 (P28472), human GABAA γ1 (Q8N1C3), human GABAA γ2 
(P18507), human GABAA γ3 (Q99928), human GABAA δ (O14764), human GABAA ε 
(P78334), human GABAA π (O00591), human GABAA θ (Q9UN88), human GABAA ρ1 
(P24046), human GABAA ρ2 (P28476), human GABAA ρ3 (A8MPY1), human α7 nAChR 
(P36544), human 5-HT3A (P46098), mouse 5-HT3A(P23979), GLIC (Q7NDN8), and ELIC 
(P0C7B7). B) Homology model based on C.elegans GluCl channel showing the location of 
the Q266 residue in one subunit of GlyR α1 (see Yu et al., 2014). 
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Figure  3.16 sensitivity of the human α1(Q266H) GlyRs to glycine. 
(A) Representative whole-cell current traces evoked by U-tube application of glycine (black 
bars) to HEK293 cells expressing recombinant α1(Q266H) GlyRs. Glycine concentrations in 
mM are indicated above the traces. Cells were held at – 50 mV. B) Average glycine 
concentration-response curve obtained from α1(Q266H) GlyRs is shifted to the right by the 
mutation, with EC50 value of 0.68 ± 0.17 mM. The solid line is a fit to the Hill equation. nH = 
1.38 ± 0.40, Imax = 5.27 ± 2.68 nA, n = 4 cells. Error bars indicate ± SEM.  
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Figure  3.17 Glycine  concentration-response curve of the human α1(Q266H)β GlyR. 
A) Sample whole-cell glycine current traces evoked by U-tube application of different 
concentrations to HEK293 cells expressing α1(Q266H)β GlyR (at – 50 mV). Concentrations 
of glycine are shown in mM. B) Average glycine concentration-response curves obtained 
from α1(Q266H)β GlyR is shifted to the right by ~12 fold, with EC50 value of 1.16 ± 0.19 
mM. Solid lines are fits to the Hill equation. nH = 1.35 ± 0.10, Imax = 9.07 ± 1.16 nA, n = 5 
cells. Error bars indicate ± SEM.  
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Figure  3.18 α1(Q266H)β GlyR mutation reduced the maximum Popen in response to 
saturating concentration of glycine (50 mM).  
The single-channel traces (cell-attached, pipette potential + 100 mV) show that the mutant 
receptor opens at lower maximum open probability. The average maximum Popen = 0.61 ± 
0.06, average amplitude = 3.06 ± 0.08 pA, n = 20 apparent clusters.   
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3.2.17 The (15’) S267N mutation 
3.2.17.1 Location 
The S267 residue is located in the 15’ position of the α1 GlyR TM2 domain (Figure 3.5). The 
serine residue is similar to the asparagine (present in the mutant) in that both are uncharged.  
However asparagine has a larger side chain that can affect vital interactions in the channel 
pore. Serine in the 15’ is conserved in twenty five pLGICs reviewed by Swiss-Prot (Figure 
3.19). It is conserved in all of the human GlyR alpha subunits α1, α2, α3, and α4. Bovine 
GlyR α1 and Danio rerio (zebrafish) GlyRαZ1 have a conserved residue in this location. 
Residues equivalent to S267 GlyR α1 are conserved in rat α1, α2, α3, and α4 GlyRs. Mouse 
α1, α2, α3, and α4 GlyR subunits have a conserved serine in the indicated position. The 
amino acid of interest is also conserved in the GluCl α of Caenorhabditis elegans and in 
some, but not all human GABAA receptor subunits (α1, α2, α3, α4, α5, α6, β1, γ1, γ2, and γ3 
subunits do have a S in 15’TM2) 
3.2.17.2 Reported hyperekplexia case 
A study conducted by Becker et al., (2008) reported a case of hyperekplexia due to S267N 
substitution of 15’ TM2 in a father and his son. A five weeks old patient was diagnosed with 
hyperekplexia as he had severe muscular hypertonia and hyperreflexia shortly after birth. 
With neurophysiological testing, acoustic stimuli resulted in the child startle response that 
affected the muscles of the head, neck and upper arms. The father reportedly had showed 
symptoms of hyperekplexia with later onset, but the mother was normal. The patient’s father 
had no symptoms of acoustic startle response in adulthood, but he displayed exaggerated 
reflexes. For both the father and the son epilepsy was excluded on the basis of EEG 
recordings. The patients were found to have a point mutation in the 267 residue of the GlyR 
shift from serine to asparagine. The cell membrane expression of GlyR with the S267N 
mutation was similar to wild-type as investigated by immunobloting. However, the 
electrophysiological recordings of α1 S267N GlyR expressed in HEK293 cells showed a 17 
fold increase in glycine EC50. In the same study heteromeric-heterozygous GlyR expressed at 
1:1:8 (α1WT/α1S267N/β), had a glycine sensitivity decreased by 5.5 fold. In homomeric 
S267N GlyR, the efficacy of β-alanine and taurine relative to glycine was reduced by 17% 
and 2%, respectively. Furthermore, this 15’ GlyR mutation abolished ethanol modulation of 
the mutant channel (Becker et al., 2008). 
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3.2.17.3 Other mutations in the same residue in GlyR 
S267I  
Testing different chimeric receptor constructs of GlyR α1 and GABAA ρ1 receptors 
expressed in Xenopus oocytes led to the finding of TM2 and TM3 residues important for 
alcohol and volatile anesthetic modulation (Mihic et al., 1997). The S267 residue in GlyR 
was found to be necessary for the ethanol modulation, as the S267I mutation resulted in loss 
of the enhancement by 200 mM ethanol. The potentiation of glycine submaximal responses 
by the volatile anaesthetic enflurane (1 mM) was reduced in the α1(S267I) GlyR (Mihic et 
al., 1997). 
S267Y 
In the same Mihic et al., (1997) study, the effect of enflurane was investigated on other 
mutations in the same position. α1(S267Y) GlyR was found to be resistant to the enhancing 
effect of 1 mM enflurane.  
S267Q    
S267Q is not a natural occurring hyperekplexia mutation. Transgenic mice with α1(S267Q) 
GlyR mutation were produced by the Blendnov group (Findlay et al., 2002). 
Electrophysiological recordings in Xenopus oocytes expressing α1(S267Q) GlyR showed that 
this mutation had no effect on the glycine EC50, in homomeric GlyR, however, with β subunit 
insertion there was a reduction in glycine potency by 5 fold (Findlay et al., 2003). Another 
study using the HEK293 expression system obtained completely different results, the S267Q 
mutation was found to increase glycine EC50 by nearly 3 fold for the homomeric receptors 
and to have no effect in heteromeric GlyR (Xiong et al., 2014).  
The same study examined whether the mutation has an effect on channel gating by outside-
out single-channel recordings of HEK293 cells transfected with α1(S267Q) GlyR (Findlay et 
al., 2003). The recordings showed brief openings with very unstable opening current 
amplitude. Also, a lack of burst like structure of openings was noticed. The records were 
interpreted only visually and the Popen was not measured (Findlay et al., 2003). 
In vivo assessment of the heterozygous knock-in mice bearing the α1(S267Q) mutation 
revealed an increased acoustic startle response (Findlay et al., 2003). The exaggerated startle 
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behaviour of the heterozygous α1(S267Q) mutant mice was observed also in another study 
(Xiong et al., 2014). The homozygous knock-in mice bearing the α1(S267Q) GlyR mutation 
displayed seizures and survived for only 20 days after birth (Findlay et al., 2003).  
Protein levels of GlyR α1 subunits for the heterozygous S267Q knock-in mice were assessed 
by immunoblotting and [
3
H] strychnine binding. The expression of alpha subunits of GlyR in 
the brain stem and spinal cord was not changed by the mutation (Findlay et al., 2003).  
3.2.17.4 Homologous residue in GABAA receptor subunits  
The role of GABAA receptor residues homologous to S267 GlyR was evaluated for the effect 
of ethanol and general anesthetics. Ethanol modulation of GABAA receptor α and β subunits 
was investigated. Ethanol enhancement of GABA evoked submaximal responses was reduced 
in α1(S270I)β1 and α2(S270I)β1, α1β1(S265I), and α1β3(N265I) GABAA receptors 
expressed in Xenopus oocytes (Mihic et al.,, 1997). The modulation effect of the volatile 
anesthetic enflurane was also decreased in homologous GABAA α1(S270I)β1, α2(S270I)β1, 
and α1β1(S265I) receptors (Mihic et al., 1997).  
Another study investigated by whole-cell recording the modulatory effect of the volatile 
anesthetics sevoflurane, desflurane and isoflurane on GABAA receptors bearing mutations in 
this position. The apparent GABA affinity for α1(S270W)β2γ2s, α1β2(N265W)γ2s, and 
α2(S270I)β3γ2s GABAA receptors expressed in HEK293 cells was reduced by 8, 2, 3 fold 
respectively. The α1(S270W)β2γ2s, α2(S270I)β3γ2s, GABAA receptors were found to be 
completely resistant to the potentiating effect of clinically relevant concentration of the 
anaesthetics (on responses to GABA EC20), and α1β2(N265W)γ2s showed a reduced 
response. This led the Authors to propose that the S270 residue of the α1 and α2 GABAA 
receptor subunits is essential for the action of the volatile anesthetics sevoflurane, desflurane 
and isoflurane (Nishikawa et al., 2003). 
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3.2.18 Whole-cell recordings from human homomeric GlyR bearing the 
α1(S267N) hyperekplexia mutation 
The literature suggests that the S267 residue is important for the GlyR and GABAA normal 
function. To examine the effect of the α1(S267N) GlyR mutation on the glycine potency, a 
concentration-response curve was obtained. Inward currents induced by glycine (0.5 to 50 
mM) were recorded. Representative recordings of the glycine-induced currents are shown in 
Figure 3.20.A. Desensitization was observed at 1 mM glycine (~ EC10). Decreased glycine 
potency was obvious as glycine EC50 shifted by around 18 fold, from 0.25 ± 0.03 in wild-type 
to 4.41 ± 0.36 in S267N (n = 6 for both; p < 0.001, unpaired t test; Figure 3.20.B; Table 3.2).  
Hill slope was not changed (1.71 ± 0.12; n = 6; p > 0.05, unpaired t-test, Table 3.2) and the 
average Imax was not significantly diffent from corresponding wild-type 6.41 ± 2.07 nA (n = 
6; p > 0.05; Table 3.2). 
3.2.19 Whole-cell recordings from human heteromeric GlyR bearing the 
α1(S267N) hyperekplexia mutation 
The effect of co-expression of wild-type β GlyR with α1(S267N) was examined. Current 
responses elicited by glycine applied at 1 - 50 mM are shown in Figure 3.21.A. 
Desensitization was observed from 1 mM (~ EC10). The α1(S267N)β mutation reduced the 
GlyR sensitivity to glycine. Glycine EC50 was increased significantly by 35 fold from 0.10 ± 
0.03 mM to 3.52 ± 0.46 (n = 6, 5, respectively; p < 0.01, unpaired t test; Table 3.3). Wild-
type and α1(S267N)β GlyR displayed comparable Hill slope: 1.48 ± 0.09 (wild-type; n = 6) 
and 1.54 ± 0.17 (α1(S267N)β; n = 5; p > 0.05, unpaired t-test). The average Imax was 3.93 ± 
1.03 nA, similar to values in wild-type receptors 1.48 ± 0.09 nA (n = 5, 6, respectively; p > 
0.05, unpaired t test; Table 3.4). 
3.2.20 Single-channel recordings of S267N GlyR 
Single-channel recordings of homomeric α1(S267N) GlyR were obtained in the cell-attached 
configuration using a saturating concentration of glycine (50 mM; Figure 3.22). It was 
impossible to analyze the records obtained from single-channel recordings of the homomeric 
S267N GlyR. Figure 3.22 shows the best recording that I could obtain, which is clearly 
uninterpretable.  All of the 10 recorded patches showed similar activity, although obtained on 
different days and different transfections.  While the traces may appear to be poor quality 
135 
 
recordings, due to poor seals, this was not the case, and  recordings from wild-type GlyRs 
obtained on the same day were normal and of good quality.     
Single-channel recordings of the heteromeric α1(S267N)β GlyR were obtained in the cell-
attached configuration using saturating concentration of glycine (50 mM; Figure 3.23). It 
seems that β subunit insertion has slightly improved the single-channel activity compared to 
homomeric α1(S267N) GlyRs. Even so, throughout the records there was a mixture of brief 
and long openings which suggests a profound disruption of the channel behaviour. 
Measurement of Popen was conducted when the openings looked similar to the cluster outlined 
by the blue box in the figure. The average approximate Popen was reduced significantly from 
0.98 ± 0.01 (n = 29 clusters obtained from 6 records) to 0.37 ± 0.06 (n = 6 clusters obtained 
from 3 records; p < 0.001, unpaired t-test; Table 3.5). The current amplitude was similar to 
wild-type 3.09 ± 0.24 pA vs 3.07 ± 0.06 pA (p > 0.05, unpaired t-test; Table 3.5). 
Conclusion- the S267N GlyR mutants. This 15’ hyperekplexia mutation caused a marked 
reduction in glycine potency. This effect is more noticeable in the heteromeric channel (18 cf 
~ 35 fold change).  The reduction in the potency is associated with a disturbance of channel 
gating. The maximum open probability recorded in the cell-attached configuration was 
measured for the heteromeric α1(S267N)β GlyR and indicated a significant reduction in 
channel gating. 
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Figure  3.19 Partial sequence alignment of TM2 S267 GlyR with a selection of related 
pLGICs.  
A) Equivalent residues to the selected human α1 GlyR hyperekplexia mutation S267 are 
highlighted in purple. Serine in this location is conserved in twenty five receptors. Uniprot 
accession numbers are indicated: human glycine α1 (P23415), human glycine α2 (P23416), 
human glycine α3 (O75311), human glycine α4 (Q5JXX5), human glycine β (P48167), 
bovine glycine α1 (P57695), bovine glycine β (Q9GJS9), zebrafish glycine α1 (O93430), rat 
glycine α1 (P07727), rat glycine α2 (P22771), rat glycine α3 (P24524), rat glycine α4 
(P28471), rat glycine β (P20781), mouse glycine α1(Q64018), mouse glycine α2 (Q7TNC8), 
mouse glycine α3 (Q91XP5), mouse glycine α4 (Q61603), mouse glycine β (P48168), C. 
elegance GluCl α (G5EBR3), C. elegans GluCl β (Q17328), D. melanogaster GluCl α 
(Q94900), H. contortus GluCl β (P91730), human GABAA α1 (P14867), human GABAA α2 
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(P47869), human GABAA α3 (P34903), human GABAA α4 (P48169), human GABAA α5 
(P31644), human GABAA α6 (Q16445), human GABAA β1 (P18505), human GABAA β2 
(P47870), human GABAA β3 (P28472), human GABAA γ1 (Q8N1C3), human GABAA γ2 
(P18507), human GABAA γ3 (Q99928), human GABAA δ (O14764), human GABAA ε 
(P78334), human GABAA π (O00591), human GABAA θ (Q9UN88), human GABAA ρ1 
(P24046), human GABAA ρ2 (P28476), human GABAA ρ3 (A8MPY1), human α7 nAChR 
(P36544), human 5-HT3A (P46098), mouse 5-HT3A (P23979), GLIC (Q7NDN8), and ELIC 
(P0C7B7). B) Homology model based on C.elegans GluCl channel showing the location of 
the S267 residue in one subunit of GlyR α1 (see Yu et al., 2014).  
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Figure  3.20 The human homomeric hyperekplexia S267N GlyR mutation reduces the 
channel sensitivity to glycine.  
A) Whole-cell current responses from HEK293 cells expressing human S267N α1 GlyR. 
Glycine-evoked currents recorded at 50 mV. Glycine concentrations in mM are indicated 
above the traces; the bars show the duration of the application. B) Glycine concentration-
response curve (normalized to their maximal response) is shifted to the right by ~18 fold, 
with EC50 value of 4.41 ± 0.63 mM. Data points in this figure represent mean values fitted to 
the Hill equation. nH = 1.71 ± 0.12, Imax = 6.41 ± 2.07 nA, n = 6 cells. Error bars indicate 
SEM (shown only when larger than the symbol).  
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Figure  3.21 Human α1(S267N)β mutant GlyR expressed in HEK293 cells have a 
reduced sensitivity to glycine.  
A) Example whole-cell traces showing inward chloride current responses to the indicated 
glycine concentrations in mM.  Glycine-evoked currents recorded at 50 mV. Bars above the 
traces show the duration of glycine application glycine.  B) Average glycine concentration-
response curve for the heteromeric α1(S267N)β GlyR is shifted to the right by ~35 fold, with 
EC50 value of 3.52 ± 0.46 mM.  The curve is a fit to the Hill equation. nH = 1.54 ± 0.17, Imax = 
3.93 ± 1.03 nA, n = 5 cells. Error bars represent SEM (shown only when larger than the 
symbol).  
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Figure  3.22 Example of single channel activity of the α1 (S267N) GlyR in response to 
saturating concentration of glycine (50 mM).  
Openings of the channels were recorded in the cell-attached configuration at a holding 
potential of + 100.  There is no clear clustering of the openings. Measurement of Popen is not 
possible. Channel openings upward. (3 kHz filtered for display). 
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Figure  3.23 The S267N mutation decreases the maximum Popen of heteromeric GlyR in 
response to saturating concentration of glycine (50 mM).    
Representative single channel cell-attached trace recorded at pipette potential +100 mV. 
Average maximal Popen was reduced to 0.37 ± 0.06 in mutant GlyR (n = 6). Expanded view of 
the cluster is shown in the lower panel. 
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Table  3.3 Functional properties of the selected human homomeric  hyperekplexia 
mutant GlyR.   
Receptor 
Glycine  
EC50 (mM) 
EC50  
Fold change 
I max (nA) nH n 
α1WT  0.25 ± 0.03 - 10.34 ± 2.47 1.87 ± 0.37 6 
α1(E103K)  0.71 ± 0.11#  2.84 2.73 ± 1.41 1.32 ± 0.07 3 
α1(S231N)  1.16 ± 0.13 ‡ 4.64 2.05 ± 0.50 * 1.11 ± 0.06 4 
α1(Q266H)  0.68 ± 0.17 ‡  2.7 5.27 ±  2.68 1.38 ± 0.40 4 
α1(S267N)  4.41 ± 0.36 # 17.64 6.41  ± 2.07 1.71 ± 0.12 6 
Data are expressed as mean ± SEM, statistically different from WT α1 GlyR (* p < 0.05, ‡ p 
< 0.01, # p < 0.001) unpaired t-test.  
Table  3.4 Functional properties of the selected human heteromeric hyperekplexia 
mutant GlyR. 
Receptor 
  Glycine  
EC50 (mM) 
EC50  
Fold change 
I max (nA) nH n 
α1β WT 0.10 ± 0.03 - 4.43 ± 1.08 1.48 ± 0.09 6 
α1(E103K)β 7.27 ± 0.58 # 72.7 3.62 ± 0.89 1.22 ± 0.08 6 
α1(S231N)β 3.81 ± 0.42 ‡ 38.1 3.84 ± 0.80 1.12 ± 0.06 * 4 
α1(Q266H)β 1.16 ± 0.19 # 11.6 9.07 ± 1.16 1.35 ± 0.10 5 
α1(S267N)β 3.52 ± 0.46 ‡ 35.2 3.93 ± 1.03 1.54 ± 0.17 5 
Data are expressed as mean ± SEM, statistically different from WT α1β GlyR (* p < 0.05, ‡ p 
< 0.01, # p < 0.001) unpaired t-test.  
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Table  3.5 Single-channel properties of the selected human hyperekplexia mutations and 
wild-type GlyRs using saturating glycine concentration 
Receptor Maximum Popen Amplitude (pA) [Glycine] mM n Clusters  n Records 
α1WT 0.99 ± 0.002 5.77 ± 0.06 10 30 4 
α1β WT 0.98 ± 0.01 3.07 ± 0.06 1 29 6 
α1(E103K)  0.73 ± 0.07 ‡ 5.24 ± 0.12 50 13 3 
α1(E103K)β 0.67 ± 0.06 ‡ 3.10 ± 0.16 50 5 3 
α1(S231N)  - - - - - 
α1(S231N)β 0.38 ± 0.06 #   2.01 ± 0.05 # 100 16 3 
α1(Q266H)  - - - - - 
α1(Q266H)β 0.61 ± 0.06 # 3.06 ± 0.08 50 20 6 
α1(S267N)  - - - - - 
α1(S267N)β 0.37 ± 0.06 # 3.09 ± 0.24 50 6  3 
Data are expressed as mean ± SEM, statistically different from WT α1 GlyR (* p < 0.05, ‡ p 
< 0.01, # p < 0.001) unpaired t-test.  
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3.2.21 Human hyperekplexia mutations that were excluded from the study 
Most of the homomeric, or heteromeric, glycine mutant receptors that I studied here 
responded to glycine with macroscopic currents that were large enough to allow further, 
single channel investigations. The exceptions were GlyRs bearing the R72H or the Y279C 
mutation in the 1 subunit (Coto et al., 2005; Shiang et al., 1995; Lynch et al., 1997).  
R72H is an autosomal recessive mutation. The residue is located in loop D of the ECD. There 
was no electrophysiology work done on it at the time that I was conducting the experiments. 
R72H homomeric GlyRs showed no detectable response to 10 or 20 mM glycine (even when 
55% or 82% of α1 cDNA was used). A recent study (Schaefer et al., 2015) reported that no 
response to glycine was detected in whole-cell recordings from homomeric R72H expressed 
in HEK293 cells. Using an immunocytochemical technique, they observed a reduction in the 
whole-cell protein expression of α1 GlyR and a huge reduction of cell surface expression of 
R72H.  The receptor failed to reach the cell surface and was retained in the endoplasmic 
reticulum, indicating a trafficking defect (Schaefer et al., 2015).  
Schaefer et al. (2015) investigated only homomeric receptors. For the heteromeric GlyR 
bearing the R27H mutation, I observed a response to glycine although it was small. For 
instance U-tube application of 20 mM glycine to HEK293 bearing α1(R72H)β GlyR (α1: β 
ratio 1:40) elicited currents of about 80 pA (n = 3 cells). Also, when a α1: β ratio of 1: 3 was 
used, the response was small (60 pA) to 100 mM glycine (n = 1 cell). Thus, it was impossible 
to include this mutation in the detailed single channel kinetic characterization study.   
Expression of homomeric GlyRs bearing the dominant Y279C hyperekplexia mutation 
(TM2-TM3 loop) did not produce a detectable response to 20 mM glycine (n = 3). This is 
maybe due to the huge maximum current reduction that was reported (Lynch et al., 1997). 
However, small currents (about 600 pA in response to 50 mM) were recorded in heteromeric 
GlyRs, suggesting that expression of the β subunit might partially rescue the channel 
activation, or expression (n = 2). Since the responses were too small for proper kinetic 
characterisation of the mutant, no further work was carried out for these mutants. 
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3.3 Discussion 
There are many α1GlyR missense mutations related to hyperekplexia. Characterizing their 
functional consequences might help us in expanding our knowledge about the structure 
function relation of GlyRs.  
What do we know about how hyperekplexia mutations affect the activation mechanism of 
GlyRs?  The most solid way to establish this is to characterise the activation mechanism of 
the mutant channel by single channel kinetics.  This is not an easy task, as witnessed by the 
fact that this has been achieved only for the heteromeric K267E GlyRs (Lape et al., 2012). It 
was shown that the TM2-TM3 K276E human hyperekplexia mutation impaired the channel 
gating by slowing down access to the several intermediate shut states that occur before the 
channel opens. The open channel probability of the heteromeric α1(K276E)β GlyR at 100 
mM glycine was reduced from 96% in wild-type to 45% (Lape et al., 2012).  
A less complete single channel characterisation was carried out on another human 
hyperekplexia mutation, Q266H, by Moorhouse et al. (1999).  This study proposed that this 
mutation affected channel gating, because they detected a significant reduction in the channel 
open time. Whereas the mean open time for the wild-type receptors in response to low 
glycine concentrations was 4.75 ± 0.86 ms, it was reduced to 0.98 ± 0.12 ms for the 
homomeric Q266H GlyRs. The response to a saturating glycine concentration was not 
reported (Moorhouse et al., 1999). In both cases K267E and Q266H, channel impairment was 
accompanied by changes in glycine sensitivity.  
The initial aim of my Thesis was to screen mutations and identify one that was suitable for a 
full kinetic characterisation, but this aim was found not to be realistic in the time available, as 
many of the mutant receptors were found to be hard to characterise at the single channel level 
because of heterogeneity and lack of clustering. 
Nevertheless, by measuring where possible glycine maximum open probability I found that 
many of the mutations were likely to act by causing impairments in gating.  
This makes sense, because what matters for pathological impairment in human disease is the 
effect of mutations on glycinergic synaptic transmission. It is estimated that in the synaptic 
cleft glycine reaches relatively high concentrations (2.2-3.5 mM, Beato et al., 2008).  Thus 
glycinergic IPSCs would be expected to be relatively robust to changes in GlyR binding 
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affinity. Note also that the most important receptor type to examine is the heteromeric GlyR, 
which is the subtype found at adult glycinergic synapses. In addition to that, it is to be 
expected that the most accurate in vitro reproduction of hyperekplexia GlyR would be with 
recessive mutations, as with dominant mutations in vivo receptors would contain a mixture of 
WT and mutant subunits. 
 I will review briefly my findings below. 
The E103K, S231N, Q266H, and S267N human hyperekplexia mutations are in positions  
that are conserved in many pLGICs. Measuring the Popen of the single-channel activity gave a 
reasonable explanation behind the altered glycine sensitivity.  
E103K. The residue E103 is located in the ECD at loop A of the principal subunit.  In the 
E103K GlyR mutant the glycine EC50 is shifted by 2.8 and ~70 fold for α1 and α1β, 
respectively (Table 3.3; Table 3.4). The incorporation of wild-type β subunit with α1 E103K 
was expected to reduce the observed impairment of the glycine EC50 but it did not.  
A change in glycine sensitivity was also reported for other non-hyperekplexia mutations in 
this location, e.g. E103A and E103C (Han et al., 2001; Vafa et al., 1999; Table 3.2). Also, 
glycine sensitivity was affected by mutating nearby residues like N102A, N102C, K104C, 
and K104A (Han et al., 2001; Vafa et al., 1999; Schmieden et al; 1999; Table 3.2). Single-
channel recordings in the cell-attached configuration of GlyR bearing E103K showed a 
significant reduction of maximum channel Popen (Table 3.5). The reduction in the Popen was 
similar for the homomeric and heteromeric channels, from 0.99 ± 0.002 to 0.73 ± 0.07 and 
0.98 ± 0.01 to 0.67 ± 0.06, respectively. So this residue might have an effect on gating 
although it is in the extracellular domain. Further discussion regarding this location will 
follow in Chapter five. 
S231N. This residue is located in the TM1 domain. The hyperekplexia mutation leads to a 
shift in the glycine EC50 whether expressed in homomeric, or heteromeric, GlyRs. 
Interestingly, the effect of the S231N mutation was much greater in heteromeric channels, 
with a reduction in glycine sensitivity of 38 fold cf.~ 5 fold for homomers response (Table 
3.3; Table 3.4). This supports earlier findings obtained by whole-cell recordings from 
HEK293 cells bearing α1 (S231N), or α1 (S231N) β GlyR mutations (Chung et al., 2010). 
Glycine maximal current was reduced for another hyperekplexia mutation in the same region 
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α1 S231R GlyR (Humeny et al., 2002) and resulted from deficient plasma membrane 
insertion (Villman et al., 2009). 
It was recently reported that another GlyR TM1 α1 subunit mutation, Q226E, induces 
spontaneous channel opening, probably by changing an electrostatic attraction to the TM2 
R271 (Bode et al., 2013). As a result of the attraction the top part with the TM2 domain is 
tilted toward the TM1 domain away from the channel pore. So even though the mutation is in 
the TM1 domain, it can have an effect on channel gating. In this particular case, there might 
be an interaction between the side-chain of Q266 and S231. S231N can introduce some steric 
effect to the local region. This might affect the interactions between the TM1 and TM2 
domains affecting channel gating. 
I showed here that the channel gating is affected by the TM1 domain S231N. The single-
channel recordings of α1β GlyR showed that the average maximum glycine Popen was 
reduced from 0.98 ± 0.01 in wild-type to 0.38 ± 0.06 (Table 3.5). This reduction in maximum 
Popen was accompanied by heterogeneity in the channel openings where variable modes were 
noticed.  Different modes within the cluster were seen in most, or all, clusters and absent 
from wild-type recordings. We do not know what causes the gating modes. We have no 
explanation for that, but now we can speculate that this residue has a role in maintaining 
homogeneous modes of openings. We also show that this residue can have an impact on 
channel gating. Taking into consideration that this residue is conserved in 22 pLGIC might 
point to the importance of this residue. To date at this locus there are two human 
hyperekplexia mutations (S231N and S231R) and both are recessive (Table 3.1).   
Q266H. Q266H is a human hyperekplexia mutation affecting the 14’ residue at TM2 domain 
of the α1 subunit. Given that is part of the pore-lining domain, close to the presumed channel 
gate, it is possible that the presumed charge change with the replacement of glutamine to 
histidine may affect channel gating. I showed that glycine potency is reduced by this 
mutation by ~ 3 fold for homomeric and ~ 12 fold for heteromeric receptors (Table 3.3; Table 
3.4). Previous studies had indicated that α1 Q266H reduced glycine sensitivity by 5 fold 
(Castaldo et al., 2004) and 6 fold (Moorhouse et al., 1999). Glycine potency was reduced by 
another mutation in the same location, α1 Q266I GlyR which also affected sensitivity to 
alcohols (Borghese et al., 2012; Xiong et al., 2014).   
In the introduction to this Chapter I have described the conflicting reports on the effect of this 
mutation on channel open times (Moorhouse et al., 1999 and Borghese et al., 2012) in 
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homomeric and heteromeric mutant GlyRs.  What seems most important to me is my 
measurement of a reduced maximum Popen for the heteromeric Q266H (from 0.98 ± 0.01 to 
0.61 ± 0.06 (Table 3.5).   
A hypothesis for the mechanism of the functional effect of the Q266H mutation was put 
forward by a high-resolution NMR structure study of α1 human GlyR TM2 in isolation (Tang 
et al., 2002). The study indicated that the side chains of Q14’ narrow the channel pore during 
the movement of the TM2 from open to closed state. In case of the presence of an anion near 
the positive side chains of histidine (in case of Q266H) the channel tended to favour the 
closed channel state. While the NMR study indicated that the side chains of the Q266 are 
exposed to channel lumen, the mutagenesis study indicated it is not (Moorhouse et al., 1999; 
Tang et al., 2002).  
S267N. The S267N human hyperekplexia mutation alters a highly conserved residue located 
at the 15’ of the pore lining TM2 domain of the α1 subunit. This residue was found to be vital 
for ethanol and general anesthetic modulation (Mihic et al., 1997; Lobo et al., 2005). It 
appears that this residue is vital for GlyR function, as homozygous S267Q knock-in mice 
died within three weeks after birth and heterozygous mice survived with a markedly 
increased acoustic startle response (Findely et al., 2003).  
I found that glycine potency was reduced significantly for both the α1 (S267N) and α1 
(S267N) β GlyRs (Table 3.3; Table 3.4). This supports the previous findings (Becker et al., 
2008). The reduced glycine sensitivity was more marked for the heteromeric receptors than 
the homomeric receptors (35 fold vs 18 fold). 
Single-channel recordings of the homomeric S267N mutant with a saturating glycine 
concentration showed a high frequency of brief individual openings and proper clustering of 
the openings was missing. This unfortunately made the records not useful for Popen analysis. 
Nonetheless, the profound disturbance in channel opening supports the hypothesis that the 
mutation impairs channel gating. A shortening of channel opening was reported for a 
different mutation in the same residue (α1 S267Q GlyR, Findely et al., 2003). Whereas the 
gating was severely impaired in case of the homomeric receptor, the heteromeric S267N 
receptors were somewhat less impaired. This can be explained by the fact that the homomeric 
receptors have the mutation in all of the five subunits in the pentamer, but in the heteromeric 
receptor there are at least two wild-type β subunits which may improve the response. Partial 
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rescue of the channel function was previously observed for the heteromeric K276E 
hyperekplexia mutant (Lape et al., 2012). 
The α1(S267N)β GlyR when saturated by 50 mM glycine reached less than half (0.37 vs 
0.98; Table 3.5) the Popen of the wild-type GlyR, so the reduction of the maximum Popen was 
still marked. So both of the TM2 domain mutations 14’ Q266H and 15’ S267N which are 
described here affect glycine potency and channel gating. What about other human 
hyperekplexia mutations next to those mutations? Do they affect glycine potency, efficacy or 
both? There are many reported dominant human hyperekplexia mutations affecting the TM2 
domain. Mutation of 13’ T265I reduced glycine EC50 by 15, 33 fold for homomeric, 
heteromeric receptors, respectively (Chung et al., 2010). The effect of this pore-forming TM2 
domain on single-channel Popen was not reported. The functional effect of the 16’ 
hyperekplexia mutation is not determined (Lapunzina et al. 2003).  
The pattern of single-channel activation of the E103K, S231N, Q266H, and S267N human 
hyperekplexia mutations using saturating glycine concentration was different from the 
previously examined wild-type glycine receptors rat α1, α1β (Beato et al., 2004; Burzomato 
et al., 2004) or the wild-type receptor in this study. Also it differed from the murine 
hyperekplexia heteromeric α1 (A52S) β and from the human hyperekplexia heteromeric 
K276E GlyR (Plested et al., 2007; Lape et al., 2012). The presence of different modes within 
the cluster in case of α1(S231N)β, absence of the cluster pattern in α1(S267N) are good 
examples of how changing single amino acid can disrupt the normal channel behaviour.  
 
Conclusion 
I showed that E103K, S231N, Q266H, and S267N human hyperekplexia mutations within the 
α1 subunit changed glycine potency. The change in glycine sensitivity was more marked in 
the heteromeric than in the homomeric receptors. These hyperekplexia mutations affected the 
channel gating by reducing the maximum Popen (Table 3.5). Notice that two mutations 
reduced the maximum Popen to above 50% and the other two to less than 50%. This study 
shows that there are residues in addition to the pore lining elements can contribute to channel 
gating including the ECD E103 and TM1 domain S231 residues. The next step was to 
determine whether the glycine response of the heteromeric mutant GlyRs can be rescued 
using GlyR modulators. 
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4 Chapter 4: The effect of propofol on 
human hyperekplexia mutant α1β GlyR 
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4.1 Introduction 
4.1.1 Modulators of GlyRs 
A number of allosteric modulators of the GlyRs have been identified. These include 
avermectins (e.g. ivermectin), cannabinoids (e.g. anandamide), neuroactive steroids (e.g. 
alphaxalone and minaxalone), volatile general anaesthetics (e.g. isoflurane and enflurane), 
intravenous general anaesthetics (e.g. propofol), tropeines (e.g. tropisetron), bivalent cations 
(zinc), glutamate, and alcohols (e.g. ethanol and trichloroethanol). The binding site of the 
modulator can be either to the glycine binding site or to an allosteric site (Lynch, 2004; 
Yevenes and Zeilhofer, 2011). 
 
4.1.2 Propofol 
Since the mid of the 19
th
 century general anaesthetics have been in use in clinical practice. In 
addition to loss of consciousness these drugs can introduce amnesia, analgesia and muscle 
relaxation. It is believed that most of the general anaesthetics produce their modulatory 
actions by either binding or modulating the response of  pLGICs, however, the precise 
mechanism governing their action is not clear (Franks and Lieb, 1994, Chau et al., 2010). 
Currently used inhaled general anaesthetics include nitrous oxide (N2O), sevoflurane, 
isoflurane, desflurane, and xenon. The intravenous general anaesthetics include propofol, 
ketamine, methohexital, etomidate, and thiopental (Garcia et al., 2010, Chau et al., 2010).  
Propofol (2-6 diisopropylphenol) was first introduced in the 1980s.  In man the estimated 
clinical concentration of propofol not bound to plasma proteins during total intravenous 
anaesthesia is in the sub micro molar range (0.5 to 1.1 µM) (Pistis et al., 1997, Franks et al., 
2008, Garcia et al., 2010). Although propofol is used extensively in clinical anaesthesia, its 
mechanism of action on the CNS is still not well understood with regards to the exact areas of 
the CNS responsible for the effect of propofol on consciousness.  A review of functional 
imaging studies suggests that in human brain the frontal and parietal lobes, thalamus, 
hypothalamus, posterior cingulate cortex and pons areas are associated with the anesthetic 
effects of propofol (Song and Yu, 2014). It is generally accepted that propofol acts by 
increasing GABA-mediated inhibitory neurotransmission in the CNS. Propofol has two 
opposing effects on pLGICs. While it potentiates the anion selective channels i.e. GABAA 
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and glycine receptors (Zeller et al., 2008, Nguyen et al., 2009), it inhibits the cation-selective 
5HT3Rs (Rüsch et al., 2007), and the nAChRs (Flood et al., 2007). It also inhibits GluCl 
(Lynagh and Laube, 2014) and GLIC (Ghosh et al., 2013, Sauguet et al., 2013).  
4.1.3 Propofol action on GABAA receptors  
Propofol is well known for its ability to enhance GABAA receptor activity as a PAM and high 
concentrations of propofol can directly activate GABAA receptors. This was supported by 
various studies performed using different native, or expression, systems:  
In murine cultured spinal neurons propofol (1.7-16.8 µM) reversibly enhanced GABAA 
receptor activity measured as whole-cell submaximal (100 µM) GABA-activated currents 
(Hales and Lambert, 1991). 
The effect of propofol on GABAA α1β1 γ2L receptors expressed in oocytes was evaluated by 
Pistis et al. (1997). Whole-cell currents elicited by GABA at EC10 were potentiated by 
propofol (0.03-10 µM). The observed potentiation was nearly equal to the maximum current 
produced from GABA at saturating concentration. Direct activation of GABAA receptors by 
propofol (10-300 µM) was also observed in the absence of GABA (Pistis et al., 1997). In 
addition, the positive allosteric modulation of 0.3 – 60 µM propofol was tested on oocytes 
expressong wild-type GABAA α6β3 γ2L receptors (Belelli et al., 1999). Propofol was found to 
enhance EC10 GABA evoked current to achieve 180 ± 26 % of the GABA maximum 
response. Propofol (10-300 µM) in the absence of GABA induced currents reaching up to 41 
± 4% of the GABA Imax (Belelli et al., 1999). 
The effect of propofol on agonist efficacy was tested by whole-cell recordings from HEK293 
cells expressing α1β1γ2S GABAA receptors (O’Shea et al., 2000). The efficacy of the partial 
agonist piperidine-4-sulphonic acid (P4S) was increased by propofol. Propofol (2 µM) was 
effective in potentiating the response to submaximal P4S concentration and no direct receptor 
activation was found at this low concentration. The relative efficacy of P4S was increased 
from 0.65 ± 0.03 to 0.86 ± 0.02 in the presence of propofol. This might indicate an effect of 
propofol on channel gating (O’Shea et al., 2000). 
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4.1.4 Propofol action on GlyRs 
While propofol is well known for its action on the GABAA receptor, it also enhances the 
function of the glycine receptor. The ability of propofol to potentiate wild-type glycine 
receptor currents was tested in several electrophysiology studies (Table 4.1).  
Propofol (5µM) potentiation of glycine EC2 current was around 120% as evaluated by whole-
cell recordings from Xenopus oocytes expressing human wild-type α1 GlyR (Mascia et al., 
1996). The potentiation effect of propofol was reversible. Similar results were found for the 
homomeric α2 GlyRs (Mascia et al., 1996).     
The positive allosteric modulation of glycine receptors by propofol was tested in another 
study, also in Xenopus oocytes. Glycine (EC10) evoked currents were potentiated by 100 µM 
propofol to reach 85 ± 5% of the of the glycine Imax in α1GlyR. In heteromeric α1β GlyR, 
glycine (EC10) activated currents were potentiated to 98 ± 6% of the glycine Imax by 300 µM 
propofol. The effect of propofol potentiation was similar in the homomeric and heteromeric 
GlyRs expressing wild-type channels (Pistis et al., 1997). Also, it was reported that 100 µM – 
1mM propofol in the absence of glycine activated both the homomeric and heteromeric 
GlyRs resulting in small currents of 12 ± 6%, 8 ± 2% of the glycine Imax. Propofol induced 
currents were inhibited by the glycine antagonist strychnine and potentiated by zinc (Pistis et 
al., 1997). 
In another study also in oocytes expressing wild-type homomeric GlyRs, lower propofol 
concentrations were tested (1-100 µM). The response to glycine EC10 was potentiated by 
propofol 100 µM to reach 85 ± 5 % of the glycine maximum current (Belelli et al., 1999). 
Similarly, by the allosteric action of propofol was tested on oocytes bearing wild-type 
homomeric GlyRs O’Shea et al. (2004). Propofol (1 µM) potentiated submaximal glycine 
currents, but the maximum potentiation was found with 0.5 mM propofol. However, at 
saturating glycine concentration no potentiation effect was found when propofol was co-
applied with glycine to the wild-type α1 GlyRs. The glycine, β-alanine, and taurine EC50 
values were reduced by 10, 23, and 32 fold, respectively, in response to 0.5 mM propofol co-
application. Also, the same study indicated that during the pre-application of 0.5 mM 
propofol no direct activation occured. The maximal response of wild-type α1GlyR to the 
partial agonists β-alanine and taurine was potentiated by 0.5 mM propofol to about the 
maximum response of glycine (O’Shea et al., 2004). 
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HEK293 cells expressing wild-type α1 and α1β GlyRs were tested for propofol modulation. 
Co-application of propofol (3-300 µM) with glycine EC20 potentiated the glycine-gated 
currents up to 100 ± 5 % Imax (Ahrens et al., 2008). The same study reported the ability of 
100 µM propofol to directly activate the GlyRs in the absence of glycine. This effect was 
observed for both the homomeric and heteromeric receptors (Ahrens et al., 2008). The effect 
of propofol modulation on HEK293 cells expressing wild-type α1GlyRs was evaluated in 
another study. Co-application of glycine EC10 with 30 µM propofol potentiated the glycine 
gated current by ~350 % (Moraga-Cid et al., 2011).  
The modulatory effect of propofol on wild-type homomeric GlyRs expressed in oocytes was 
also reported recently (Lynagh and Laube, 2014). Co-application of glycine EC20 with 
variable propofol concentrations (0.01 - 3 mM) potentiated the recorded current. The 
maximum potentiation was 3 fold when 3 mM propofol was co-applied with glycine EC20 
(Lynagh and Laube, 2014). 
Similar effects were also described in native systems. Propofol (0.84 – 16.8 µM) potentiated 
glycine (100 μM) activated currents recorded from murine cultured spinal neurons (Hales and 
Lambert, 1991). Subsaturating glycine (30μM) evoked currents recorded from spinal dorsal 
horn neurons were potentiated by propofol (5 μM) by 1.82 ± 0.20 fold (Dong et al., 2002). In 
addition, Nguyen and his group found that propofol positively modulated GlyRs in rat 
cultured neurons (Nguyen et al., 2009). Propofol (10 - 100 µM) was found to potentiate 
glycine-gated currents in neurons isolated from the rat posterior hypothalamus. Application 
of a subsaturating concentration of glycine (10 µM) in the presence of 30 µM propofol 
enhanced glycine current by 385.6 ± 128.9 %. Propofol was also found to induce chloride 
currents in the absence of glycine. The study further reported behavioural effect of propofol 
as it induced a hypnotic state in rats marked by the loss of the righting reflex (Nguyen et al., 
2009), which indicates the involvement of GlyRs.  
In summary, all of the above studies had indicated that propofol was found to potentiate 
glycine response at wild-type GlyRs (Table 4.1). The relevant anasthetic concentration of 
propofol (1 µM) produced enhancement of the glycine submaximal response at different 
recombinant expressing systems (Mascia et al., 1996; Belelli et al., 1999; O’Shea et al., 
2004; Moraga-Cid et al., 2011). Using a higher propofol concentration of 300 µM produced 
enhancement of glycine submaximal response that reached up to 100% of the glycine Imax. 
Direct activation by propofol in the absence of glycine was observed when 100 µM propofol 
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was applied to either, homomeric or heteromeric, GlyRs (Pistis et al., 1997, Ahrens et al., 
2008). This effect was either not observed or tested in other studies (Mascia et al., 1996; 
Belelli et al., 1999; O’Shea et al., 2004; Moraga-Cid et al., 2011; Lynagh and Laube, 2014). 
4.1.4.1 Specificity of propofol action  
The sensitivity to propofol was similar between wild-type α1 GlyRs and α1β GlyRs (Pistis et 
al., 1997; Ahrens et al., 2008). Also, it was reported that both homomeric α1 and α2 GlyRs 
have a similar sensitivity to propofol (Mascia et al., 1996). There are no other reported 
studies regarding propofol subunit specificity. 
4.1.5 Sites of propofol action 
Attempts to identify the propofol binding site have been conducted by mutagenesis, 
photolabelling studies and with the help of homology modelling. Mutagenesis studies enabled 
defining of approximate sites for propofol interaction. Mutations were introduced into 
different parts of the pLGICs. If mutating particular residues within the receptor resulted in 
impairment, or abolished, the modulating effect of propofol, these residues were considered 
to be essential for propofol action. As is the case for agonists, this may mean that the residues 
are in the propofol binding site, or that the residues are important in transducing its effects. A 
distinction between the two possibilities may be helped by structural information and 
photolabelling studies.  
4.1.6 Putative propofol binding sites; GABAA receptor 
The binding site for propofol in GABAA receptors is not well defined. Many studies have 
been conducted to identify the possible binding sites of propofol.  
In GABAA receptors several mutagenesis studies have determined that the transmembrane 
domains are involved in modulation by propofol (Garcia et al., 2010). These include TM2 
and TM3 (Belelli et al., 1999; Krasowski et al., 2001; Bali and Akbas 2004), and possibly 
TM4 (Richardson et al., 2007). It was further reported that GABAA receptor α, β, and γ 
subunits are all involved in modulation by propofol (Garcia et al., 2010).  
Photolabeling with ortho-propofol (a photoreactive propofol analogue) has shown that the 
propofol binding site in the GABAA receptor is near to the extracellular ends of the TM1 and 
TM2 domains. A hydrophobic cleft between the TM1 and TM2 domains was identified close 
to H267 (17’). This study also reported the involvement of the β subunit of GABAA receptors 
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in propofol binding (Yip et al., 2013). Another photolabeling study identified propofol 
binding sites in GABAA receptors. It found that propofol binds to the inter-subunit sites (β
+
 
α¯, α+ β¯, and β+ β¯ ) in the TM domains of the α1β3 GABAA receptor but not in the intra-
subunit binding pocket (Jayakar et al., 2014). 
A homology modeling study of the GABAA homomeric β3 receptor based on the structures 
of GluCl and GLIC supported these findings (Franks, 2015). Two possible propofol binding 
sites were predicted: one was postulated to be in a hydrophobic pocket between the TM1 and 
TM2 domains of an individual subunit and with some interaction with the TM2 domain of the 
adjacent subunit. The other was predicted to be in a hydrophobic cavity between TM2 
domains from adjacent subunits with some interaction with residues in TM1 of one of the 
subunits. Both of the predicted binding sites were adjacent to residue H267 (17’) (Franks, 
2015).  
A recent functional study tested the involvement of the predicted inter-subunit cavity in 
propofol action (Eaton et al., 2015). The study suggested involvement of residues within the 
inter-subunit cavity in propofol allosteric modulation by testing the effect of propofol on 
Xenopus oocytes expressing GABAA β3 and α1β3 receptors. GABAA β3 residues which were 
suggested to be involved in propofol activation are Y143, F221, Q224, and T266 in TM2 
(Eaton et al., 2015).  
4.1.7 Putative propofol binding sites; GlyR receptor 
A number of studies have suggested that propofol is a positive allosteric modulator of GlyR. 
Several studies have been conducted to determine propofol binding sites in GlyRs. The amino 
acid residues that are involved in the effects produced by propofol were identified by 
functional experiments performed on GlyR α1 mutants. These sites include the GlyR α1 
subunit transmembrane and intracellular domains. 
4.1.7.1 Transmembrane domain 
The binding site for other allosteric modulators of GlyR is generally thought to be within the 
TM domain. This is supported by studies evaluating the allosteric effects of alcohols and 
general anaesthetics on chimeric constructs that indicated that I229 in M1, S267 in TM2, and 
A288 in M3 of the α1GlyR participate in the allosteric modulation (Mihic et al., 1997, Lobo 
et al., 2005). In contrast to the many studies have been conducted to determine the action of 
propofol on GABAA receptors, our knowledge of propofol interaction with the GlyR is poor.   
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GlyR residues that may contribute to propofol-binding sites were identified by analyses of the 
functional properties of S267 mutant homomeric and heteromeric GlyRs expressed in 
HEK293 cells. Mutating the TM2 domain 15’ into S267I, or S267M, reduced the 
enhancement effect of propofol from 100 ± 5 % Imax to 63 ± 3% in S267I and 71 ± 9% in 
S267M α1 GlyRs. In the heteromeric GlyRs propofol enhancement was reduced from 90 ± 
4% Imax  to 71 ± 9%, 68 ± 11% in S267I and S267M, respectively (Ahrens et al., 2008). 
Propofol markedly restored the function of the R271K and the R271Q GlyR loss-of-function, 
startle disease mutants by enhancing apparent glycine affinity and efficacy (O’Shea et al., 
2004). However, this TM2 19’ residue is apparently not involved in the propofol binding site 
as indicated by Lynagh et al. who studied the influence of propofol on cysteine substitution 
on R271 and the adjacent Q226 residues (Lynagh et al., 2013).  
A recent study identified a possible propofol binding site by mutating residues in GlyR and 
GluCl as propofol has opposite effects on these receptors (Lynagh and Laube, 2014). 
Residues which were suspected to be essential for propofol modulation were tested by whole-
cell patch clamp recordings of oocytes expressing homomeric GlyR, or GluCl, channels. 
Mutating the TM2 18’ residue of the GluCl converted the propofol inhibition of the 
glutamate-gated current to enhancement. Mutation of the corresponding residue in GlyR α1 
S270I markedly increased the propofol enhancement of the glycine submaximal current 
(Lynagh and Laube, 2014). Accordingly the 18’ residue might participate to the propofol 
binding site, or to the transduction of the effects of propofol.  
Propofol enhancement was also tested by using a chimera with GLIC in the extracellular 
domain, α1GlyR in the transmembrane domain, and GLIC in the short cytoplasmic loop. 
Propofol is known to have opposite effects on GlyR and GLIC as it potentiates α1GlyR and 
inhibits GLIC (Duret et al., 2011). The chimera was activated by protons and potentiated by 
propofol. Whole-cell recordings from oocytes bearing the GLICEC-α1GlyRTM chimera 
determined up to 10 fold propofol enhancement of the current elicited by EC30 proton 
concentration. Even without the GlyR cytoplasmic loop and different extracellular domain, 
potentiation of propofol was found in the study indicating the importance of transmembrane 
domains as major binding sites for propofol (Duret et al., 2011). 
As indicated earlier propofol has an inhibitory effect on GLIC, however, it is worth to 
mention some related studies with the presence of the x-ray crystal structure of pLGIC bound 
to propofol. An atomic resolution structure of GLIC bound with propofol indicated a propofol 
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binding site in the upper part of the transmembrane domain (Nury et al., 2011). Two general 
anasthetic cavities were suggested to be involved in the allosteric modulation, one located 
intra-subunit at the middle of the TM domains in each subunit and the other inter-subunit 
(Nury et al., 2011). The crystal structure of GLIC in the presence, or absence, of propofol 
supported the involvement of an inter-subunit cavity in propofol modulation (Sauguet et al., 
2013). Propofol allosteric modulation of GLIC was examined by Ghosh et al. (2013). 
Propofol binding was found to contribute to the structural rearrangements of the inter-subunit 
and intra-subunit cavities in the transmembrane domain and modified the local environment 
adjacent to these subunits (Ghosh et al., 2013). 
4.1.7.2 Intracellular domain 
Other regions of the GlyR might be involved in the modulatory effect of propofol as well. It 
has been demonstrated that a mutation in the intracellular loop of α1GlyR resulted in a 
decrease of the propofol effect when compared to the potentiation produced in the wild-type 
GlyR (Moraga-Cid et al., 2011). Using the alanine replacement method on the intracellular 
loop (E326-A384), whole-cell recordings of HEK293 cell expressing mutant GlyRs identified 
residue F380 as essential for propofol modulation: The F380A GlyR α1 mutation markedly 
reduced propofol potentiation. However, the sensitivity to other modulators, like alcohols, 
trichloroethanol, etomidate, and isoflurane was maintained. Mutation of a conserved residue 
(α1 F385A) of a homologous position in the TM3-TM4 loop in GABAA α1β2 receptor had 
similar effects. These results support the involvement of the intracellular domain in propofol 
sensitivity (Moraga-Cid et al., 2011).     
The specific residues of GlyR which are responsible for propofol action remain to be clearly 
elucidated.  
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Table  4.1 Wild-type GlyR tested for the modulatory effect of propofol. 
Receptor 
Expression 
system 
Effective 
propofol 
concentrations 
(µM) 
Glycine 
concentration 
Maximum 
Potentiation 
effect 
Direct 
activation 
by 
propofol 
Reference 
GlyR α1 Oocytes 1 - 5 EC2 Up to 120% 
Not 
indicated 
Mascia et 
al. (1996) 
GlyR α1 Oocytes 10 - 300 EC10 85 ± 5% of Imax 
Yes with 
100 µM Pistis et al. 
(1997) 
GlyR α1β Oocytes 10 - 300 EC10 98 ± 6% of Imax 
Yes with 
100 µM 
GlyR α1 Oocytes 1 - 100 EC10 85 ± 5 % of Imax 
Not 
indicated 
Belelli et 
al. (1999) 
GlyR α1 Oocytes 1 - 500 
Submaximal, 
Imax 
No potentiation 
with Imax, 
Potentiation with 
submaximal 
concentration 
No with 
0.5 mM 
O’Shea et 
al. (2004) 
GlyR α1 Oocytes 10 - 3000 EC20 Up to 3 fold 
Not 
indicated 
Lynagh and 
Laube  
(2014) 
GlyR α1 HEK293 3 - 300 EC20 100 ± 5 % of Imax 
Yes with 
100 µM Ahrens et 
al. (2008) 
GlyR α1β HEK293 3 - 300 EC20 90 ± 4 % of Imax 
Yes with 
100 µM 
GlyR α1 HEK293 1 - 100 EC10 100-700 % 
Not 
indicated 
Moraga-
Cid et al. 
(2011) 
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4.2 Results 
4.2.1 The effect of propofol on human hyperekplexia mutant α1β GlyR  
As the effects of propofol on wild-type receptors indicate that it facilitates gating at 
submaximal glycine concentrations, it would seem reasonable that if could produce some 
degree of functional rescue if gating is impaired by a hyperekplexia mutation.  Indeed, 
propofol was reported to potentiate the reduced macroscopic glycine maximal response (Imax) 
of some hyperekplexia GlyR α1 mutations, such as TM2-TM3 R271Q, or R271L (O’Shea et 
al., 2004).  Note that propofol does not increase equilibrium responses to maximum 
concentrations of glycine in wild-type receptors (O’Shea et al., 2004).  
I tested the ability of propofol to enhance the function of the hyperekplexia E103K, S231N, 
Q266H, and S267N GlyRs mutants. Different concentrations of propofol (0.1 – 50 μM) were 
first tested, in order to determine the best concentration to use for the experiments (Figure 
4.1). A Glycine submaximal concentration of 30 M (EC20) was selected for the experiments. 
For the primary experiments propofol was co-applied with glycine (see Methods) and the  
potentiation of the glycine submaximal current measured. For wild-type α1β GlyR the 
average increase in glycine EC20 response induced by 0.1 μM, 1 μM, 10 μM, and 50 μM 
propofol were 1.55 ± 0.08, 1.51 ± 0.08, 2.11 ± 0.07, and 6.29 ± 2.13 fold (n = 4, 4, 3, 2, 
respectively). A propofol concentration of 10 μM was selected as the concentration of choice 
for the first experiments as it seems to be effective. 
After selecting propofol concentration, the next step was to test whether this concentration 
can potentiate the glycine maximal response. Co-application of glycine submaximal 
concentration of 30 μM with 10 μM propofol was repeated in these experiments (Figure 
4.2.A). Figure 4.2 shows glycine EC20 induced current of 0.67 nA, and propofol co-
application doubled the response to around 1.40 nA. Potentiation of glycine submaximal 
response was observed with average fold change of 2.04 ± 0.13 (n = 4 cells; p < 0.01, paired 
t-test; Figure 4.2.C).  
On the other hand, co-application of propofol (10 M) with a glycine maximal concentration 
(10mM) did not potentiate the glycine response (Figure 4.2.B). The recorded current for the 
illustrated example was 6.90 nA before propofol application and 6.25 nA with propofol 
application. The average fold change was barely reduced 0.87 ± 0.06 but reached significant 
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(n = 3; p < 0.05, paired t-test, Figure 4.2.C). So the application of 10 M propofol enhanced 
glycine I20 response but not the maximal response.  
After the application protocol was established, I started with the E103K mutation. 
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Figure  4.1 Concentration-dependence of propofol modulation of EC20 glycine-gated 
currents in HEK293 cells expressing human wild-type α1β GlyRs. 
A) Sample whole-cell current traces evoked by U-tube application of submaximal glycine 
concentration in the presence or absence of propofol (at – 50 mV).  The solid bars above the 
current traces indicate the time of application with black and blue bars corresponding to 
application of glycine and propofol, respectively. B) Summary of the results ± SEM.  
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Figure  4.2 Propofol modulation of the wild-type α1β GlyR submaximal and maximal 
glycine responses.  
A) Traces show the effect of propofol co-application (10 μM) with EC20 glycine  (30 μM). 
Response to EC20 glycine vs response to EC20 glycine + propofol, p < 0.001, paired t-test. B) 
Co-Application of 10 μM propofol with maximal glycine concentration (10 mM). Response 
to Imax glycine vs response to Imax glycine + propofol, p < 0.05, paired t-test. The solid bars 
above the traces indicate the time of application. C) The calculated average modulation fold 
change by propofol for the submaximal and maximal glycine evoked currents are listed. Data 
are reported as fold change ± SEM. 
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4.2.2 Co-application of glycine with 10 μM propofol to α1(E103K)β GlyR 
The effect of propofol on the α1(E103K)β GlyR whole-cell current was examined. As 
indicated earlier, the human hyperekplexia mutation shifted glycine EC50 by 72.2 fold (Table 
3.3) and reduced  the maximum Popen in response to saturating glycine concentration from 
0.98 to 0.67 (Table 3.4). The aim was to find out if the response of the heteromeric E103K 
GlyR can be enhanced by propofol. 
Co-application of 10 μM propofol with a glycine submaximal concentration (2 mM) 
produced a small increase in the glycine response (Figure 4.3.A). The glycine I20 in the 
experiment shown was 0.57 nA before propofol application and increased to 0.84 nA with 
propofol application. The average fold change was 1.21 ± 0.11 (n = 4; p > 0.05, paired t-test, 
Figure 4.3.E).  The enhancement of the glycine submaximal response was smaller than that 
obtained in the wild-type receptor (2.04 ± 0.13 fold change, Figure 4.2.A).  
Glycine maximal response was similar in the presence, or absence, of 10 μM propofol. Figure 
4.3.B shows the α1(E103K)β GlyR response to 100 mM glycine in the absence and in the 
presence of propofol. Glycine current was 1.99 nA and glycine with propofol response was 
2.05 nA. The average I Glycine + propofol/ I Glycine of the E103K receptor was 1.08 ± 0.03 at 
saturating glycine (n = 4; p > 0.05, paired t-test).  
 
4.2.3 Co-application of β-alanine with 10 μM propofol to E103K GlyR 
In order to verify if the effect of propofol was similar if a partial agonist was tested, β-alanine 
was selected. Application of 10 μM propofol to α1(E103K)β receptor increased the 
submaximal β-alanine response (EC20; note that the maximum response to β-alanine in this 
mutant is 103 % of the maximum response to glycine;   Figure 4.3.C). Response to EC20 β-
alanine was 1.17 nA and the measured current response to β-alanine in the presence of 
propofol was 1.87 nA. Co-application of propofol to 3 mM β-alanine trends to potentiate the 
whole-cell submaximal response by 1.48 ± 0.11 fold but statistical significant is not achived 
(n = 3; p > 0.05, paired t-test, Figure 4.3.E).   
Responses to saturating β-alanine concentrations were not affected by 10 M propofol 
(Figure 4.3.D). In this example, the β-alanine Imax response was 3.28 nA before propofol 
application and 3.02 nA with propofol. Co-application of 10 μM propofol with 100 mM β-
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alanine did not change the response as the average ratio of Iβ-alanine + Propofol / Iβ-alanine was 1.01 ± 
0.02 (n = 5; p > 0.05, paired t-test). Thus, propofol did not affect maximal glycine and β-
alanine responses in the heteromeric α1(E103K)β mutant GlyRs, with average fold change 
for glycine and β-alanine 1.08 ± 0.03 and 1.01 ± 0.02, respectively (Figure 4.3.E). 
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Figure  4.3 Potentiation of agonist currents in α1(E103K)β mutant GlyR by 10 μM 
propofol. 
A) Whole-cell current traces evoked by U-tube application of glycine EC20 to E103K 
receptors in the absence, or presence, of propofol. B) Glycine maximum responses in the 
absence, or presence, of 10 μM propofol. C) The same experiment for   β-alanine. D) 
Response to Imax β-alanine vs response to ECmax β-alanine + propofol.  E) Data is presented as 
fold change ± SEM. 
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4.2.4 Propofol (50 μM) co-application with glycine to wild-type GlyRs 
As we did not observe an enhancement by 10 M propofol of the maximal responses to 
glycine, or β-alanine, in α1 (E103K) β mutant GlyR, we proceeded to test the effect of higher 
concentration of propofol with the same application method. Co-application of 50 μM 
propofol with submaximal glycine concentration significantly increased glycine-gated 
currents in wild-type receptors. The average fold change was 2.97 ± 0.41 (p < 0.01, paired t-
test; n = 5; Figure 4.4.A). In the example shown, the peak amplitude of glycine with propofol 
was higher (1.33 nA) than the value without the modulator (0.46 nA). This confirms that the 
higher propofol concentration of 50 μM had a greater effect than 10 μM propofol on 
submaximal glycine responses 2.97 ± 0.41 vs. 2.04 ± 0.13, however this was not significant 
(p > 0.05, unpaired t-test; n = 5, 3 respectively). 
Co-application of 50 μM propofol with 10 mM glycine did not potentiate the glycine 
maximal response (Figure 4.4.B).  In the example shown, the glycine response was similar in 
control (4.36 nA) and during propofol co-application (4.36 nA). The average IGly + Propofol / IGly 
was 1.01 ± 0.02 for 5 cells (p > 0.05, paired t-test). Even at this higher concentration propofol 
did not potentiate maximum glycine-gated currents for the wild-type heteromeric GlyRs. 
4.2.5 Pre-incubation of 50 μM propofol to wild-type GlyRs 
Another step was added to the modulator application method. Pre-application of 50 μM 
propofol for about 30 seconds followed by co-application of glycine and propofol was tested. 
U-tube application of 50 μM propofol and glycine to the heteromeric wild-type GlyRs 
increased the glycine submaximal response (Figure 4.5.A). During the pre-application period 
of propofol no direct activation was observed. Glycine responses in propofol showed clearer 
and more extensive desensitisation than control responses. The magnitude of current 
potentiation induced by propofol to glycine EC20 of 30 μM was around 5 fold change. (5.60 ± 
1.4; p < 0.05, paired t-test; n = 5). 
Adding pre-incubation of propofol did not change the results with saturating glycine 
concentration, which was not enhanced by propofol (Figure 4.5.B). The peak response to 10 
mM glycine was similar in the presence (1.64 nA) or in the absence (1.99 nA) of 50 μM 
propofol with average of IGly + Propofol / IGly 0.94 ± 0.05 for 4 cells (p > 0.05, paired t-test). 
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Pre-application vs co-application 
The previous results showed that the average enhancement of glycine I20 responses by 
propofol is larger for pre-application followed by co-application than for co-application alone 
(5.60 vs 2.97). However, for the Imax , the lack of modulation was similar (0.94 vs 1.01). Pre-
application of 50 μM propofol for around 30 seconds followed by co-application by the 
indicated concentration of the ligand with propofol was considered as the method of choice. 
In the following parts of the Chapter this method was used.   
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Figure  4.4 Propofol (50 μM) modulation of α1β wild-type GlyRs; Co-application 
method.  
A) Sample glycine EC20 current before and after propofol application. B) Whole-cell traces 
showing inward currents elicited by U-tube application of saturating glycine concentration 
with, or without, propofol. Solid lines above the traces indicate the time of application. C) 
Summary of the calculated modulation ratio. 
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Figure  4.5 Propofol (50 μM) modulation of α1β wild-type GlyRs; Pre-application 
followed by co-application method. 
 A) Representative macroscopic whole-cell traces showing inward currents elicited by U-tube 
application of EC20 glycine to HEK293 cells expressing α1β human wild-type GlyRs with, or 
without, propofol. B) Current traces gated by saturating glycine concentration in the absence, 
or presence, of propofol. Propofol is pre-applied for 30s, and bars are not to scale. The effects 
of propofol on glycine submaximal, or maximal, response are summarized in (C).   
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4.2.6 The effect of propofol (50 μM) on the α1(E103K)β GlyR 
The loop A hyperekplexia mutant reduced glycine potency and efficacy as demonstrated in 
the previous Chapters (Table 3.3, 3.4). 
Propofol at 50 μM concentration enhanced glycine I20 in HEK293 cells expressing the E103K 
mutation (Figure 4.6.A). Pre-application of propofol did not evoke a current. Application of 
propofol with 2 mM glycine to heteromeric E103K GlyR enhanced the submaximal glycine 
current by 5.35 fold for the illustrated example. The response to EC20 glycine and propofol 
compared to that of glycine alone did not reach significance (p > 0.05, paired t-test). The 
average modulation was 3.18 ± 0.58 fold for α1(E103K)β GlyR (n = 5) compared to 5.60 ± 
1.40 for wild-type (p > 0.05, unpaired t-test, n = 4). 
Glycine maximal response in presence of propofol for the heteromeric α1 (E103K) β receptor 
is illustrated in Figure 4.6.B. During the application of propofol alone no current was found. 
Propofol appeared to speed up the channel desensitization. In this example glycine maximum 
current was 0.70 nA before propofol application and 0.60 nA after propofol application. The 
ratio of IGly+ Propofol / IGly was 0.91, 0.54 (n = 2). Thus propofol did not potentiate maximum 
glycine responses in E103K mutants cf. 0.94 ± 0.05 fold in wild-type GlyR (Figure 4.6.C). 
 
Conclusion 
Propofol potentiated the submaximal glycine response of the α1 (E103K) β receptor but to 
lower extent than wild-type receptors. Propofol application was did not potentiate the glycine 
maximal response. Even that this mutation has reduced glycine gating efficacy as evaluated 
by single channel method, application of propofol to saturating glycine concentration was not 
enough to rescue the channel maximal response obtained by whole-cell experiments.  
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Figure  4.6 Propofol modulation of the α1(E103K)β GlyR mutant. 
A) Records of glycine current without or with propofol (50 μM) in HEK-293 cells expressing 
α1 (E103K) β GlyRs. B) Application of propofol to saturating glycine concentration. C) The 
average change in response ratio is listed. Lines above the traces show the time of application 
in case of propofol application was even earlier. Data are expressed as fold change ± SEM. 
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4.2.7 Propofol modulation of the α1(Q266H)β GlyR 
The whole-cell concentration response curves from the previous chapter indicated a shift in 
glycine sensitivity by ~ 12 fold for the heteromeric Q266H GlyR mutation (Table 3.4). The 
maximum Popen obtained from single-channel records indicated that this mutation reduces the 
channel open probability from 0.98 to 0.61 (Table 3.5). The aim was to examine if we are 
able to potentiate glycine EC20, or maximal response, with propofol, and whether these 
effects were different than in wild type GlyRs.  
Application of a submaximal concentration of glycine (200 μM, EC20) produced inward 
current responses (Figure 4.7.A). During the pre-application of 50 μM propofol there was no 
observed direct activation effect. This finding is similar to the corresponding wild-type GlyRs 
results. Co-application of propofol following the pre-application period resulted in 
potentiation of the glycine-gated response. Propofol application increased the onset of 
desensitization. Measurement of the response before and after propofol application allowed 
fold change measurement for each individual cell. For the illustrated example the response to 
glycine was 1.32 nA but the response to glycine and propofol was increased to 3.35 nA. The 
α1(Q266H)β GlyR response to EC20 glycine and propofol was significantly larger than 
response to EC20 glycine, (n = 4; p < 0.05, paired t-test,). The average fold change was 5.19 ± 
1.35 for n = 4 cells (Figure 4.7.C). This result is similar to propofol modulation of glycine 
submaximal response of wild-type GlyRs 5.60 ± 1.4 (n = 5; p > 0.05, unpaired t-test;  Figure 
4.7.C).   
Propofol potentiation of glycine maximal response was also tested. Application of saturating 
glycine concentration of 50 mM produced an inward current. In the example shown, this 
current was almost identical before and after application of 50 μM propofol (4.68, 4.56 nA; 
Figure 4.7.B). This result was consistent from one cell to another. There was no significant 
difference between the response to Imax glycine and the response to Imax glycine + propofol (n 
= 4; p > 0.05, paired t-test). The average fold change for the Imax glycine response was 1.05 ± 
0.06, n = 4. These results are similar to those observed in wild-type glycine receptors (0.94 ± 
0.05 fold change; n = 5; p > 0.05) (Figure 4.7.C).   
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Conclusion 
Propofol potentiates the glycine EC20 response of the heteromeric Q266H GlyR mutation but 
not the maximal response. Propofol effects (or lack thereof) for submaximal, or maximal, 
glycine concentrations were similar to the results obtained from wild-type GlyRs. So this 
GlyR mutation does not interfere with the normal potentiation effect of propofol. 
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Figure  4.7 Effect of propofol on α1(Q266H)β GlyR.  
A) Response to EC20 glycine vs response to EC20 glycine + propofol. B) Maximal glycine 
response before and after application of 50 μM propofol. The solid bars above the traces 
indicate the time of application (in case of propofol not to the scale). C) The calculated 
average modulation fold change by propofol for the submaximal and maximal glycine evoked 
currents are indicated. Data are represented as fold change ± SEM. 
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4.2.8 Potentiation of the glycine responses at the α1(S267N)β GlyRs 
As I indicated earlier, this mutation (15’ of TM2) increased glycine EC50 by ~35 fold (Table 
3.4) and also reduced the maximal channel Popen from 0.99 to 0.37 (Table 3.5).  For this 
mutation I tested whether propofol can enhance currents evoked by glycine EC20 and by a 
maximal concentration of the agonist. A Glycine concentration of 1.5 mM was selected as 
EC20 and 50 mM was selected as the saturating concentration (see Figure 3.21). Enhancement 
of the EC20 glycine-gated currents in the presence of propofol is shown in Figure 4.8.A, 
where the submaximal glycine current was 2.55 nA vs 4.71 nA, in control and in propofol, 
respectively. Propofol significantly enhanced glycine submaximal response (n = 6; p < 0.05, 
paired t-test,). The average potentiation of submaximal glycine response for α1(S267N)β 
GlyR was 2.71 ± 0.41 fold (n = 6) compared to wild-type receptor response 5.60 ± 1.40 fold 
(n = 6; p > 0.05, unpaired t-test; Figure 4.8.C). The effect of propofol varied considerbly 
across cells, and ranged between 2-5 fold change.   
The response to maximal concentration of glycine (50 mM) showed a slight potentiation with 
propofol application (Figure 4.8.B). Peak currents measured at saturating glycine 
concentration were consistently larger in the presence of propofol (n = 6, p < 0.01, paired t-
test,). In the illustrated example, the peak measured current was 4.55 nA for glycine and 5.49 
nA for glycine and propofol. The average modulation ratio was 1.29 ± 0.09 for 6 cells. Note 
that propofol did not increase the maximum response to glycine in wild-type receptors (0.94 
± 0.05; n = 5; p < 0.05, unpaired t-test, Figure 4.8.C). 
Work published by other groups is consistent with my results, and shows that the 
enhancement produced by allosteric modulators on submaximal glycine responses can be  
reduced by introducing mutations in S267 (Mihic et al., 1997; Ahrens et al., 2008). 
In attempt to define the ethanol site Mihic et al., investigated different TM2 and TM3 
residues in glycine and GABAA receptors. They found that in oocytes expressing homomeric 
GlyR the S267I GlyR mutation abolished the potentiation effect of ethanol and reduced the 
potentiation effect of the anaesthetic enflurane. Potentiation effect was estimated at glycine 
EC10 (Mihic et al., 1997). From my results, it seems that propofol behaves in a manner 
similar to that of enflurane, in that their effects were reduced by the mutation.    
Another study evaluated the modulating effect of propofol on HEK293 cells bearing S267I or 
S267M glycine receptor mutations using the whole-cell patch clamp technique (Ahrens et al., 
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2008). They found that the heteromeric S267I and S267M GlyR mutations reduced glycine 
sensitivity by 2 and 3 fold respectively. They then co-applied glycine EC20 with 3-300 μM 
propofol. They found that propofol potentiates the glycine submaximal response of the GlyR 
mutations S267M and S267I. However, the enhancing effect of propofol was smaller than 
that observed in the wild-type receptors. Thus, co-application of 50 uM propofol resulted in 
around 100 % potentiation of response in S267I compared to ~ 400% potentiation in wild-
type receptors. Propofol modulation was reduced in the S267M GlyR mutation from ~400 to 
200% (Ahrens et al., 2008). The same Authors observed that propofol at concentrations equal 
to, or greater than, 100 μM directly activates the wild-type glycine receptor, but not the tested 
GlyR mutants (Ahrens et al., 2008).  
 
Conclusion 
Glycine-gated submaximal currents at the heteromeric 15’ α1(S267N)β GlyR are enhanced 
by propofol (n = 6, p < 0.05, paired t-test). The maximum glycine response of the HEK293 
cells bearing the heteromeric S267N mutation was significantly potentiated by propofol (n = 
6; p < 0.01, paired t-test,).  
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Figure  4.8 Propofol modulation of the α1(S267N)β GlyR mutant. 
A) Trace records shows the effect of 50 μM propofol application to EC20 glycine induced 
current. Response to EC20 glycine vs response to EC20 glycine + propofol. B) Example traces 
showing inward chloride current responses to saturating glycine concentrations before and 
after propofol application. The solid bars above the traces indicate the time of application 
(not to the scale). C) Average calculated modulation ratio is indicated. Data are expressed as 
fold change ± SEM. 
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4.2.9 Propofol enhancement of the glycine current at the α1(S231N)β 
GlyRs 
The EC50 for glycine on the α1(S231N)β GlyRs shifted from 0.10 mM in the wild-type to 
3.81 mM in the mutant (Table 3.4). This change in glycine potency was accompanied with a 
decrease in the maximum Popen from 0.98 to 0.38 (Table 3.5). I proceeded to test whether the 
function of the mutant α1(S231N)β GlyRs can be rescued by propofol.  
Application of 50 μM propofol was found to enhance the response to the current produced by 
submaximal glycine concentration in all of the tested cells (Figure 4.9.A). Glycine (1 mM) 
was used as the submaximal concentration according to our established protocol (Figure 
3.13). At these low concentrations, responses to U-tube application of submaximal glycine 
concentration showed no apparent desensitisation, however, this became apparent in the 
presence of propofol. Also, propofol addition made the rise time of the current response 
faster. During the pre-application period of 50 M propofol no direct activation was 
observed. The response to submaximal glycine concentration shown in the figure was 0.25 
nA in control and 1.72 nA in the presence of propofol. Propofol significantly potentiated 
glycine submaximal response (n = 6; p < 0.01, paired t-test,). The average change of propofol 
modulation of the glycine submaximal response was 5.48 ± 1.38 fold (n = 6). The magnitude 
of average potentiation induced by 50 μM propofol was similar to that observed in wild type 
GlyRs (5.60 ± 1.40; n = 5; p > 0.05, unpaired t-test) (Figure 4.9.C). 
A clear enhancement of the glycine maximal response by propofol was observed for this 
mutant (Figure 4.9.B). A glycine concentration of 50 mM was used with, or without, the 
presence of 50 μM propofol. No direct activation was noticed in the pre-application period of 
propofol. Desensitization was faster and reached a greater proportion of the peak response 
when propofol was co-applied with glycine. The ratio of the I Glycine + Propofol /I Glycine was 1.97 
for the illustrated example. Application of propofol was effective in potentiating the glycine 
maximal response (n = 6, p < 0.05, paired t-test). Unlike wild-type receptors which has 
average fold change of 0.94 ± 0.05, the response of α1(S231N)β GlyRs to an maximally 
effective concentration of glycine was markedly increased by propofol (1.98 ± 0.29; p < 0.05, 
unpaired t-test, n = 6 both). 
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4.2.10 Single-channel recordings of the α1(S231N)β GlyR in the presence of 
propofol 
The pronounced effect of propofol on maximum glycine responses in this mutant warranted 
further investigation.  To test whether propofol modulation affects channel gating, 
singlechannel recordings were done at saturating (100 mM) glycine concentration in the 
presence of 50 μM propofol (Figure 4.10). Propofol significantly increased the maximum 
Popen of the α1(S231N)β GlyR mutant by 1.7 fold, from 0.38 ± 0.06 to 0.65 ± 0.04 (n = 16, 
28, respectively; p < 0.0001, unpaired t-test). There was no change in the single-channel 
current amplitude in the absence, or presence, of propofol (2.01 ± 0.05 vs 1.94 ± 0.04 pA; n = 
16, 28, respectively; p > 0.05, unpaired t-test). Similar to the single-channel records obtained 
for the S231N mutant without propofol (Figure 3.14), modes of openings within the cluster 
were detected. These single-channel results supported the results obtained from the whole-
cell experiments. 
In order to further characterize the effects of this mutation, I attempted to record responses to 
the partial agonist β-alanine, but was unsuccessful. It was impossible to obtain a full 
concentration-response curve for β-alanine with the α1(S231N)β mutation because U-tube 
application of 100 mM β-alanine to HEK293 cells expressing the mutant GlyR produced only 
a very small current (~ 300 pA).  
 
Conclusion 
In the α1(S231N)β GlyR mutant, propofol potentiates the whole-cell responses to both 
submaximal and maximal glycine concentrations.  Propofol increases the maximal Popen  of 
the α1(S231N)β GlyR mutant. 
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Figure  4.9 Potentiation of the glycine submaximal and maximum responses of the        
α1(S231N)β GlyR mutation. 
A) Whole-cell traces showing inward currents elicited by U-tube application of EC20 glycine 
concentration with, or without, propofol. B)  Responses obtained by application of saturating 
glycine concentration in the absence, or presence, of propofol. The solid bars above the traces 
indicate the time of application (not to the scale). C) Summary of the effect of propofol. Data 
are expressed as fold change ± SEM.  
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Figure  4.10 Single-channel activity at saturating (100 mM) glycine concentration for 
HEK293 expressed α1(S231N)β GlyR in the presence of 50 μM propofol.  
Single-channel traces (cell-attached, pipette potential + 100 mV) show that the mutant 
receptor opens in clusters and propofol increased glycine maximum P
open 
. 
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Summary of the effect of propofol on selected human hyperekplexia mutations 
Propofol (50 μM) was found effective in potentiating glycine submaximal response for 
α1(Q266H)β, α1(S267N)β, α1(S231N)β GlyRs mutants. The level of modulation varied from 
mutation to another and ranged from 2 to 5 fold change (Figure 4.11). 
On the other hand, potentiation of the glycine maximal response was only found for the 
α1(S231N)β and α1(S267N)β GlyR mutations (Figure 4.11). 
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Figure  4.11 Summary of propofol modulation of the heteromeric α1(Q266H) β, α1 
(S267N) β, α1(S231N)β, and α1(E103K)β GlyRs mutations responses.  
A) Comparison of the effect of propofol on glycine EC20 between wild-type receptors and the 
indicated mutations. B) Comparison of the effect of propofol on glycine Imax and the 
indicated mutations. Fold change = response to ligand + propofol / response to ligand. * p < 
0.05, unpaired t-test. Data are presented as fold chnage ± SEM. 
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4.3 Discussion  
While propofol is widely used as an intravenous anaesthetic, its mechanism of action is not 
fully understood. There is strong evidence that GABAA receptors are involved (Hales and 
Lambert, 1991; Jurd et al., 2003), but it is unclear whether GlyRs contribute to the action of 
therapeutic concentrations of propofol.  
As described in the introduction section of this Chapter, propofol potentiation of GlyR 
responses was reported by Mascia et al. (1996) for Xenopus oocytes expressed receptors and 
by Nguyen et al. (2009) for cultured rat neurons and in vivo receptor type.  
In the literature, there is little about the effect of hyperekplexia mutations on propofol 
modulation of GlyR.  Indeed only two mutations (R271Q and R271L in TM2) were 
evaluated. These mutant receptors are still sensitive to propofol, which rescued the glycine 
response, by enhancing glycine apparent affinity and efficacy. Treatment of transgenic mice 
carrying R271Q α1 GlyR mutation with propofol improved the hyperekplexia symptoms 
(O’Shea et al., 2004).  
More extensive studies have been done with other GlyR modulators, which have been 
assessed for their ability to improve the function of mutated GlyRs. For example, 
dehydroxylcannabidiol (DH-CBD), a nonpsychoactive synthetic cannabinoid, is effective in 
rescue the impaired glycine response (by lowering the glycine EC50 in HEK293 expressed 
receptors) in several α1 GlyR hyperekplexia missense mutations, such as R218Q, P250T, 
V260M, R271Q, K276E, and M287L (Xiong et al., 2014). Whereas DH-CBD enhanced the 
reduced maximal glycine-induced currents of R218Q, R271Q, and K276E α1 mutants GlyRs, 
the enhancement effect was absence in P250T, V260M, Q266I, S267Q, The restoration effect 
is seen also in vivo, where treatment with DH-CBD (50 mg/body weight) resolved the 
hyperekplexia exaggerated startle symptoms in heterozygous mice that carry α1R271Q or 
α1M287L GlyR mutations (Xiong et al., 2014).  The cannabinoid was not effective in 
rescuing the hyperekplexia symptoms in mice heterozygous for α1Q266I or α1S267Q GlyR 
mutations (which were also resistant to cannabinoid potentiation in vitro, Xiong et al., 2014).   
Zinc (100 nM), another GlyR modulator, was found to potentiate glycine submaximal 
response of the M287L and Q266I α1 GlyR mutations, in a manner similar that observed in 
wild-type receptors (Borghese et al., 2012). 
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In my experiments I investigated whether propofol enhances responses of wild type and 
mutant α1β GlyRs expressed in HEK293 cells. Testing different protocols and concentrations 
of propofol on wild-type α1β GlyRs showed that propofol can enhance glycine submaximal 
responses, but not the maximal currents. 
E103K hyperekplexia mutant In these GlyRs, a low concentration of propofol (10 µM) with 
glycine, or β-alanine, did not have any noticeable effects (Figure 4.3), whereas a higher 
concentration of 50 µM propofol resulted in a slight increase of glycine submaximal currents, 
but this failed to reach statistical significance (Figure 4.6).  Despite the fact that gating is 
damaged in E103K receptors, no detectable increase of the maximal glycine current was 
observed by propofol. It is unlikely that this mutation is in the propofol binding site, so it is 
hard to explain why the maximum current is not rescued by propofol. A possible explanation 
is that if propofol in this case, affects only the early pre-open conformational changes (flip) 
and the increase in affinity with activation, the reduction in maximum glycine Popen cannot be 
rescued if the mutation damages channel opening (E). Compensation cannot be achieved with 
increase in flip in this case. 
Q266H hyperekplexia mutant Propofol (50 µM) significantly enhanced the glycine 
submaximal response of this mutant but it failed to do so for the maximum response (Figure 
4.7). This result is in agreement with previous findings that the propofol effects (eg the 
enhancement of submaximal responses) are not changed (vs. wild type) by the Q266K, 
Q266E, and Q266F α1 GlyR mutations (Lynagh and Laube, 2014).  Interestingly, the Q266I 
GlyR mutation made the receptor resistant to DH-CBD (Xiong et al., 2014) and abolished 
ethanol potentiation of the glycine submaximal response (Borghese et al., 2012). This argues 
that different modulators may bind to different sites and activate different transduction chains 
that are differentially sensitive to mutations. 
S267N hyperekplexia mutant The S267 residue has been proposed to be one of the key 
residues involved in ethanol action (Mihic et al., 1997). Ethanol potentiation was absent in 
the S267N mutant (Becker et al., 2008) and S267Q GlyR was also found to be insensitive to 
cannabinoid modulation (DH-CBD; Xiong et al., 2014). However, mutations at this positions 
did not affect some of the action of propofol and the submaximal glycine response of S267I 
and S267M mutant GlyR (note these are not hyperekplexia mutations) were potentiated by 
propofol (Ahrens et al., 2008). Consistent with this observation, my results showed that both 
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the submaximal and the maximal responses of the heteromeric S267N GlyR are potentiated 
by propofol (Figure 4.8).  
S231N hyperekplexia mutant Propofol restored the functional deficiency in the α1(S231N)β 
hyperekplexia mutant GlyRs.  Importantly in this mutant both submaximal and maximal 
responses to glycine were enhanced by propofol (Figure 4.9).    
Thus, we saw a different picture depending on the mutation considered.  In the S267N and 
S231N mutants we saw that propofol enhanced both submaximal and maximal responses to 
glycine, whereas in the E103K and Q266H mutants only submaximal responses were 
potentiated.  The enhancement of maximum responses was substantially larger for the S231N 
mutants. The reasons for these differences are not clear. It is unlikely that they are linked to 
greater, or smaller, effects of the mutations on overall gating, because the reduction in 
maximum Popen is 0.38  and 0.37  for the S231N and S267N mutants, respectively and 0.67  
0.61  for E103K and Q266H.  It could be that we need to dissect the effects of the mutation 
into greater detail and establish whether some mutations affect preferentially the early pre-
open conformational changes (flip) or the actual opening of the channel.  It could be that 
propofol can rescue more fully one but not the other impairment. 
More mutations need to be tested to have clear idea about propofol binding site in GlyRs. The 
homology model obtained recently from the GluCl structure by our collaborators at Oxford 
University, Biggin and Yu, proposed that propofol biding site involve residues from principal 
subunit: V280, I285, M287, A288, R271, L291 and I225, I229, P230 from the 
complementary subunit.  Note that P230 is very close to the S231 position, whose mutation 
was the most sensitive to propofol. 
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5 Chapter 5: Critical E103-R131            
salt-bridge interaction that modifies 
channel gating 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter follows from work published as a paper and I am the first author (Safar et al., 
2017). 
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5.1 Introduction 
Channels in the Cys-loop superfamily are activated by agonists and neurotransmitters with 
very different structures and sizes (from glycine to GABA, glutamate to 5-HT). How these 
channels achieve this agonist recognition is an area of intense investigation. In the present 
study we have investigated the role of residues at the back of the binding site, in loops A and 
E, E103 and R131, respectively, and established that they interact. This Chapter is part from 
work published as a paper of which I was a first author. 
Little is known of how the hyperekplexia mutations in the receptor binding site might act. If 
such mutations do not abolish agonist binding, they might be interesting to investigate, as 
they are likely to interfere with the signal transduction that follows the agonist binding. Thus, 
these mutations could throw light on how the binding site contributes to agonist efficacy, a 
poorly understood phenomenon. One such mutation is E103K, whose effects on glycine 
response were discussed in detail in Chapter three. The E103 residue is conserved in all 
human and mouse glycine receptor subunits Figure (5.1) as described earlier in Chapter three.  
This suggests it has a vital role in channel function. Briefly, in homomeric GlyR, the 
mutation reduces glycine potency by 2.84 fold and reduces glycine efficacy from 0.992 ± 
0.002 to 0.73 ± 0.07. In the heteromeric GlyR, the mutation has a much greater effect in 
reducing glycine potency by 72.7 fold and reducing glycine efficacy from 0.98 ± 0.01 to 0.67 
± 0.06. Further investigations of the effect of this mutation will be included in this Chapter. 
The initial experiments were conducted on the heteromeric receptor, but as the homology 
model of GlyR based on GluCl was established (Yu et al., 2014), the later experiments were 
conducted on the homomeric expressed receptors that allowed comparison with the model. 
The position of the E103 residue in a view taken from the GlyR homology model (Yu et al., 
2014) based on GluCl structure (Hibbs and Gouaux, 2011) is shown in Figure (5.2) E103 is 
located at (or just near) Loop A of the principal (+) subunit. The negatively charged side 
chain of the E103 is close to the positively charged side chain of R131 in Loop E on the 
complementary (-) side of the binding site.  Arginine (R131) in this location is conserved in 
all subunits where E103 is conserved, and is conserved also in other receptors, such as, 
human GABAA β3 (where 103 is an Asp), Gloeobacter violaceus GLIC and Dickeya 
chrysanthemi ELIC, where E103 is not conserved. 
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 (R131 part will be discussed in another PhD thesis by Elliot Hurdiss). The distances between 
the sidechain hydrogen atoms of R131 to the sidechain oxygen atoms of E103 are 2.5 ~ 2.8 
Å. This range is compatible with the presence of a salt bridge, and it is worth investigating 
whether the charged side chains of E103 and R131 have an effect on channel gating. The side 
chains of both E103 and R131 are quite far from both the centre of the channel pore (distance 
of  ~16 Å obtained from our model) and from the agonist (~8 Å from glycine).  This suggests 
that it is unlikely that the side chains of these residues affect conductance directly and that 
any effects on agonist binding are likely to be indirect. However, we can not exclude that 
mutating either residues might affect conductance as the nearby K104 residue has been 
determined to affect the conductance in pLGIC (Hansen et al., 2008; Moroni et al., 2011a). 
In order to test the hypothesis that a salt bridge between E103 and R131 stabilizes loops A 
and E, we decided to test the effects of the E103K hyperekplexia mutation on the GlyR 
responses to the partial agonist sarcosine (N-methyl glycine), as the effect to the full agonist 
glycine on E103K was established in Chapter three. Note that sarcosine is slightly bulkier 
than glycine. 
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Figure  5.1 Partial sequence alignment of α1(E103) GlyR and α1(R131) GlyR residues 
with other pLGICs and proteins. 
The E103 human hyperekplexia mutation residue in the ECD of the GlyR α1 is highlighted in 
blue and R131 highlighted in green. Glutamate is conserved in 21 receptors (see text). 
Uniprot accession numbers are indicated at the left side for each receptor,  human glycine α1 
(P23415), human glycine α2 (P23416), human glycine α3 (O75311), human glycine α4 
(Q5JXX5), human glycine β (P48167), bovine glycine α1 (P57695), bovine glycine β 
(Q9GJS9), zebrafish glycine α1 (O93430), rat glycine α1 (P07727), rat glycine α2 (P22771), 
rat glycine α3 (P24524), rat glycine β (P20781), mouse glycine α1(Q64018), mouse glycine 
α2 (Q7TNC8), mouse glycine α3 (Q91XP5), mouse glycine α4 (Q61603), mouse glycine β 
(P48168), C. elegans GluCl α (G5EBR3), C. elegans GluCl β (Q17328), D. melanogaster 
GluCl α (Q94900), H. contortus GluCl β (P91730), human GABAA α1(P14867), human 
GABAA β3 (P28472), human α7 nAChR (P36544), L. stagnalis AChBP (P58154), human 5-
HT3A (P46098), mouse 5-HT3A (P23979), Gloeobacter violaceus GLIC (Q7NDN8), and 
Dickeya chrysanthemi ELIC (P0C7B7).  
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Figure  5.2 Homology modelling indicates a possible salt-bridge between residues E103 
and R131 of α1 GlyR. 
Homology model based upon the structure of GluCl showing the bottom of the binding site. 
The residues R131 and E103 are labeled. This model was first described in Yu et al. (2014). 
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5.2 Results 
5.2.1 Whole-cell recordings of heteromeric wild-type GlyRs responses to  
β-alanine  
Since in our lab we did not have established whole-cell concentration response curves for the 
wild-type GlyRs with β-alanine, I started with that, using   0.1 – 50 mM β-alanine and 
obtaining in each cell a response to saturating glycine concentration (10 mM) in order to 
normalise the β-alanine response. As it is shown in Figure 5.3, desensitization was clear with 
1 mM (~ EC80) β-alanine.  EC50, Imax ,and nH were 0.45 ± 0.08 mM, 5.54 ± 0.856 nA, and 
1.15 ± 0.10, respectively, n = 4 cells. The maximum β-alanine response relative to glycine 
was 0.79 + 0.06.  
5.2.2 Whole-cell recordings of α1(E103K)β GlyR responses to β-alanine 
Whole-cell recordings of the heteromeric E103K GlyR with 1-200 mM β-alanine were 
obtained (Figure 5.4). Responses to a saturating glycine concentration of 100 mM were 
obtained in each cell to normalise the β-alanine responses. The β-alanine EC50 was increased 
significantly by the mutation from 0.45 ± 0.08 mM to 11.17 ± 1.43 mM (n = 6 cells; p < 0.01, 
unpaired t-test). The Imax was 6.78 ± 1.40 nA and the nH was similar to wild-type 1.00 ± 0.10. 
The maximum β-alanine response relative to glycine was increased significantly from 0.79 ± 
0.06 (n = 4) to 1.03 ± 0.04 (n = 6; p < 0.05, unpaired t-test). So although the mutation 
reduced β-alanine sensitivity, it increased the β-alanine efficacy relative to glycine. A change 
in relative maximum response to a partial agonist would indicate that the mutation alters 
channel gating.  
 
To have a better evaluation of the effect of the heteromeric E103K mutation on the potency 
and the efficacy of glycine and β-alanine, concentration-response curves for the response of 
wild type and E103K GlyRs to both glycine and β-alanine, normalised to glycine  are shown 
in Figure 5.5. As a result of the heteromeric α1(E103K)β GlyR mutation, the potency of 
glycine and β-alanine is reduced by 72.7 and 24.8 fold, respectively (Table 5.1). The fold 
change for glycine is almost three times the fold change for β-alanine. So the effect of the 
heteromeric GlyR mutation on the β-alanine response is less profound than for glycine. The 
β-alanine efficacy was also increased compared to wild-type receptors.  
 
194 
 
 
Figure  5.3 Sensitivity of the human heteromeric wild-type GlyRs to β-alanine. 
Representative whole cell current traces evoked by U-tube application of β-alanine (black 
bars) to HEK293 cells expressing wild-type α1β GlyR (A). Cells were held at – 50 mV. B) 
Average β-alanine concentration-response curve obtained from α1 wild-type GlyR. The curve 
is a fit to the Hill equation. EC50 = 0.45 ± 0.08 mM, Imax = 5.54 ± 0.856 nA, nH = 1.15 ± 0.10, 
n = 4 cells. The maximum β-alanine response relative to glycine was 0.79 + 0.06. Error bars 
indicate ± SEM.  
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Figure  5.4 The heteromeric α1(E103K)β  hyperekplexia  mutation reduces the 
sensitivity of GlyR to β-alanine. 
A) Representative whole-cell current responses evoked by U-tube β-alanine application to 
HEK293 cells expressing α1(E103K)β GlyR (upper panel). Black bars above the traces show 
the timing of the applications.  The response to a saturating concentration of glycine obtained 
in the same cells (first trace) is also shown. B)  Average β-alanine concentration-response 
curves obtained from α1(E103K)β GlyR. Solid curve is a fit to the Hill equation. EC50 = 
11.17 ± 1.43 mM, Imax = 6.78 ± 1.40 nA, nH = 1.00 ± 0.10, n = 6 cells. The maximum β-
alanine response relative to glycine = 1.03 ± 0.04. Error bars indicate ± SEM. 
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Figure  5.5 The effect of α1(E103K)β GlyR on the potency and efficacy of glycine and β-
alanine. 
Whole-cell concentration-response curves for the effect of α1(E103K)β mutant GlyR on 
glycine and β-alanine responses.  β-alanine curves are normalized to the maximum glycine 
peak obtained from the same cell. For glycine wild-type α1β GlyR, EC50 = 0.10 ± 0.03, nH = 
1.48 ± 0.09, Imax = 4.43 ± 1.08 nA, n = 6. For β-alanine WT α1β GlyR, EC50 = 0.45 ± 0.08, nH 
= 1.15 ± 0.10, Imax = 5.54 ± 0.86 nA, n = 4. For glycine α1(E103K)β, EC50 = 7.27 ± 0.58, nH 
= 1.22 ± 0.08, Imax = 3.62 ± 0.89 nA, n = 6. For β-alanine α1(E103K)β, EC50 = 11.17 ± 1.43, 
nH = 1.00 ± 0.10, Imax = 6.78 ± 1.4 nA, n = 6. Error bars indicate ± SEM. 
 
 
Table  5.1 Functional properties of heteromeric α1(E103K)β GlyR 
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5.2.3 Whole-cell recordings of GlyR bearing α1(E103K) hyperekplexia 
mutation  
In order to test whether the effect of mutating E103 depends on the agonist, the response to 
the partial agonist sarcosine was examined. Whole-cell concentration response curves 
obtained from HEK293 cells expressing homomeric E103K GlyR were investigated. Figure 
5.6 shows sample currents responses for the α1(E103K) GlyR to 10 – 300 mM sarcosine. 
Application of saturating concentration of glycine of 20 mM in the same cell was used to 
normalize the sarcosine current response relative to glycine. 
In wild-type cells sarcosine is a partial agonist. Whole-cell recordings from our lab showed 
that sarcosine maximum current responses reached 80% of the maximum responses to 
glycine, when glycine was applied at the saturating concentration of 10 mM.  The E103K 
mutation markedly reduced the channel sensitivity to sarcosine and prevented us from 
obtaining a full concentration-response curve as the response did not saturate even at 300 mM 
(Figure 5.6). We could not establish the whole-cell sarcosine maximum response in the 
mutant. EC50 > 80 mM, nH = 1.37 ± 0.03, Imax = 1.5 ± 0.4 nA, n = 4 cells. 
The clearest way to assess whether a mutation has an effect on gating is to measure the 
channel maximum Popen in single channel records.  The wild-type trace shown previously in 
Chapter three (Figure 3.3), shows a cluster of single channel activity in a cell-attached patch 
at saturating glycine concentrations with very high Popen. The channel exposed to 10 mM 
glycine is practically either desensitized, or open, almost all the time, with a maximum Popen 
of 0.992 ± 0.002 (n = 30 clusters; measured as cluster open time/total cluster time). The 
measurement of cluster open probability has the advantage that it measures only changes in 
receptor activation and is not affected by desensitization (as the desensitized intervals are not 
included in the analysis).  This is why we decided to display some concentration-response 
curves as whole cell responses scaled to the maximum open probability measured by single-
channel analysis.   
 
Single-channel clusters activated by a saturating sarcosine concentration (100 mM, not shown 
Hurdiss personal communication) confirmed that sarcosine is a partial agonist in wild-type 
receptors, with a maximum Popen of 0.70 ± 0.03 (n = 22 clusters from 4 records). As shown 
previously in Figure 3.9, the E103K mutation clearly decreased the cluster Popen elicited by 
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saturating glycine to 0.73 ± 0.07 (n =13 clusters from 3 records).  This effect strongly 
suggests that the E103K mutation must impair channel gating.   
 
In order to test the hypothesis that there is a salt bridge between E103 and R131, we mutated 
both residues individually to alanine.  Also, the charge was inverted to arginine and 
glutamate, respectively. The effects of mutating E103, or R131, residue or both on the 
channel response to the full agonist glycine were evaluated. In my Thesis I will focus on the 
effect of mutating the E103 residue.  
 
5.2.4 Whole-cell and single channel recordings of GlyR bearing α1(E103A) 
mutation  
Whole-cell recordings of the homomeric E103A responses to glycine are were obtained  by 
U-tube application of 0.1-100 mM glycine.  The concentration-response curve is shown in 
Figure 5.7. Desensitization was clear starting from 0.5 mM (~ EC 50). Glycine EC50 was 
increased by 1.72 fold to 0.43 ± 0.05 mM (p < 0.05 , unpaired t-test; Table 5. 2). The Imax was 
5.91 ± 0.26 nA and nH was 1.24 ± 0.06, n = 3 cells (Table 5.2).  
 
Single-channel recordings using saturating concentration of 100 mM glycine were examined. 
Sample cell-attached trace is shown in Figure 5.8. There were clear channel openings and the 
cluster pattern was similar to wild-type GlyR channels shown previously in Chapter three 
(Figure 3.3.3). The maximum Popen was measured for each cluster. The efficacy of glycine 
was unchanged and the maximum Popen was high (0.97 ± 0.01, n = 11 clusters from 3 
patches). The current amplitude was 5.64 ± 0.23 pA. There was a change in glycine 
sensitivity but not the efficacy a result of the E103A GlyR mutation. The effect of inverting 
the charge in the side chain of E103 was then evaluated. 
 
5.2.5 Whole-cell and single channel recordings of GlyR bearing α1(E103R) 
mutation  
Whole-cell recordings of homomeric E103R were obtained. Sample current responses to 0.1 
– 100 mM glycine are shown in Figure 5.9. Desensitization was detectable from 0.1 mM 
(EC10) glycine. Glycine sensitivity was reduced by ~ 15 fold as EC50 was shifted from 0.25 ± 
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0.03 to 3.68 ± 1.18 mM (p < 0.01, unpaired t-test, n = 6, 4, respectively). The reduction in 
glycine sensitivity to glycine is accompanied with increase in the slope of its concentration-
response curve from 1.87 ± 0.37 (n = 6) to 0.71 ± .07 (p < 0.05, unpaired t-test; n = 4; Table 
5. 2).  The Imax was 9.03 ± 3.86 nA comparable with wild-type GlyR (p > 0.05, unpaired t-
test; n = 4). Thus charge inversion had a very noticeable effect on the potency of glycine and 
on the slope of its concentration-response curve. 
 
The effect of charge inversion mutations on the maximum Popen was then evaluated. Single-
channel clusters activated by a saturating glycine concentration (100 mM; Figure 5.10) were 
examined for the α1(E103R) GlyR. It was noticed that the mutation affected the maximum 
Popen. The maximum Popen was reduced significantly from 0.992 ± 0.002 to 0.87 ± 0.02 (n = 
30 and 42, respectively; p < 0.001, unpaired t-test; Table 5.2). The current amplitude was 
similar to wild-type with value of 5.75 ± 0.10 nA (p > 0.05, unpaired t-test).  
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Figure  5.6 The α1(E103K) startle mutation reduces the sensitivity of α1 GlyR to 
sarcosine. 
A) Representative whole-cell current responses evoked by U-tube sarcosine application to 
HEK293 cells expressing E103K α1 GlyR (upper panel). Black bars above the traces show 
the timing of the applications.  The response to a saturating concentration of glycine obtained 
in the same cell is also shown. B) Incomplete concentration-response curve. The dashed blue 
curve is sarcosine wild-type concentration-response curve not scaled to glycine. EC50 > 80 
mM, nH = 1.37 ± 0.03, Imax = 1.5 ± 0.4 nA, n = 4 cells. Error bars indicate ± SEM.  
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Figure  5.7 The effect of α1(E103A) GlyR on the potency of glycine. 
A) Representative whole cell current responses to glycine applied to homomeric E103A. 
Black bars above the traces show the timing of the applications. B) Whole-cell concentration-
response curves for the effect of glycine on E103A GlyR. EC50 = 0.43 ± 0.05 mM, nH = 1.24 
± 0.06, Imax = 5.91 ± 0.26 nA, n = 3 cells. Error bars indicate ± SEM.     
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Figure  5.8 The effect of α1(E103A) GlyR on the efficacy of glycine. 
Cluster of single channel activity elicited by saturating concentrations of glycine (100 mM) 
on homomeric E103A GlyR. Cell-attached configuration (pipette potential +100 mV), 
Channel openings are upward. Popen = 0.97 ± 0.01, Amplitude = 5.64 ± 0.23 pA. 
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Figure  5.9 The effect of α1(E103R) GlyR on the potency of glycine. 
A) Representative whole-cell current responses to glycine applied to homomeric E103R. B) 
Whole-cell concentration-response curves for the effect of glycine on α1(E103R) GlyR. The 
lines above the tracing refer to application of glycine (in mM). B) Average glycine 
concentration-response curve fitted with the Hill equation. EC50 = 3.68 ± 1.18 mM, Imax = 
9.03 ± 3.86, nH = 0.71 ± 0.07, n = 4 cells. Error bars represent SEM. 
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Figure  5.10 Single channel recordings of homomeric α1(E103R) GlyR with glycine. 
Single channel cluster elicited by saturating concentrations of glycine (100 mM) on 
homomeric E103R GlyR. Cell-attached configuration (pipette potential +100 mV), Channel 
openings are upward. Popen= 0.87 ± 0.02, Amplitude = 5.75 ± 0.10 pA. 
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5.2.6 Whole-cell and single channel recordings of GlyR bearing the 
α1(E103A) mutation elicited by sarcosine 
The effect of the E103 residue on the response to the partial agonist sarcosine was examined. 
Whole-cell concentration-response curves from HEK293 cells expressing homomeric E103A 
GlyR were obtained. Typical current responses to 5 - 200 mM sarcosine are shown in Figure 
5.11.  Desensitization was observed at 10 mM (~ EC 20) sarcosine. In the same cell glycine 
was applied at the saturating concentration of 100 mM. Sarcosine elicited maximum current 
responses that reached 56 % of those to glycine in the illustrated example. Sarcosine 
sensitivity was reduced by 1.71 fold, as the average EC50 increased significantly from 13.63 ± 
1.06 mM to 23.31 ± 2.81 mM (p < 0.05, unpaired t-test, n = 3, 4 respectively). The sacosine  
Imax for α1(E103A) was comparable to the one obtained from wild-type receptors (5.11 ± 1.69 
nA and 1.46 ± 0.06 nA; p > 0.05, unpaired t-test; n = 4 and 3, respectively) Also, the nH was 
similar to that of wild-type receptors (nH = 1.84 ± 0.17 for α1(E103A) and 1.46 ± 0.06 for 
wild-type GlyR;  p > 0.05, unpaired t-test; n = 4 and 3, respectively) The average sarcosine 
maximum response relative to glycine was 0.76 ± 0.03 (Table 5.3). 
 
Single-channel recordings of GlyR expressing α1(E103A) were obtained (Figure 5.12) at 
saturating sarcosine concentration of 100 mM. The average maximum Popen elicited by 
sarcosine was similar to that of wild-type GlyR (0.67 ± 0.08 and 0.70 ± 0.03; p > 0.05, n 
clusters = 8, 22, respectively (4 records each). The current amplitude was 4.55 ± 0.41 pA (n = 
8 clusters from 4 records) similar to the wild-type receptor amplitude (5.64 ± 0.30 pA; p > 
0.05, unpaired t-test, n = 22 from 4 records; Table 5.3). 
 
5.2.7 Whole-cell and single-channel recordings of GlyR bearing α1(E103R) 
mutation using sarcosine 
Whole-cell recordings of GlyRs expressing α1 E103R were obtained. Sample current traces 
elicited by U-tube applications of 1 – 200 mM sarcosine are shown in Figure 5.13. 
Desensitization was apparent at 1 mM (~ EC5) for sarcosine. The average sarcosine EC50 was 
12.72 ± 0.85 mM (n = 3) similar to sarcosine EC50 obtained from wild-type GlyR (13.63 ± 
1.06 mM; p > 0.05, unpaired t-test, n = 3). The effect of the E103R mutation was small with 
0.93 fold shifts in the macroscopic EC50. The nH for α1(E103R) was similar to that of wild-
type GlyR (nH = 1.46 ± 0.06, 1.30  0.03; p > 0.05, unpaired t-test; n = 3 for both). The Imax 
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was also similar between α1(E103R) GlyR and  wild-type GlyR (2.72  1.03 nA, 4.40 ± 0.9 
nA, respectively; p > 0.05, unpaired t-test; n = 3 for both; Table 5.3). A saturating 
concentration of 300 mM glycine was used in the same cell to determine the ratio of Imax 
sarcosine /Imax Glycine. The Imax sarcosine /Imax Glycine ratio was higher than the one measured in wild-
type cells 0.80 ± 0.03 vs 0.95 ± 0.004, n = 3 for both (Table 5.3).   
 
Single-channel recordings using a saturating sarcosine concentration of 200 mM were 
obtained in cell-attached configuration (Figure 5.14). The average maximum Popen for 
α1(E103R) was 0.79 ± 0.03 (n = 31 clusters obtained from four records) similar to that of 
wild-type 0.70 ± 0.03 (p > 0.05, unpaired t-test; n = 22 clusters obtained from four records). 
The current amplitude was comparable to its wild type value (4.96 ± 0.05 pA, 5.64 ± 0.30 
pA; p < 0.05, unpaired t-test, n = 31, 22 clusters, from four records each, respectively; Table 
5.3).  
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Figure  5.11 Whole-cell recordings of α1(E103A) GlyR using sarcosine. 
A) Representative whole-cell current responses to sarcosine in homomeric E103R GlyR. 
Black bars above the traces show the timing of the applications. B) Sarcosine whole-cell 
concentration-response curves in mutant α1(E103R) GlyR. EC50 = 23.31 ± 2.81, nH = 1.84 ± 
0.17, Imax = 5.11 ± 1.69 nA, n = 4. The dashed blue curve is sarcosine wild-type GlyR 
concentration-response curve not scaled to glycine. Error bars represent SEM.  
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Figure  5.12 Single-channel recordings of α1(E103A) GlyR using sarcosine. 
Cluster of single-channel E103A GlyR activity elicited in cell-attached patches by 100 mM 
concentration of sarcosine. The average maximum Popen = 0.67 ± 0.08, n clusters = 8 obtained 
from 4 records. Amplitude = 4.55 ± 0.41 pA. 
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Figure  5.13 Whole-cell recordings of currents evoked by sarcosine from α1(E103R) 
GlyR. 
A) Representative current traces evoked by U-tube application of sarcosine (1 – 200 mM) to 
HEK293 cells bearing homomeric E103R GlyR. The response to saturating concentration of 
glycine in the same cell (300 mM) is also shown. The timing of application is illustrated by 
black bars. B) Sarcosine concentration-response curve. EC50 = 12.72 ± 0.85 mM. , nH = 1.30 
± 0.03, Imax = 2.72 ± 1.03 nA.  The Imax sarcosine /Imax Glycine ratio = 0.95 ± 0.004. Error 
bars represent SEM. 
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Figure  5.14 Single-channel recordings of α1(E103R) GlyR using sarcosine. 
Cluster of single-channel activity elicited by saturating concentration (200 mM) of sarcosine 
on homomeric E103R GlyR. Cell-attached configuration, channel openings are upwards. 
Single-channel Popen = 0.79 ± 0.03, amplitude = 4.96 ± 0.05 pA, n = 31 clusters from 4 
records. 
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5.2.8 Whole-cell and single channel currents elicited by glycine in GlyR 
bearing α1(E103R/R131E) mutation  
In order to investigate whether the E103 and R131 form a salt bridge, we reversed the 
charges on both residues and made an E103R/R131E double mutant. Whole-cell recordings 
of responses to 0.1 - 50 mM glycine of the double mutant α1(E103R/R131E) GlyR are shown 
in Figure 5.15. Desensitization was observed from 1 mM (~ EC20). The average glycine EC50 
for the E103R/R131E mutant was 0.43 ± 0.04 mM (n = 5) close to the wild-type value of 
0.25 ± 0.03 mM, but significnt (p > 0.05; unpaired t-test; n = 6; Table 5.2). This indicates that 
the GlyR E103R/R131E mutation rescued the receptor function with respect to either of the 
single charge reversal mutants. Results regarding the R131 residue and its mutants are shown 
for comparison in Table 5.2 (courtesy of E. Hurdiss). 
The Imax was reduced in comparsion to wild type 3.74 ± 0.40 nA and 10.34 ± 2.47 nA, 
respectively, (p > 0.05; unpaired t-test; n = 5, 6, respectively). The slope of the concentration 
curve was lower than in wild-type 0.95 ± 0.02 and 1.87 ± 0.37 (p > 0.05; unpaired t-test; n = 
5, 6, respectively). 
 
Single-channel recordings using a saturating concentration of 100 mM glycine were 
examined (Figure 5.16). The traces in the five records looked similar to that of wild-type 
(Popen = 0.992 ± 0.002, n = 30 clusters) as both had long openings clusters with high 
maximum Popen 0.996 ± 0.001 (p > 0.05; unpaired t-test; n = 9 clusters). The current 
amplitude was lower than  amplitude in wild-type 4.81 ± 0.12 pA (n = 30 clusters from 4 
records) and 5.77 ± 0.06 pA (p <0.05; unpaired t-test; n = 9 clusters from 5 records).   
 
 
5.2.9 Whole-cell and single channel currents elicited by sarcosine in GlyR 
bearing α1(E103R/R131E) mutation using sarcosine 
We further investigated the effect of the double mutant on GlyR with the partial agonist 
sarcosine. Whole-cell recordings of homomeric E103R/R131E using 1 - 100 mM sarcosine 
are shown in Figure (5.17). Desensitization was observed at 10 mM sarcosine (EC50). 
Sarcosine sensitivity was similar to that of wild-type receptors 12.64 ± 0.33 mM and 13.63 ± 
1.06 mM for the double mutant and wild type, respectively (p > 0.05, unpaired t-test; n = 3 
each). The Imax was lower for α1(E103R/R131E) 1.32 ± 0.03 nA than for wild-type 4.4 ± 0.9 
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nA (p < 0.05, unpaired t-test; n = 3 each).  The slope of the concentration curve for 
α1(E103R/R131E) was similar to wild-type 1.20 ± 0.15 and 1.46 ± 0.06 (p > 0.05, unpaired t-
test; n = 3 each; Table 5.3). In each cell, responses to saturating glycine (50 mM) were 
obtained. The maximum sarcosine current response relative to glycine was similar to wild-
type 0.86 ± 0.19 for the double mutant GlyR and 0.80 ± 0.03 for wild-type GlyR. 
 
Single-channel recordings of GlyR bearing the E103R/R131E mutation using 100 mM 
sarcosine are shown in Figure 5.18. Clusters had very high open probability. The maximum 
Popen elicited by sarcosine in the double mutant was significantly higher than the wild-type 
0.97 ± 0.01 vs 0.70 ± 0.03 (p < 0.01, unpaired t-test; n = 23 clusters from 8 records, n = 22 
clusters from 4 records, respectively). It resembles the R131E GlyR mutation (0.91 ± 0.04). 
The current amplitude was 4.51 ± 0.12 pA (n = 23 clusters obtained from eight records) 
similar to that of wild-type 5.64 ± 0.30 pA (p > 0.05, unpaired t-test, n = 22 clusters from 4 
records). 
 
The overall effects of the α1(E103R), α1(R131E) and the double mutant α1(E103R/R131E) 
on glycine and sarcosine responses are illustrated in Figure 5.19.  The concentration-response 
curves in Figure 5.19 are displayed as whole cell responses scaled to the maximum open 
probability measured by single channel analysis. In this way the desensitized intervals are not 
included in the analysis and only the changes in receptor activation are included. It clearly 
shows how the double mutant rescued the glycine response (Figure 5.19.A). The figure shows 
how the double charge reversal mutant EC50 of 0.43 ± 0.04 mM (black circles; n = 5) was 
close to the wild-type EC50 value of 0.25 mM. It is much lower in either of the single mutants 
E103R or R131E (3.68 ± 1.18 mM and 1.60 ± 0.15 mM, respectively; shown as dashed and 
dotted curves in Figure 5.19; Table 5.2).  For sarcosine the picture is slightly different. While 
the double mutant has a sarcosine EC50 similar to that of wild-type receptors (12.64 ± 0.33 
and 13.63 ± 1.06), sarcosine efficacy resemble more the reverse charge mutant R131E (0.91 
± 0.04) than it does the wild-type (0.70 ± 0.03) Table (5.3). 
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Figure  5.15 Whole-cell recordings of α1(E103R/R131E) GlyR using glycine. 
A) Representative double mutant GlyR responses to glycine (0.1 – 50 mM). Black bars above 
the traces show the timing of the applications. B) Whole-cell concentration-response curves 
to glycine in homomeric E103R/R131E GlyR. EC50 = 0.43 ± 0.04 mM, nH = 0.95 ± 0.02. Imax 
= 3.74 ± 0.40 nA, n = 5. Error bars represent SEM. 
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Figure  5.16 Single-channel recordings of α1(E103R/R131E) GlyR using saturating 
concentration of glycine 
Cluster of single-channel activity elicited by 100 mM glycine in the homomeric 
E103R/R131E mutant. Cell-attached configuration, channel openings are upwards. Single-
channel Popen = 0.996 ± 0.001, current amplitude = 4.81 ± 0.12 pA, n = 9 clusters from 5 
records. 
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Figure  5.17 Whole-cell recordings of α1(E103R/R131E) GlyR using sarcosine.  
A) Representative whole-cell current responses to sarcosine (1-100 mM) in the double charge 
reversal mutant α1(E103R/R131E) GlyR. Black bars above the traces show the timing of the 
applications. B) Sarcosine whole-cell concentration-response curves in the double mutant 
GlyR. EC50 = 12.64  0.33 mM, Imax = 1.32 ± 0.03 nA, the nH = 1.20 ± 0.15, n = 3 cells. 
Saturating concentration of 50 mM glycine was used in the same cell. The Imax sarcosine /Imax 
Glycine ratio = 0.86 ± 0.19. Error bars represent SEM.  
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Figure  5.18 Single-channel recordings of GlyR bearing α1( E103R/R131E) using 
sarcosine. 
Cluster of single-channel mutant GlyR activity elicited in cell-attached record by saturating 
concentrations of sarcosine (100 mM). Cell-attached configuration, channel openings are 
upwards. The maximum Popen elicited by sarcosine in the double mutant = 0.97 ± 0.01. The 
current amplitude = 4.51 ± 0.12 pA, n = 23 clusters obtained from eight records. 
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Figure  5.19 E103R/R131E mutation rescues GlyR α1 response to glycine and sarcosine. 
Glycine and sarcosine whole-cell concentration-response curves in wild-type and double 
 mutant GlyR. Curves are scaled to the appropriate maximum Popen measured by single- 
channel recordings.  
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Table  5.2 E103R/R131E mutation rescues GlyR α1 response to glycine 
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Table  5.3 E103R/R131E mutation rescues GlyR α1 response to sarcosine 
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5.3 Discussion 
How a dominant mutation affects glycine transmission by substitutions of a single amino acid 
in hyperekplexia causing mutation (E103K) is unknown. Mutating a negative to a positive 
residue in the ECD just near to the binding site has an influence on channel gating as 
observed in chapter three (Figure 3.9, Table 3.5) but how E103K has a role in channel gating 
is not known. Here we identified key residues in the ECD that can influence channel gating 
of the homomeric α1 GlyRs. This is based on site-directed mutagenesis combined with 
homology modeling based on the crystal structure of GluCl. Since GluCl displays up to 42% 
amino acid identity to human α1 GlyR it has been used as a template for the modeling (Yu et 
al., 2014). The oppositely charged E103 and R131 are conserved in all human GlyR subunits 
(Figure 5.1).  E103 and R131 residues were predicted to form a salt bridge interaction. E103 
and R131 were mutated to explore the validity of the prediction and to identify the role of key 
residues in the transduction of channel binding to channel gating. The predicted salt-bridge 
between E103 and R131 might be essential in maintaining the correct conformation of Loop 
A, which in turn influences the direct bonds of other residues with the agonist such as F99 of 
loop A which forms interactions with glycine. E103 and R131 residues were exchanged to 
alanine. Also the influence of E103R/R131E on glycine and sarcosine responses was 
investigated. Our results as highly suggestive of a salt-bridge interaction between α1E103 
located on the positive side and α1R131 located on the negative side. 
The effect of the E103 and R131 mutations is different for glycine vs. sarcosine. The glycine 
response seems indifferent to alanine substitutions as E103A glycine sensitivity shifted by 
1.72 fold and the maximum Popen was similar to wild type 0.97 ± 0.01, 0.9992 ± 0.002 (n = 
11, 30, Table 5.2). R131A shifted glycine sensitivity by 1.32 only and the maximum Popen 
was similar to wild-type GlyRs 0.95 ± 0.01 (n = 16, Table 5.2). 
For sarcosine homomeric E103K EC50 could not be established as the sarcosine response did 
not saturate up to 300 mM (Figure 5.6), however, it is worth to mention that the relative 
efficacy of the partial agonist β-alanine to glycine was increased as a result of the heteromeric 
E103K mutation (Figure 5.4). This indicates that this position has effect on gating that 
depends on the agonist and maybe the β subunit has an influence. E103R and E103A did not 
do much as glycine sensitivity changed by 0.93, 1.71 fold respectively. Glycine efficacy also 
did not change much as it was 0.79 ± 0.03, 0.67 ± 0.08 for E103R and E103A, respectively 
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(Table 5.2). On the other hand, R131 mutations R131A and R131E increase efficacy from 
0.70 ± 0.03 to 0.95 ± 0.01 in R131A and to 0.91 ± 0.04 in R131E but their EC50 effects were 
not similar. R131A shifted sarcosine sensitivity by 0.30 and R131E decreased sarcosine 
sensitivity by 6.40 fold. An earlier study using the Xenopus laevis oocyte expression system 
found that R131A homomeric α1 GlyR did not affect glycine sensitivity as it increased 
glycine sensitivity by 0.58 fold only (this was not significant). On the other hand taurine 
sensitivity significantly changed from 3.6 ± 1.6 to 0.42 ± 0.16 mM and its efficacy relative to 
glycine was increased by double (Grudzinska et al., 2005). Also, R131A homomeric α1 GlyR 
can be activated by zinc alone (Grudzinska 2008). 
The substantial rescue with charge reversal double mutant suggests that there is a salt bridge 
that matters.  Reversal is good for glycine as it improved glycine response.  However, the 
double mutant fails to make sarcosine partial as in the wild-type GlyRs (Figure 5. 17). This 
could mean that the salt bridge may have the right length, but the position of the interacting 
charged moieties (guanidinium in Arg and carboxylate in glutamate) might be different.  
 
Here we show interaction between E103 and R131 is crucial for gating function of the 
glycine receptor. Our results show a role of salt bridge interaction between E103 and R131 by 
demonstrating rescue of glycine response to homomeric mutant GlyRs. This might be a good 
explanation for the deterioration of glycine receptor function in the hyperekplexia causing 
mutation E103K. 
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6 Chapter 6: General Conclusions 
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GlyRs are ligand gated ion channels that are vital for synaptic inhibitory neurotransmission in 
the mammalian CNS. The understanding of the structure-function relation of GlyR is 
enhanced by the availability of human hyperekplexia mutations that highlight residues 
essential for channel function. The α1 GlyR human hyperekplexia mutations are found in 
different parts of the GlyR, from the ECD to the TM4. Each region might provide us with 
valuable information about the function of the receptor.  
To characterize α1 GlyR mutations that contribute to human hyperekplexia pathogenesis, 
functional measurements of the effect of GlyR mutations on glycine potency and efficacy 
were determined by whole-cell and single-channel recordings. The effect of homomeric 
α1(E103K), α1(S231N), α1(Q266H), α1(S267N) and heteromeric α1(E103K)β, α1(S231N)β, 
α1(Q266H)β, α1(S267N)β GlyR mutations expressed in HEK293 cells was studied. This was 
done after establishing data for homomeric and heteromeric wild-type human GlyRs, as for 
previous controls rat GlyR had been used in our lab (Lape et al., 2012).  
E103K is located at the ECD (loop A of the principal side of the binding site). It causes a 
marked reduction in glycine potency that is more marked in the heteromeric than the 
homomeric channel (2.8 cf ~ 72 fold change in EC50). This reduction is associated with a 
significant reduction in glycine maximum Popen from 0.99 ± 0.002 to 0.73 ± 0.07 (homomeric 
α1(E103K) and 0.98 ± 0.01 to 0.67 ± 0.06 (heteromeric α1(E103K)β).  
 
The S231N hyperekplexia mutation which is found in the TM1 also reduced glycine 
sensitivity. Glycine EC50 increased significantly from its wild-type value of 0.25 ± 0.03 mM 
(n = 6) to 1.16 ± 0.13 mM (n = 4) for α1(S231N) GlyR and from 0.10 ± 0.03 mM (n = 6) to 
3.81 ± 0.42 mM (n = 4) for α1(S231N)β GlyR. The reduction in glycine potency is more 
marked in the heteromeric than the homomeric receptors (5 vs 38; EC50 fold change). This 
reduction is related to a significant reduction in glycine maximum Popen from 0.98 ± 0.01 
(α1β wild-type GlyR) to 0.38 ± 0.06 (α1(S231N)β GlyR). 
The Q266H GlyR mutation located on the TM2 reduced glycine potency significantly and the 
effect is more marked in the heteromeric channel (2.7 vs. ~ 12 fold change). This reduction is 
associated with a significant reduction in maximum glycine Popen from 0.98 ± 0.01 (n = 29) to 
0.61 ± 0.06 in heteromeric α1(Q266H)β GlyR (n = 20). 
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The S267N GlyR hyperekplexia mutation produced a significant reduction in glycine 
potency. This effect is more noticeable in the heteromeric channel (18 cf ~ 35 fold change). 
The reduction in glycine sensitivity is associated with a channel-gating disturbance. The 
maximum glycine Popen for the heteromeric α1(S267N)β was significantly reduced from 0.98 
± 0.01 (n = 29) to 0.37 ± 0.06 (n = 6) suggesting improper channel gating. 
The main finding in Chapter Three of the thesis is that the E103K, S231N, Q266H and 
S267N human hyperekplexia mutations within the α1 subunit of GlyR reduce the channel 
sensitivity to glycine. The change in glycine potency was more marked in the heteromeric 
than in the homomeric receptors. The data suggests that the gating efficacy is interrupted by 
those mutations as glycine maximum Popen was reduced (Table 3.5).  
It would be of interest to screen all α1 human hyperekplexia mutations that are documented 
in the literature. By comparing the effect of mutations on glycine EC50 it would be possible to 
know which residues are most important for glycine sensitivity. Also, it might be useful to 
correlate the location of the mutation with the severity of the hyperekplexia symptoms. 
Testing α1 mutations in both homomeric and heteromeric GlyR helps in understanding 
whether incorporation of the β-subunit improves the function of human hyperekplexia 
mutations or not. Exploring this within a single lab will expand our knowledge despite there 
being some difficulty in working with these mutations knowing that the function of the GlyR 
is disturbed.    
Can the reduced glycine response of the hyperekplexia mutant GlyRs be rescued? 
Given the importance of the proper function of GlyR, the intravenous anaesthetic propofol 
was used to study the possibility of improving the function of the hyperekplexia mutant α1β 
GlyR. In the present study, I described how the application of propofol can improve glycine-
gated currents of α1(E103K)β, α1(S231N)β, α1(Q266H)β, and α1(S267N)β hyperekplexia 
GlyR mutations expressed in HEK293 cells.  
The function of GlyR can be modulated by a variety of allosteric modulators such as Zn
2+
, 
ethanol and anaesthetics (Harvey et al., 1999; Mihic et al., 1997; Miller et al., 2005a; 
Yevenes and Zeilhofer, 2011). Most of the enhancement effects of these modulators are 
observed when the submaximal concentrations of glycine are tested. However, application of 
these allosteric modulators with saturating concentrations of glycine has minimal modulation 
effects. Therefore, both saturating and subsaturating concentrations of glycine were used in 
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this study. The aim was to examine whether propofol can potentiate glycine EC20 and/or 
maximal response and whether these effects were different than in wild-type GlyRs.  
Propofol-potentiated glycine submaximal current of α1(E103K)β GlyR (3.18 ± 0.58 fold 
change; although not significant, n = 5). Propofol failed to potentiate glycine maximal 
responses for the same mutation in whole-cell experiments (0.72 ± 0.19 fold change; n = 2).   
Propofol potentiation of glycine submaximal and maximal responses of the α1(Q266H)β 
were investigated. This study suggests that propofol can significantly enhance submaximal 
glycine-gated currents for the α1(Q266H)β (5.19 ± 1.35 fold change; n = 4), however,  
glycine maximal response could not be restored (1.05 ± 0.06 fold change; n = 4). Similar 
effects were observed for the wild-type GlyRs.  
α1(S267N) GlyR hyperekplexia mutation, which reduced ethanol modulation, was also tested 
(Becker et al., 2008). The submaximal glycine response of HEK293 cells bearing 
α1(S267N)β hyperekplexia GlyR mutation was significantly potentiated by propofol (2.71 ± 
0.41 fold change; n = 6). At the same residue other non-hyperekplexia mutations S267I and 
S267M were tested for propofol modulation. Their results were consistent with my study, as 
propofol modulation of glycine sub-maximal response was not affected by the mutations 
(Ahrens et al., 2008). Enhancement of glycine-gated maximal currents by propofol were 
observed (1.29 ± 0.09 fold change, n = 6). Therefore, both submaximal and maximal 
responses to glycine were significantly potentiated for this mutation. The results are 
consistent with role of the S267 residue in mediating allosteric modulation.  
 
Propofol enhancement of the glycine current at the α1(S231N)β GlyR mutation was also 
found. Similar to wild-type GlyR, glycine-gated submaximal currents at the heteromeric 
α1(S231N)β GlyR are enhanced by propofol (5.48 ± 1.38 fold change; n = 6). Unlike in wild-
type receptors, propofol potentiates glycine-gated maximal currents (1.98 ± 0.29 fold 
change). This residue might be essential for propofol sensitivity in GlyR. Indeed, single-
channel recordings of α1(S231N)β GlyR at saturating glycine concentration in the presence 
of 50 l propofol showed that the maximum glycine Popen was increased significantly from 
0.38 ± 0.06 to 0.65 ± 0.04 (n = 16, 38 clusters, respectively) without affecting single channel 
current amplitude (2.01 ± 0.05 pA vs 1.94 ± 0.04 pA). In the α1(S231N)β GlyR mutation the 
functional deficiency was restored by propofol as both the submaximal and maximal response 
to glycine were potentiated by propofol. Allosteric modulators such as zinc have minimal 
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effects when applied with maximal glycine concentration (Farley and Mihic, 2015). Here we 
observed enhancement of currents elicited by saturating concentration of glycine. This effect 
might be explained by increasing gating of the channel (Popen) as it cannot be explained by 
increasing glycine affinity as glycine is already at saturating concentration.  
Altogether, propofol (50 M) was effective in potentiating glycine submaximal and maximal 
response in α1(S231N)β and α1(S267N)β hyperekplexia mutations; however, only the 
submaximal responses were potentiated in the α1(E103K)β and α1(Q266H)β hyperekplexia 
mutations. Why S231 was most sensitive to propofol is not clear. According to the GlyR 
homology model based on GluCl structure, the proposed propofol binding site involves P230 
which is close to S231. The reason behind the lack of propofol potentiation of glycine 
maximal current for α1(E103K)β and α1(Q266H)β hyperekplexia mutations is not clear. If 
we assume that propofol affects only flip and the increase in affinity with activation. It could 
not reverse the decrease in maximum Popen if this is produced by a mutation that damages 
channel opening (E), as per E103K.  No increase in flip can compensate. If a mutation affects 
both flip and channel opening, its effects on maximum Popen could be partially reversed by 
propofol, if flip has become rate limiting for the maximum Popen (as it is for a partial agonist). 
In summary, my results indicate that propofol can partially rescue the reduced maximal 
glycine response of α1(S231N)β and α1(S267N)β GlyR (in a recombinant system). However, 
the modulation property of propofol cannot be generalized to all hyperekplexia mutations as 
the response varied from one residue to other. Testing different mutations will allow a better 
understanding of the mechanism behind propofol modulation of glycine in GlyR. 
 
The startle disease mutation E103K impairs activation of human homomeric α1 glycine 
receptors by disrupting an intersubunit salt bridge across the agonist binding site  
Results from our lab demonstrated that hyperekplexia mutation located at the TM2 (where 
most of the α1 GlyR mutations are expressed) exerts its effect by interfering with channel 
gating. This was based on characterization of K276E (Lewis et al., 1998; Lape et al., 2012). 
Little is known about how mutations near the binding site disrupt the normal glycinergic 
synaptic transmission. As a possible explanation, it has been recently suggested that the 
α1(N46K) GlyR, which is a lethal hyperekplexia in mice, speeds up the deactivation of GlyR 
(Wilkins et al., 2016). Exploring hyperekplexia mutations that are located at the binding site 
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but do not suppress agonist binding might provide valuable information about signal 
transduction to the gate once the agonist has bound.  
A salt bridge at the back of the binding site between the charged side chain of E103 in loop A 
to that of R131 in loop E is suggested by homology modeling of α1GlyR (Yu et al., 2014) 
based on GluCl (Hibbs and Gouaux, 2011) and the recent structure of the zebrafish α1(GlyR) 
(Du et al., 2015). Interaction between these two residues is confirmed by our study using site-
directed mutagenesis, whole-cell and single-channel recordings (Safar et al., 2017). This was 
based on investigating the effect of different mutations in which the side-chain charge was 
either eliminated (by Ala mutations) or reversed. The effect of the double mutation 
E103R/R131E was also tested. We concluded that despite the α1(E103K) hyperekplexia 
mutation being located in the ECD it impairs the efficacy of glycine. The effect of E103 and 
R131 mutations on GlyR response to the full agonist glycine was different from the partial 
agonist sarcosine. Since sarcosine is a partial agonist its maximum Popen should change 
clearly due to gain or loss of function mutations (in this case). For sarcosine, the effect of 
mutating E103 residue was minimal for α1(E103A) or α1(E103R) GlyR mutations. On the 
other hand, both α1(R131A) and α1(R131E) enhanced sarcosine efficacy. Whereas 
α1(R131A) increased sarcosine potency, α1(R131E) decreased it. This suggests that 
α1(R131E) causes a reduction in sarcosine binding affinity. A small loss of affinity and 
efficacy for glycine was caused by α1(R131E) GlyR mutation. These findings indicate that 
the efficacy determinants for glycine are different from those of sarcosine, being the first time 
that such findings have been reported at the single-channel level. An alanine scan of other 
residues within loop A of GlyR such as K104, F108 and T112 suggested a gain of function in 
response to a range of agonists. The maximum whole-cell response of taurine (partial agonist) 
relative to glycine was increased for those mutations (Schmieden et al., 1999). The 
R131E/E103R experiments provide strong evidence for the existence of the salt bridge, as 
swapping the side chains of E103 and R131 residues rescued most of the effects of the single 
point mutations. The increased efficacy of the α1(R131) GlyR mutation in response to 
sarcosine, however,  persisted in the double mutation. The reason behind this is unknown. It 
might be that in the R131/E103 mutation the salt bridge is of a correct length but the 
interaction between the charged moieties is in a different position. Our results show that even 
with the availability of a validated homology model and measurements of efficacy by single-
channel recordings, it is difficult to fully understand the network of interactions at the ECD of 
GlyR.  
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In conclusion, this study provides insight into the role of different residues of α1GlyR using 
human hyperekplexia mutations. It demonstrates the molecular explanation behind E103K, 
S231N, Q266H, and S267N α1 GlyR mutations. The study also indicates that the human 
hyperekplexia mutations tested here affect the channel gating of GlyR. This might interrupt 
the normal glycinergic synaptic inhibition of GlyRs leading to hyperekplexia. It also shows 
that the function of some of the hyperekplexia mutations can be rescued using propofol. 
Furthermore, improper salt-bridge interaction at the binding site influences the normal 
function of GlyR.   
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